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Bipolar disorder (BD) and major depressive disorder (MDD) are characterised by a 
fundamental disturbance of mood, with strong support for overlapping causal 
pathways. Structural brain and neurocognitive abnormalities have been associated 
with mood disorders, but it is unknown whether these reflect early adverse effects 
predisposing to mood disorders or emerge as a consequence of illness onset.  
The Bipolar Family Study is well-suited to examine the origin of structural brain 
and neuropsychological abnormalities in mood disorders further. The volumes of 
subcortical brain regions, cortical thickness and surface area measures of frontal 
and temporal regions of interest and neuropsychological performance over a two-
year time interval was compared at baseline and longitudinally between three 
groups: young individuals at high risk of mood disorders who subsequently 
developed MDD during the follow-up period (HR-MDD), individuals at high risk 
of mood disorders who remained well (HR-well), and healthy control subjects 
(HC).  
The longitudinal analysis of cortical thickness revealed significant group effects for 
the right parahippocampal and right fusiform gyrus. Cortical thickness in both of 
these brain regions across the two time points was reduced in both high-risk groups 
relative to controls, with the HR-MDD group displaying a thinner 
parahippocampus gyrus than the HR-well group. Moreover, a significant 
interaction effect was observed for the left inferior frontal and left precentral gyrus. 
The HR-well subjects had progressive thickness reductions in these brain regions 
relative to controls, while the HR-MDD group showed cortical thickening of these 
areas. Finally, longitudinal analyses of neuropsychological performance revealed a 
significant group effect for long delay verbal memory and extradimensional set-
shifting performance. Reduced neurocognitive performance during both tasks 
across the two time points was found in the HR-well group relative to controls, 
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with the HR-MDD group displaying decreased extradimensional set-shifting 
abilities as compared to the HC group only.  
These findings indicate, that reduced left parahippocampal and fusiform thickness 
constitute a familial trait marker for vulnerability to mood disorders and may thus 
form potential neuroanatomic endophenotypes. Particularly strong thickness 
reductions of the parahippocampal gyrus appear be linked to an onset of MDD. 
Moreover, progressive thickness reductions in the left inferior frontal and 
precentral gyrus in early adulthood form a familial trait marker for vulnerability to 
mood disorders, potentially reflecting early neurodegenerative processes. By 
contrast, an absence of cortical thinning of these brain regions in early adulthood 
appears to be linked to the onset of MDD, potentially reflecting a lack or delay of 
normal synaptic pruning processes. Reduced long delay verbal memory and 
extradimensional set-shifting performance across time constitute a familial trait 
marker for vulnerability to mood disorders, likely representing disturbances of 
normal brain development predisposing to illness. These findings advance our 
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1.1 Clinical characteristics of mood disorders 
The diagnostic term ‘mood disorders’ refers to a range of conditions in which the 
most prominent symptom is a fundamental disturbance in the person’s mood to 
either depression or elation (World Health Organization, 2004). Based on whether 
an episode of mania or hypomania has ever been present, mood disorders are 
divided into depressive disorders or bipolar disorders (BD) as outlined in the fourth 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; 
American Psychiatric Association, 1994).  
There are three main types of depressive disorders. The first is major depressive 
disorder (MDD). A diagnosis of MDD requires the presence of at least a single 
major depressive episode. Such an episode consists of a broad range of symptoms 
that are experienced for most of the time, nearly every day, for at least two weeks 
and represent a significant change from previous functioning. The core feature of a 
major depressive episode is either a depressed mood or anhedonia, although both 
can occur simultaneously. Furthermore, the presence of at least four (or three if 
both depressed mood and anhedonia are present) of the following symptoms are 
required for a diagnosis: change in appetite or sleep patterns (insomnia or 
hypersomnia), psychomotor agitation or retardation, fatigue, feelings of 
worthlessness or guilt, poor concentration, recurrent thoughts of death and suicide. 
The symptoms cause significant distress or impairment in social, occupational or 
other areas of functioning to the person concerned (American Psychiatric 
Association, 1994). The precise criteria for a major depressive episode according to 




Table 1.1 DSM-IV criteria for a major depressive episode 
A. Five (or more) of the following symptoms have been present during the same 2-week 
period and represent a change from previous functioning; at least one of the 
symptoms is either (1) depressed mood or (2) loss of interest or pleasure. 
Note: Do not include symptoms that are clearly due to a general medical condition, or 
mood-incongruent delusions or hallucinations. 
(1) Depressed mood most of the day, nearly every day, as indicated by either 
subjective report (e.g., feels sad or empty) or observation made by others (e.g., 
appears tearful). Note: In children and adolescents, can be irritable mood 
(2) Markedly diminished interest or pleasure in all, or almost all, activities most of the 
day, nearly every day (as indicated by either subjective account or observation 
made by others) 
(3) Significant weight loss when not dieting or weight gain (e.g., a change of more 
than 5% of body weight in a month), or decrease or increase in appetite nearly 
every day. In children, consider failure to make expected weight gains 
(4) Insomnia or hypersomnia nearly every day 
(5) Psychomotor agitation or retardation nearly every day (observable by others, not 
merely subjective feelings of restlessness or being slowed down) 
(6) Fatigue or loss of energy nearly every day 
(7) Feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being sick) 
(8) Diminished ability to think or concentrate, or indecisiveness, nearly every day 
(either by subjective account or as observed by others) 
(9) Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing 
suicide 
B. The symptoms do not meet criteria for a Mixed Episode. 
C. The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning. 
D. The symptoms are not due to the direct physiological effects of a substance or a 
general medical condition. 
E. The symptoms are not better accounted for by bereavement. 
 
Other subtypes of depressive disorders include dysthymic disorder and depressive 
disorder not otherwise specified. Given that these two conditions are not the focus 
of this thesis, only a brief description of them is provided. Dysthymic disorder is a 
milder but more chronic type of depression. Criteria include the presence of 
depressed mood for the majority of time during a time period of at least two years. 
Moreover, two or more of the following symptoms are evident when the person is 
depressed: change in appetite or sleep patterns, fatigue, reduced self-esteem, poor 
concentration or decision making abilities, feelings of hopelessness or pessimistic 
thoughts. Depressive symptoms that do not meet criteria for any mental disorder 
outlined in DSM-IV can be classified as depressive disorder not otherwise 
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specified. This category applies for example to cases in which fewer than the 
required five depressive symptoms for a diagnosis of MDD are present for at least 
two weeks (American Psychiatric Association, 1994). 
The main features of BD are intermittent episodes of mania or hypomania, 
commonly interlaced with episodes of depression. Several types of BD can be 
distinguished, including bipolar I disorder (BD-I) and bipolar II disorder (BD-II). A 
diagnosis of BD-I is made when at least a single manic or mixed episode, with or 
without a depressive episode, has ever occurred. A manic episode is defined as a 
period of excessively elevated, expansive or irritable mood that lasts for one week 
or longer. At least three (or four if mood is only irritable) of the following 
symptoms are required to meet criteria for a manic episode: increased feelings of 
self-esteem or grandiosity, less need for sleep, increased talkativeness, enhanced 
distractibility, increased goal-directed activity or psychomotor agitation, exorbitant 
involvement in pleasurable activities that have a high potential for painful 
consequences (such as buying sprees or risky business investments). A mixed 
episode by contrast concerns the presence of symptoms that fulfil criteria for both a 
manic episode and a major depressive episode (except for duration) over a period 
of at least one week. The mood disturbance is causing marked impairment in social 
or occupational areas of function (American Psychiatric Association, 1994). The 
detailed criteria for a manic episode and a mixed episode are provided in Tables 1.2 










Table 1.2 DSM-IV criteria for a manic episode 
A. A distinct period of abnormally and persistently elevated, expansive or irritable mood, 
lasting at least 1 week (or any duration if hospitalization is necessary). 
B. During the period of mood disturbance, three (or more) of the following symptoms 
have persisted (four if the mood is only irritable) and have been present to a 
significant degree: 
(1) Inflated self-esteem or grandiosity 
(2) Decreased need for sleep (e.g., feels rested after only 3 hours of sleep) 
(3) More talkative than usual or pressure to keep talking 
(4) Flight of ideas or subjective experience than thoughts are racing 
(5) Distractibility (i.e., attention too easily drawn to unimportant or irrelevant external 
stimuli) 
(6) Increase in goal-directed activity (at work, at school, or sexually) or psychomotor 
agitation) 
(7) Excessive involvement in pleasurable activities that have a high potential for 
painful consequences 
C. The symptoms do not meet criteria for a Mixed Episode. 
D. The mood disturbance is sufficiently severe to cause marked impairment in 
occupational functioning or in usual social activities or relationships with others, or to 
necessitate hospitalization to prevent harm to self or others, or there a psychotic 
features. 
E. The symptoms are not due to the direct physiological effects of a substance (e.g., a 
drug of abuse, a medication or other treatment) or a general medical condition (e.g., 
hyperthyroidism). 
 
Table 1.3 DSM-IV criteria for a mixed episode 
A. The criteria are met both for a Manic Episode and for a Major Depressive Episode 
(except for duration) nearly every day during a 1-week period. 
B. The mood disturbance is sufficiently severe to cause marked impairment in 
occupational functioning or in usual social activities or relationships with others, or to 
necessitate hospitalization to prevent harm to self or others, or there are psychotic 
features. 
C. The symptoms are not due to the direct physiological effects of a substance or a 
general medical condition. 
 
A diagnosis of BD-II is made when at least one major depressive episode and at 
least one hypomanic episode has occurred. Hypomanic episodes are milder forms 
of manic episodes and are characterised as a period of persistently elevated, 
expansive or irritable mood that lasts for at least four days. At least three (or four if 
mood is only irritable) of the symptoms of a manic episode are required to meet 
criteria for a hypomanic episode. In contrast to a manic episode however, the 
symptoms do not cause significant distress or impairment in social, occupational or 
5 
 
other areas of functioning (American Psychiatric Association, 1994). The precise 
criteria for a hypomanic episode are outlined in Table 1.4.  
 
Table 1.4 DSM-IV criteria for a hypomanic episode 
A. A distinct period of persistently elevated, expansive or irritable mood, lasting 
throughout at least 4 days, that is clearly different from the usual non-depressed 
mood. 
B. During the period of mood disturbance, three (or more) of the following symptoms 
have persisted (four if the mood is only irritable) and have been present to a 
significant degree: 
(1) Inflated self-esteem or grandiosity 
(2) Decreased need for sleep (e.g., feels rested after only 3 hours of sleep) 
(3) More talkative than usual or pressure to keep talking 
(4) Flight of ideas or subjective experience that thoughts are racing 
(5) Distractibility (i.e., attention too easily drawn to unimportant or irrelevant external 
stimuli) 
(6) Increase in goal-directed activity (at work, at school, or sexually) or psychomotor 
agitation 
(7) Excessive involvement in pleasurable activities that have a high potential for 
painful consequences 
C. The episode is associated with an unequivocal change in functioning that is 
uncharacteristic of the person when not symptomatic. 
D. The disturbance in mood and the change in functioning are observable by others. 
E. The mood disturbance is not severe enough to cause marked impairment in social or 
occupational functioning, or to necessitate hospitalization, and there are no psychotic 
features. 
F. The symptoms are not due to the direct physiological effects of a substance or a 
general medical condition. 
 
Apart from BD-I and BD-II, other subtypes of BD include cyclothymia or BD not 
otherwise specified. Given that these two conditions are not the focus of this thesis, 
only a brief description of them is provided. Cyclothymia is characterised by the 
presence of hypomanic episodes with periods of major depressive symptoms that 
do not meet criteria for MDD over a period of at least two years. A diagnosis of 
BD not otherwise specified can be made if there are symptoms of BD that do not 
fall within one of the other established subtypes. For example, an individual may 
experience intermittent manic and depressive symptoms that only last for a few 
days or may experience recurrent hypomanic episodes in the absence of any 
depressive symptoms (American Psychiatric Association, 1994). 
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1.2 Epidemiology of mood disorders 
With an estimated lifetime prevalence of more than 20%, mood disorders are one 
of the most common mental disorders worldwide and a leading cause of disability 
(Kessler et al., 2005). Although classified together as mood disorders, MDD and 
BD are heterogeneous with respect to their epidemiological characteristics. MDD is 
far more common in the population than BD, with lifetime prevalence estimates 
being about 16% for MDD and about 2% for BD-I and BD-II as a whole (Kessler 
et al., 2003; Merikangas et al., 2007).  
The median age at onset of MDD is about 29-32 years but only 21-25 years for BD 
(Kessler, et al., 2005; Perlis, Brown, Baker, & Nierenberg, 2006). Earlier ages at 
onset of MDD have been associated with a more severe course of illness, including 
greater symptom severity, more lifetime episodes of depression and suicide 
attempts, increased social and occupational impairment, poorer quality of life and 
greater comorbidity as compared to individuals with later age onset  (Zisook et al., 
2007). Similarly, early onset BD has been linked to particularly severe clinical 
features and a worse course of illness that is characterised by more lifetime 
psychotic symptoms, more rapid cycling of episodes, increased suicide attempts, 
greater comorbidity and poorer response to lithium pharmacotherapy (Carter, 
Mundo, Parikh, & Kennedy, 2003; Schurhoff et al., 2000; Suominen et al., 2007). 
While woman suffer approximately twice as frequently from MDD than men, both 
genders appear to be equally often affected by BD (Piccinelli & Wilkinson, 2000; 
Viana & Andrade, 2012).  
Relatively few studies have examined the course of illness of mood disorders 
across lifetime, although attempts have been made to draw conclusions about their 
persistence by comparing 12-month and lifetime prevalence rates (Kessler, 
Merikangas, & Wang, 2007). The ratios indicate a higher persistence of BD-I 
(63%) than MDD (40%) (Kessler, et al., 2007). These estimates are broadly in line 
with retrospective and prospective assessments in community and clinical samples 
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that point towards mood disorders being mainly episodically chronic-recurrent in 
nature. For MDD, the recurrence rates of a major depressive episode after an initial 
recovery have been estimated to be between 38% and 78% (Angst & Merikangas, 
1997; Mueller et al., 1999; van Weel-Baumgarten, van den Bosch, van den 
Hoogen, & Zitman, 1998). However, findings also highlight that the majority of 
MDD patients recover within a time frame of one year from a major depressive 
episode whilst only a minority of individuals experiences no recovery or remission 
of symptoms and their condition can take a chronic course for years (Richards, 
2011). When compared to MDD, the clinical course of BD-I is generally 
characterised by a higher but shorter number of episodes and cycles (Angst & 
Preisig, 1995; Perlis, et al., 2006). In a prospective longitudinal study, 93% of the 
82 BD-I patients experienced at least one affective episode within a 10-year time 
period following their intake, with the average number of episodes being three, 
lasting on average ten weeks (Judd et al., 2003).  
Comorbidity in mood disorders is generally high. In particular, anxiety disorders, 
substance use disorders and impulse control disorders occur frequently within the 
context of MDD and BD-I. About 60% of MDD patients and 87% of BD patients 
suffer from a comorbid lifetime anxiety disorder, most commonly generalised 
anxiety disorder or phobic disorder (Kessler, et al., 2003; Kessler, et al., 2007). 
MDD and BD have been associated with high rates of lifetime substance use 
disorders of 24% and 60%, respectively (Kessler, et al., 2003; Kessler, et al., 2007). 
Moreover, impulse control disorders such as intermittent explosive disorder, 
pathological gambling, bulimia nervosa, conduct disorder, oppositional defiant 
disorder or antisocial personality disorder occur in approximately 32% of MDD 
patients and 72% of BD individuals throughout their life (Kessler, et al., 2003; 
Kessler, et al., 2007). Comorbidity has also been established between mood 
disorders and physical conditions such as cardiovascular disorders, diabetes 
mellitus or respiratory syndromes (Kupfer, 2005; Richards, 2011). Moreover, the 
presence of a comorbid disorder has also been associated with greater severity of 
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symptoms, lower treatment response rates, greater social and occupational 
impairment (Richards, 2011; N. M. Simon et al., 2004).  
Mood disorders are highly disabling conditions and provide a substantial social and 
economic burden to society (G. E. Simon, 2003). They cause marked social and 
functional impairment that ultimately results in a decreased quality of life 
(Papakostas et al., 2004; G. E. Simon, Bauer, Ludman, Operskalski, & Unutzer, 
2007) and have been associated with highly increased morbidity and mortality 
rates. The risk of completed suicide is about 20 times higher among both BD and 
MDD inpatients than for the general population (Holma et al., 2010; Osby, Brandt, 
Correia, Ekbom, & Sparen, 2001).  
The effective treatment of mood disorders involves pharmacotherapy or 
psychotherapy, either as monotherapy or in combination. Antidepressants are the 
most commonly prescribed medication for MDD (Nemeroff & Owens, 2002), 
while mood stabilizers such a lithium are the most frequently applied 
pharmacological treatment for BD (Blanco, Laje, Olfson, Marcus, & Pincus, 2002). 
This discrepancy in pharmacological treatment approaches together with the 
heterogeneity of symptoms and epidemiological characteristics suggests a partly 
distinct underlying pathology of MDD and BD. However, research on the aetiology 
of mood disorders also points towards an at least partly shared biological basis of 
the two – an important topic that will be discussed in the next paragraph. 
 
1.3 Aetiology of mood disorders 
Environmental and genetic factors both play an important role in the aetiology of 
mood disorders and recent findings suggest that their interaction is of relevance, 
too (Lau & Eley, 2010). Since human brain development is influenced by 
continuing complex interactions of genetic and environmental influences, genetic 
and environmental factors that have been found to be associated with an onset of 
mood disorders will be discussed in this paragraph. It should be noted that 
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relatively little is known about the relative impact of genes and environment on 
grey matter while the brain is actively developing (Lenroot & Giedd, 2008). 
Nevertheless, this paragraph aims at describing genetic and environmental factors 
that have been associated with mood disorders and are thus likely to impact on grey 
matter pathology commonly observed in mood disorders. 
 
1.3.1 Genetic susceptibility factors 
The first indication that genes may contribute towards the pathogenesis of mood 
disorders initially derived from the observation that mood disorders frequently run 
in families (Lau & Eley, 2010). Many different approaches have since been applied 
to examine the role of genetic factors in the aetiology of mood disorders, including 
family and twin study designs as well as molecular genetic analyses such as linkage 
and association approaches. 
 
1.3.1.1 Family and twin studies 
Family studies have shown that mood disorders aggregate within families and as 
such provided the first line of evidence to suggest that they may be heritable (Lau 
& Eley, 2010). Familial aggregation cannot, however, differentiate shared genetic 
from shared environmental influences, but family studies nevertheless provide very 
important information. It has now been established that first-degree relatives of 
MDD patients have a three-fold enhanced risk of developing MDD and that they 
are also three times more likely to suffer from BD as compared to the general 
population (Smoller & Gardner-Schuster, 2007; Sullivan, Neale, & Kendler, 2000). 
By contrast, first-degree relatives of BD patients have a 10-fold excess risk of BD 
as compared to the general population, and a 3-fold increased risk of MDD 
(Smoller & Finn, 2003). Given that MDD is more prevalent in the population than 
BD, the overall risk of developing MDD in first-degree BD relatives is about twice 
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as high as developing BD (Smoller & Gardner-Schuster, 2007). Importantly, these 
findings provide a first line of evidence towards pathogenic overlap between the 
two conditions. 
To estimate the relative contributions of genetic and environmental factors in the 
aetiology of mood disorders, twin study designs provide a powerful tool. In a twin 
study, the concordance rates for a given phenotype (such as MDD or BD) are 
compared between monozygotic twins, who share about 100% of their genetic 
makeup, and dizygotic twins, who share about 50% of their genes. Since pair 
members of both monozygotic and dizygotic twins are considered to be exposed to 
similar family, social, and cultural environmental influences, a comparison of the 
concordance rates for a given phenotype between both groups of twins enables one 
to estimate the extent to which genetic factors play a role in the pathogenesis of the 
condition. Twin studies have consistently demonstrated that there is a strong 
genetic component of susceptibility to mood disorders, with heritability estimates 
ranging from 31-42% for MDD and from 60-85% for BD (Barnett & Smoller, 
2009; Sullivan, et al., 2000). These findings illustrate that there is a strong genetic 
component in the aetiology of mood disorders and that the heritability of BD 
exceeds that of MDD.  
 
1.3.1.2 Molecular genetic studies 
Based on the high heritability estimates from twin studies, it became apparent that 
genes play an important role in the aetiology of mood disorders. However, a large 
magnitude of heritability does not provide any insights into the genetic architecture 
of a disorder such as the specific genes contributing to its development, their 
number and magnitude of effect or their mode of inheritance (Smoller & Gardner-
Schuster, 2007). In an attempt to identify susceptibility genes or chromosome loci 
which house candidate genes for mood disorders, many molecular genetic studies 
have been conducted.  
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The two commonly applied approaches in molecular genetic research are linkage 
and association analyses. Linkage studies are carried out on families with at least 
two family members sharing a specific phenotype such as BD or MDD. This 
approach examines if genetic markers co-segregate within families. Association 
analyses by contrast compare the frequency of genetic markers in non-related 
individuals who do or do not carry the phenotype. A genetic marker is said to be 
associated with the phenotype if it occurs significantly more often in individuals 
with a certain phenotype than in individuals without the phenotype. It has now 
been established that genetic liability for MDD and BD arises from the effects of 
multiple susceptibility genes that are each of small effect and are neither necessary 
nor sufficient for the onset of the disorder (Lau & Eley, 2010).  
Several genome-wide linkage analyses for MDD have been carried out, reporting 
relatively inconsistent findings across various chromosomic regions (Abkevich et 
al., 2003; Camp et al., 2005; Holmans et al., 2007; Zubenko et al., 2003). The 
potentially most important finding is a genome-wide linkage to chromosome 3p25-
26 that has been found in two independent study samples (Breen et al., 2011; 
Pergadia et al., 2011). The linked region contains the gene GRM7 which is known 
to encode a protein for the metabotropic glutamate receptor 7 but also contains 
many other genes (S. P. Hamilton, 2011). 
Association studies are grouped into candidate gene association approaches and 
genome-wide association studies (GWAS). While candidate gene studies examine 
whether a specific a priori selected gene is associated with a disorder, GWAS 
assess the whole genome for association without having to specify candidate genes 
in a hypothesis-free approach. Candidate genes can be selected based on their 
proposed involvement in biological mechanisms underlying the disorder 
(biological candidate gene) or based on their genomic location that has already 
been linked to the disorder in previous research (positional candidate gene). This 
approach suffers several limitations. Firstly, the selection of candidate genes is 
restricted by the current knowledge of the disorder’s biology or insights from 
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linkage or cytogenetic studies. Secondly, the likelihood of false-positive results is 
highly increased due to the limited prior evidence for an involvement of the gene in 
the disorder. Thirdly, most studies have been underpowered to robustly detect 
associations with genes that have small effect sizes, resulting in a disproportionally 
high number of false-negative findings (Smoller & Gardner-Schuster, 2007). The 
latter limitation also applies to GWAS although their sample sizes tend to increase 
more and more. 
Hundreds of putative candidate genes have been investigated in association 
analyses of MDD (see Bosker et al., 2011 for a summary of candidate genes). 
Many of the genes studied are implicated in serotonergic neurotransmission, coding 
for serotonergic receptors or serotonergic transporters since abnormalities of the 
serotonergic system are considered to underlie the pathophysiology of MDD 
(Levinson, 2006). However, the majority of positive findings could not be 
replicated and have not been supported by meta-analyses or GWAS (Anguelova, 
Benkelfat, & Turecki, 2003; Lau & Eley, 2010). More recently, genes involved in 
neuroplasticity have become the focus of attention as it has been hypothesized that 
MDD is caused by stress-induced neurotoxic effects that damage cells of the 
hippocampus, thereby mediating several symptoms of depression (Levinson, 2006).  
Genes involved in the expression of growth and survival-promoting factors such as 
the BDNF gene which encodes the brain derived neurotrophic factor have 
accordingly been studied, with inconsistent results (Lau & Eley, 2010).  
Nine GWAS have been published to date (Aragam, Wang, & Pan, 2011; Kohli et 
al., 2011; Lewis et al., 2010; Muglia et al., 2010; Rietschel et al., 2010; Shi et al., 
2011; Shyn et al., 2011; Sullivan et al., 2009; Wray et al., 2012) but only one of 
these detected a genome-wide association with MDD, namely for the neuron-
specific neutral amino acid transporter SLC6A15 gene (Kohli, et al., 2011). 
Although being the largest GWAS of MDD as yet, a recent GWAS mega-analysis 
failed to identify susceptibility variants on a genome-wide supported level of 
significance (Ripke et al., 2013), and the same applies to a recently conducted 
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GWAS of depressive symptoms that included nearly 35,000 individuals (Hek et al., 
2013). These results imply that the current sample sizes are still underpowered to 
detect small genetic effects that are typical for complex diseases such as MDD 
(Ripke, et al., 2013). It has also been argued that the phenotypic diversity of MDD, 
its underlying genetic heterogeneity and the influence of environmental factors 
towards liability to depression represent major obstacles for the identification of 
susceptibility genes (Kohli, et al., 2011).  
Over the last decades, many linkage studies have been conducted on BD but results 
have been inconclusive (Craddock & Sklar, 2013). An analysis combining eleven 
genome-wide linkage scans of BD has identified genome-wide significance for 
linkage on chromosome 6q for BD-I (McQueen et al., 2005). This region has also 
been identified in an earlier genome-wide linkage analysis (Dick et al., 2003) but 
not in two meta-analyses of BD linkage analyses (Badner & Gershon, 2002; 
Segurado et al., 2003). The power to detect significant results is much greater when 
analysing combined study data than conducting meta-analyses which may explain 
the inconsistencies in findings. One advantage of the linkage approach is that when 
single large families are studied, it is possible to detect rare family-specific genetic 
variants that are involved in BD. This strategy has for example led to the 
identification of the disrupted in schizophrenia 1 (DISC1) locus on chromosome 
1q24 in a large Scottish pedigree in which translocation of the gene co-segregates 
with psychiatric disorders such as BD and schizophrenia (St Clair et al., 1990). It 
has generally been difficult thus far to identify specific genes that contribute 
towards the development of BD on the basis of linkage findings. This phenomenon 
derives at least partly from the fact that the majority of linkage areas contain 
multiple plausible candidate genes which hampers the search (Nurnberger, 2012). 
For BD, candidate gene analyses have predominantly focussed on the 
dopaminergic, serotonergic and noradrenergic systems as these are targeted by 
pharmacological treatment approaches of the disorder. In particular, genes 
encoding the serotonin transporter (5HTT), monoamine oxidase A (MAOA) and 
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catechol-O-methyl-transferase (COMT) have been extensively studied (Craddock 
& Sklar, 2009). Meta-analyses support the association of variation in the gene G72 
(also called DAOA for d-amino acid oxidase activator) which deactivates NMDA 
receptors, the gene encoding 5,10 methylenetetrahydrofolate reductase (MTHFR) 
and the serotonin transporter gene SLC6A4 with BD (Smoller & Gardner-Schuster, 
2007). Moreover, a reasonably consistent association has also been established for 
BDNF (Nurnberger, 2012). GWAS have identified a genome-wide significant 
association with the genes calcium channel, voltage-dependent, L type, alpha 1C 
subunit (CACNA1C), ODZ4 and the neurocan gene NCAN (Cichon et al., 2011; P.  
Sklar et al., 2011). Calcium channels regulate neuronal excitability and are 
involved in long-term potentiation and synaptic plasticity, while the ODZ4 gene is 
potentially involved in cell surface signalling and neuronal pathfinding (Sullivan, 
Daly, & O'Donovan, 2012). NCAN encodes neurocan, an extracellular matrix 
glycoprotein, which is considered to play an important role in cell adhesion and 
migration (Cichon, et al., 2011). Several other putative susceptibility genes for BD 
have been identified through GWAS that did not reach genome-wide significance, 
including DGKH (Baum et al., 2008), MYO5B (P. Sklar et al., 2008), SKAP1 
(Ferreira et al., 2008), PALB2 (The Wellcome Trust Case Control Consortium, 
2007) and many more. 
It has recently been established that part of the genetic risk factors for MDD and 
BD are associated with a wide range of psychiatric disorders, indicating that there 
is a certain amount of pathogenic overlap between different conditions. In 
particular, variation in calcium-channel activity genes seems to play a role in the 
aetiology of many psychiatric disorders, including MDD and BD (Cross-Disorder 






1.3.2 Environmental susceptibility factors 
While genetic factors undoubtedly play an important role in the aetiology of mood 
disorders, several environmental risk factors have also been identified. It has been 
estimated that about 35% - 63% of the variance in liability to MDD and about 21% 
- 38% of the variance in liability to BD can be accounted to individual-specific 
environmental factors that are not shared by family members (Foley, Neale, & 
Kendler, 1998; Kendler, Pedersen, Neale, & Mathe, 1995; Lichtenstein et al., 2009; 
Sullivan, et al., 2000). The contribution of shared environmental effects to the 
aetiology of mood disorders by contrast appears to be minimal (Smoller & Finn, 
2003; Sullivan, et al., 2000). The latter finding does not indicate that shared 
environmental influences such as parental rearing style or poverty are irrelevant, 
but rather suggests that it may be important how an individual interacts with these 
environmental factors or how these factors influence an individual across 
developmental stages (Sullivan, et al., 2000).  
Identified individual-specific environmental risk factors for MDD include 
disturbed parent-child relationships, sexual abuse, divorce, financial difficulties, 
low optimism, stressful life events, exposure to traumatic events, premature 
parental loss, substance misuse, predisposing personality traits, social difficulties 
and low social support (Kendler & Gardner, 2001; Kendler, Gardner, & Prescott, 
2002, 2006). Similarly, susceptibility to BD has been associated with childhood 
abuse, disturbed parent-child relationships, childbirth and stressful life events 
(Alloy et al., 2005; Tsuchiya, Byrne, & Mortensen, 2003). 
 
1.3.3 Gene-environment interplay 
Although genetic and environmental risk factors for major psychiatric disorders 
appear to be easily distinguishable, there is a complex gene-environment interplay 
which complicates our understanding of their aetiology (Lau & Eley, 2010). On the 
one hand, genetic factors can influence the exposure to environmental conditions – 
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this relationship is also known as gene-environment correlation. For example, 
research has shown that there is a genetic influence on the likelihood of stressful 
life events so that genetic vulnerability can lead to a higher probability of stressful 
life events which in turn feedback and increase disease susceptibility (Kendler, 
2001). On the other hand, genetic factors can influence the responses to 
environmental events and environmental events can attenuate genetic risk factors – 
a relationship called gene-environment interaction. For example, genetic 
differences can influence the likelihood that exposure to a stressful life event 
results in pathology (Nugent, Tyrka, Carpenter, & Price, 2011). 
It has been speculated that the exposure to specific environmental experiences may 
explain why one disorder or another develops in vulnerable individuals (Kendler, 
Prescott, Myers, & Neale, 2003). The future of research on the aetiology of mood 
disorders clearly rests on investigating the underlying genetic and environmental 
susceptibility factors and their interplay to determine how these combine to 
produce the observed clinical symptoms specific to each disorder. 
 
1.4 The endophenotype concept 
Our understanding of the pathophysiological mechanisms underlying mood 
disorders is still limited. As highlighted in the previous paragraph, genetic factors 
play an important role in the aetiology of mood disorders but the specific 
susceptibility genes for MDD and BD remain largely unknown. Identifying genes 
that contribute to disease vulnerability holds the potential to obtain important 
insights into the causes of mood disorders that may help to develop novel 
diagnostic and therapeutic strategies (Glahn, Thompson, & Blangero, 2007). It is 
plausible that the heterogeneity of the clinical presentation of MDD and BD as well 
as their multifactorial and polygenic origin complicates the search for disease-
related genes. Therefore, the concept of endophenotypes has been introduced to 
research on complex psychiatric diseases. 
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Endophenotypes represent disease-associated traits that are more closely linked to 
the underlying genetics than the clinical phenotype itself (Gottesman & Gould, 
2003). They are measurable components that are not visible to the unaided eye and 
lie along the causal chain from genetic and environmental influences to their 
behavioural manifestations as symptoms (Peterson & Weissman, 2011). 
Accordingly, the rationale for identifying endophenotypes for psychiatric disorders 
is to detect more successfully susceptibility genes causing the disease, thereby 
providing new insights into the causal biological mechanisms. Gottesman and 
Gould (2003) developed the following criteria to identify endophenotypes: They 
have to be (a) associated with the illness in the population, (b) heritable, (c) 
primarily state-independent, (d) co-segregating with illness within families, and (e) 
found in unaffected relatives at a higher rate than in the general population.  
An endophenotype can be neurophysiological, biochemical, endocrinological, 
neuroanatomical or neurocognitve in nature (Gottesman & Gould, 2003). In the 
following paragraphs 1.5 and 1.6, potential structural grey matter neuroanatomical 
and neurocognitive endophenotypes for MDD and BD are discussed. The major 
focus is placed on Gottesman and Gould’s (2003) criterion 1 and 5, that is evidence 
towards neuroanatomical and cognitive pathology in BD and MDD patients as well 
as their unaffected relatives. 
 
1.5 Structural grey matter abnormalities in mood disorders 
Our understanding of the pathophysiological mechanisms underlying mood 
disorders is still limited. However, the application of neuroimaging techniques has 
remarkably expanded our knowledge of the critical neural processes and brain 
regions associated with the disease. A large body of structural magnetic resonance 
imaging (MRI) studies in mood disorders has now been published, identifying 
several neuroanatomical changes in affected patients and their close unaffected 
relatives. The majority of structural MRI studies are based on volumetric 
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representations of the brain and assess the volume of a brain structure by summing 
up the number of its voxels or by quantifying the proportion of grey matter using a 
voxel-based morphometry (VBM) approach. More recently, it has become possible 
to assess the thickness and surface area of cortical brain regions in an automated 
fashion. Given that cortical grey matter volume is a composite of cortical thickness 
and surface area, with research suggesting that cortical grey matter volume is more 
closely related to surface area than to thickness (Winkler et al., 2009), it appears 
likely that volumetric analyses of brain structures capture mainly surface area but 
not thickness differences.  
This paragraph focuses on volumetric brain abnormalities in patients with mood 
disorders and unaffected relatives because only very few studies have directly 
assessed surface area or cortical thickness in MDD or BD as yet. Accordingly, with 
no meta-analyses being published thus far, the validity of surface area or thickness 
findings remains largely unknown. The findings from cortical thickness and surface 
area studies will therefore be discussed in the context of Chapters 4 and 5. The 
review of volumetric structural brain findings in unaffected relatives of mood 
disorders patients is restricted to relatives of BD patients as this subgroup of high-
risk participants is examined further in the analyses provided in this thesis. 
 
1.5.1 Structural grey matter abnormalities in affected patients 
Structural brain abnormalities have been most consistently detected in the limbic 
system, basal ganglia, frontal and temporal lobes of mood disorders patients 
(Arnone et al., 2009; Beyer & Krishnan, 2002; Bora, Fornito, Pantelis, & Yucel, 
2012; Hallahan et al., 2011; Kempton, Geddes, Ettinger, Williams, & Grasby, 
2008; Kempton et al., 2011; Konarski et al., 2008; Koolschijn, van Haren, 
Lensvelt-Mulders, Hulshoff Pol, & Kahn, 2009; Savitz & Drevets, 2009). In detail, 
a significant enlargement of the lateral ventricles has been repeatedly documented 
in both MDD and BD patients (Dahabra et al., 1998; Hauser et al., 2000; Morys et 
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al., 2003; Zipursky et al., 1997), and been confirmed by meta-analyses for both 
conditions (Arnone, et al., 2009; Kempton, et al., 2008; Kempton, et al., 2011; 
McDonald, Zanelli, et al., 2004) and a recent mega-analysis containing 321 BD 
patients (Hallahan, et al., 2011). This ventricular abnormality has been 
hypothesized to reflect medial temporal lobe, lateral prefrontal cortex or basal 
ganglia volume reductions (Savitz & Drevets, 2009). Other commonly replicated 
structural brain findings in mood disorders are basal ganglia volume abnormalities, 
including the caudate, putamen and globus pallidus (Beyer & Krishnan, 2002; 
Konarski, et al., 2008; Lorenzetti, Allen, Fornito, & Yucel, 2009). While studies 
investigating basal ganglia in BD have been inconsistent, reporting both volumetric 
increases (Arnone, et al., 2009; DelBello, Zimmerman, Mills, Getz, & Strakowski, 
2004; Hallahan, et al., 2011; Strakowski et al., 2002; Wilke, Kowatch, DelBello, 
Mills, & Holland, 2004), decreases (Beyer et al., 2004), or no changes (Haznedar et 
al., 2005; Kempton, et al., 2008; McDonald, Zanelli, et al., 2004), recent meta-
analyses of MDD have repeatedly demonstrated volume reductions of the caudate, 
putamen and globus pallidus (Arnone, McIntosh, Ebmeier, Munafo, & Anderson, 
2012; Kempton, et al., 2011; Koolschijn, et al., 2009). It should be noted that the 
conflicting findings of basal ganglia abnormalities in BD patients are potentially 
caused by confounding effects of length of illness, age of onset and/or (anti-
psychotic) medication (Savitz & Drevets, 2009). In MDD (Arnone, et al., 2012; 
Kempton, et al., 2011; Koolschijn, et al., 2009) but not BD patients (Arnone, et al., 
2009; Hallahan, et al., 2011; Kempton, et al., 2008), the thalamus and hippocampus 
have been found to be reduced in meta-analyses or mega-analyses. Importantly, a 
significant difference between hippocampal volumes of MDD and BD patients has 
been detected, suggesting that decreased hippocampal volume is specific to MDD 
and might differentiate MDD from BD neuropathology (Kempton, et al., 2011). 
Moreover, grey matter reductions of the amygdala have been detected in a meta-
analysis of VBM studies of MDD patients (Bora, et al., 2012) and a mega-analysis 
of first-episode BD subjects (Hallahan, et al., 2011). However, several other meta-
analyses have not detected amygdala differences between affected patients and 
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control subjects (Arnone, et al., 2009; Arnone, et al., 2012; Kempton, et al., 2008; 
Koolschijn, et al., 2009; McDonald, Zanelli, et al., 2004), with findings suggesting 
particularly high heterogeneity of amygdala volume across studies (Kempton, et 
al., 2008; McDonald, Zanelli, et al., 2004) that may partially be linked to 
medication effects, at least in BD patients (Hallahan, et al., 2011). Interestingly, 
smaller amygdala volumes have been particularly observed in paediatric and 
adolescent subjects and larger volumes have been most frequently found in older 
age (Konarski, et al., 2008). 
Strong evidence also points to frontal and temporal lobe differences between 
healthy control subjects and individuals with mood disorders. Grey matter volume 
reductions of the prefrontal cortex have been consistently observed in mood 
disorders (Arnone, et al., 2009; Koolschijn, et al., 2009), particularly in the 
orbitofrontal gyrus as shown by several MDD meta-analyses (Bora, et al., 2012; 
Kempton, et al., 2011; Koolschijn, et al., 2009) and some individual studies and 
one post-mortem analysis of BD patients (Cotter, Hudson, & Landau, 2005; 
Stanfield et al., 2009; Wilke, et al., 2004). Meta-analyses have also provided strong 
evidence towards volume reductions of the inferior, middle and superior frontal 
gyrus in MDD (Bora, et al., 2012; Du et al., 2012) and inferior frontal gyrus 
decreases in BD patients (Bora, Fornito, Yucel, & Pantelis, 2010; Selvaraj et al., 
2012). There is also partial evidence for volume reductions of middle and superior 
frontal regions in BD (Lopez-Larson, DelBello, Zimmerman, Schwiers, & 
Strakowski, 2002; Lyoo et al., 2004). Moreover, anterior cingulate volume 
decreases have been found in MDD (Bora, et al., 2012; Koolschijn, et al., 2009) 
and BD meta-analyses (Bora, et al., 2010). Furthermore, grey matter reductions 
have been observed in the precentral gyrus of MDD patients (Bora, et al., 2012), 
with partial evidence towards volume decreases of this cortical brain region in BD-
I patients (Lyoo, et al., 2004). For the temporal lobe, a meta-analysis of first-
episode MDD patients has found volume reductions of the right superior temporal 
gyrus and the medial temporal lobe, particularly in the parahippocampal gyrus 
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(Bora, et al., 2012). Contrarily, a recent mega-analysis of BD patients identified 
significant temporal lobe volume increases that were most pronounced in the left 
hemisphere (Hallahan, et al., 2011), while a VBM-based meta-analysis detected a 
cluster of grey matter reductions in the right temporal cortex encompassing the 
superior temporal gyrus (Selvaraj, et al., 2012).  
Several of the brain regions altered in mood disorders are considered to participate 
in affect regulation and modulation – a core dysfunction in mood disorders. It has 
been proposed that the interplay of two neural systems is critical to facilitate 
affective processing. The ventral system, comprising the ventral prefrontal cortex, 
amygdala, insula, ventral striatum, thalamus, orbitofrontal gyrus and ventral 
anterior cingulate, is charged with the identification of the emotional significance 
of environmental stimuli, the generation of a subsequent affective state, and the 
production of an autonomic response. The dorsal system which includes the 
dorsolateral prefrontal cortex, the medial prefrontal cortex, the dorsal anterior 
cingulate and the hippocampus, is responsible for the effortful rather than 
automatic regulation of affective states (Phillips, Drevets, Rauch, & Lane, 2003a). 
Theoretically, dysfunction of specific components of the ventral or dorsal system 
or both could be underlying mood dysregulation in BD and MDD (Phillips, 
Drevets, Rauch, & Lane, 2003b). 
 
1.5.2 Structural grey matter abnormalities in unaffected relatives 
Only a few studies have examined whether structural grey matter abnormalities that 
are frequently observed in mood disorders patients also exist in unaffected close 
relatives of BD patients. Some studies did find volume reductions of the caudate in 
unaffected close relatives or twins of BD patients (McDonald, Bullmore, et al., 
2004; McIntosh et al., 2004), while others reported volumetric increases of the 
caudate instead (Hajek et al., 2009b; Noga, Vladar, & Torrey, 2001), and several 
studies did not detect any volumetric abnormality in this brain region to be 
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associated with an increased liability to BD (Ladouceur et al., 2008; Matsuo et al., 
2012; McIntosh et al., 2006). Volume reductions of the putamen have been 
associated with vulnerability to BD (McDonald, Bullmore, et al., 2004), but many 
studies, including region of interest (ROI) analyses, did not replicate this finding 
(Hajek, et al., 2009b; Matsuo, et al., 2012; McIntosh, et al., 2004; McIntosh, et al., 
2006; Noga, et al., 2001). For the pallidum, only non-significant findings have been 
reported (Ladouceur, et al., 2008; McIntosh, et al., 2004; McIntosh, et al., 2006; 
Noga, et al., 2001). McIntosh and colleagues (2004) reported reduced volume of 
the bilateral thalamus in unaffected BD relatives, but others have not shown 
thalamus reductions to be associated with enhanced vulnerability to BD 
(McDonald, Bullmore, et al., 2004; McIntosh, et al., 2006). Ladouceur et al. (2008) 
reported increased hippocampal volumes in young healthy relatives of BD patients 
but the majority of research has not replicated this finding (Connor et al., 2004; 
Hajek et al., 2009a; Matsuo, et al., 2012; McDonald et al., 2006; McIntosh, et al., 
2004; McIntosh, et al., 2006). Boccardi et al. (2010) found enlarged left amygdalae 
in their study cohort. However, others did not detect significant volumetric 
abnormalities of the amygdala or lateral ventricles in high-risk subjects (Hajek, et 
al., 2009a; Kieseppa et al., 2003; Matsuo, et al., 2012; McIntosh, et al., 2004; 
McIntosh, et al., 2006; Noga, et al., 2001). A recent ROI meta-analysis suggested 
indeed that there is no evidence for volumetric reductions of the amygdala, 
hippocampus or basal ganglia in healthy bipolar offspring (Fusar-Poli, Howes, 
Bechdolf, & Borgwardt, 2012). 
A few studies have examined if structural grey matter abnormalities exist in 
cortical brain regions of unaffected BD relatives. Using a twin study design, van 
der Schot and colleagues (2010) found genetic risk of BD to be related to decreased 
grey matter volume in the right medial/dorsolateral frontal gyrus and precentral 
gyrus. McDonald et al. (2004) similarly reported liability to BD to be associated 
with medial frontal gyrus reductions but also found decreased grey matter in the 
anterior cingulate cortex of unaffected BD relatives. One study consisting of young 
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unaffected children and adolescents of BD patients observed a nominal trend 
towards middle frontal gyrus reductions (Ladouceur, et al., 2008), and another 
study reported larger right inferior frontal gyri in unaffected BD relatives (Hajek et 
al., 2013) but many other studies did not find any frontal or temporal grey matter 
abnormalities (Kempton et al., 2009; Kieseppa, et al., 2003; McIntosh, et al., 2004; 
McIntosh, et al., 2006; van der Schot et al., 2009). For the temporal lobe, only 
research by Ladouceur et al. (2008) found increased parahippocampal volumes in 
particularly young BD relatives.  
In summary, there is large discrepancy in findings so that it remains largely 
unknown if any regional grey matter abnormality may serve as a neuroanatomic 
endophenotype for BD. Potential reasons for the observed heterogeneity of findings 
across studies are small samples sizes, small effect sizes of susceptibility genes, 
effects of age, the phenotypic heterogeneity of BD and the possible confounding 
effect of comorbid Axis-I disorders among both the unaffected relatives of BD 
patients as well as the BD patients themselves (Nery, Monkul, & Lafer, 2013). 
 
1.5.3 The importance of studying grey matter pathology in mood disorders 
Grey matter volume assessed with MRI is an indirect measure of a collection of 
various microscopic cellular elements, including neuronal cell bodies, axon 
terminals, dendrites, glial cells and blood vessels (Paus, 2005). Research has 
repeatedly shown that grey matter abnormalities commonly found in mood 
disorders are associated with histopathological abnormalities observed in 
postmortem analyses of MDD and BD patients. For example, postmortem studies 
have shown that the mean density and size of neurons in the orbitofrontal and 
dorsolateral prefrontal cortex is reduced in MDD patients (Rajkowska et al., 1999) 
and that the density of nonpyramidal neurons in the anterior cingulate is decreased 
in BD patients (Todtenkopf, Vincent, & Benes, 2005). 
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Grey matter abnormalities observed in mood disorders using MRI thus point 
towards pathological mechanisms in cellular structures and hold the potential to 
narrow the neurobiological basis of the disorder down, generate new hypotheses 
and stimulate research. For example, findings of grey matter reductions in mood 
disorders have stimulated the rise of the glutamate-induced excitotoxicity 
hypothesis and intensified research in this area (Savitz, Rauch, & Drevets, 2013). 
This theory holds that grey matter decreases in mood disorders result from a loss of 
neuropil which is associated with loss of glial cells, with each of these findings 
arising secondarily to glutamate-induced excitotoxicity (Price & Drevets, 2010). 
Similarly, studying grey matter in individuals at high familial risk of mood 
disorders because of a close family history of the disorder enables one to examine 
whether grey matter pathology in specific brain areas emerges in the absence of 
disease as a consequence of shared genetic and environmental risk factors. This 
approach is particularly suitable to disentangle the pathogenesis of mood disorders 
as it provides important information about brain morphologic vulnerability factors 
that are associated with an increased risk of developing mood disorders and may 
help in the future to predict the onset of disease with high accuracy. 
During early brain development, cortical grey matter volume increases as a 
function of thickening of the cortical mantle, expansion of the cortical surface area 
and gyrification of the cerebral cortex (Winkler, et al., 2009). In particular, grey 
matter volume in frontal and parietal brain regions increases until the ages of 10-12 
years (Giedd et al., 1999). During adolescence and early adulthood, cortical grey 
matter volume decreases in a non-linear fashion across different brain regions. 
Reductions first appear in sensorimotor areas, followed by decreases in the frontal 
cortex, parietal cortex and finally in the temporal cortex (Gogtay et al., 2004). 
These grey matter reductions occurring around late adolescence and early 
adulthood have been linked to increased synaptic and neuronal pruning processes 
taking place at that time (Gogtay, et al., 2004). Interestingly, the onset of BD and 
MDD peaks around early adulthood when pruning processes are known to be 
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taking place. Studying grey matter abnormalities during early adolescence in 
individuals at high risk of mood disorders and affected patients can thus provide 
important new leads on locations of potentially abnormal brain development that 
are associated with enhanced disease vulnerability and the development of the 
disorder, respectively. 
From a clinical perspective, studying grey matter holds the potential to identify 
structural brainmarkers for MDD and BD, thereby supporting the development of 
biologically based tests for psychiatric illnesses (Khandai & Aizenstein, 2013; 
Savitz, et al., 2013). The identification of neuroimaging biomarkers could enhance 
the differential diagnosis of mental disorders, improve the prediction of treatment 
response to pharmacotherapy and psychotherapy options, and potentially facilitate 
treating individuals at enhanced risk of disease prophylactically to prevent 
neurotoxicity and clinical deterioration (Savitz, et al., 2013). 
Next to grey matter abnormalities, white matter pathology has also been linked to 
mood disorders. For example, increased white matter hyperintensities have been 
repeatedly found in BD and MDD patients (Kieseppa et al., 2014; Mahon, Burdick, 
& Szeszko, 2010; Tham, Woon, Sum, Lee, & Sim, 2011). Moreover, regional 
volumetric white matter abnormalities have been frequently observed in BD, 
particularly in (pre)frontal brain regions (Bruno, Barker, Cercignani, Symms, & 
Ron, 2004; McIntosh et al., 2005; Stanfield, et al., 2009). In addition to these 
findings, decreases in white matter integrity in mood disorders as reflected by 
lower fractional anisotropy have been documented in a broad range of white matter 
tracts. For BD and MDD, decreased fractional anisotropy has been most commonly 
observed along prefrontal-subcortical tracts (Adler et al., 2006; Mahon, et al., 
2010; Tham, et al., 2011). Importantly, widespread white matter integrity 
reductions have also been observed in the familial high-risk subjects of this study 
cohort (Sprooten et al., 2011) and in individuals at high risk of BD because of 
subthreshold bipolar symptoms (Paillere Martinot et al., 2014). 
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White matter fibre bundles contain myelinated neuronal axons and glial cells. 
Myelinated axons connect grey matter regions and are integral to neuronal 
communication between grey matter regions (Cannon, 2010). Given the 
interdependency of grey and white matter, it appears important for our 
understanding of the neuropathology of mood disorders to focus both on grey and 
white matter.  
 
1.6 Neurocognitive functioning in mood disorders 
A broad range of cognitive deficits have been observed in mood disorders patients 
and their unaffected relatives. This paragraph focuses on neuropsychological 
deficits in BD and MDD patients as well as their unaffected relatives. The main 
focus of the neuropsychological findings in unaffected relatives of mood disorders 
patients is based on relatives of BD patients as this subgroup of high-risk 
participants is examined further in the analyses provided in this thesis. 
 
1.6.1 Neurocognitive tasks commonly employed in mood disorder research 
To assess sustained attention, variants of the Continuous Performance Task (CPT; 
Kurtz, Ragland, Bilker, Gur, & Gur, 2001) are commonly employed. During the 
task, visual stimuli are presented on a computer screen and participants are asked to 
respond as quickly as possible when a specific stimuli appears and to ignore all 
other stimuli. Relevant stimuli appear only at low frequencies on the computer 
screen and the task usually lasts at least 20 minutes to assess sustained attention 
during a monotonous condition. The most commonly studied performance 
measures include the mean or median of the time needed to respond to relevant 
stimuli (reaction time), the number of incorrect responses (i.e. responding to non-
target stimuli) and the number of omissions (i.e. non-responding to a target 
stimuli). Since neuropsychological deficits in unaffected first-degree relatives of 
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BD patients have been shown to be relatively subtle (Arts, Jabben, Krabbendam, & 
van Os, 2008), it is important to analyse task parameters that vary sufficiently 
between subjects to be able to detect mild cognitive deficits. Therefore, it appears 
advantageous to study the reaction time rather than the number of incorrect 
responses or omissions.  
To assess visual attention and processing speed, the Trail Making Test Part A 
(Reitan, 1958) is commonly used. During this part of the task, participants are 
asked to connect numbers between one and 25 in a consecutive order as fast and 
accurate as possible. The time (measured in seconds) that the subject needs to 
successfully complete the task is a good indicator of psychomotor speed. The Trail 
Making Test A is well-suited to study cognitive performance in individuals with 
mood disorders as well as their unaffected relatives since the assessment of time 
needed to complete the task is measured in seconds and thus allows to detect even 
subtle differences in processing speed. By contrast, an analysis of errors made 
during task performance appears not to be a sensible approach when aiming to 
detect cognitive dysfunction in individuals at high risk of mood disorders since 
neuropsychological deficits have been shown to be mild in this study population 
(Arts, et al., 2008). 
To assess processing speed and cognitive control, variants of Digit Symbol/Coding 
tasks such as the Digit Symbol Substitution Test (DSST; Wechsler, 1955) or the 
Symbol Digit Modalities Test (SDMT; Smith, 1982) are commonly used. During 
the DSST, subjects are required to learn a list of digit-symbol associations (e.g., 1 = 
^, 2 = #, 3 = +, etc.). Subsequently, a list of digits is shown and subjects are asked 
to write down the corresponding symbol for each digit as quickly as possible. The 
SDMT is identical to the DSST but reverses the presentation of the material so that 
a list of symbols is presented and subjects are asked to write down the 
corresponding number for each symbol as quickly as possible. The number of 
correct digit-symbol or symbol-digit associations during a time period of 90 or 120 
seconds provides an indicator of processing speed and cognitive control. Both tasks 
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are highly correlated with each other but SDMT raw scores are consistently lower 
than those of the DSST (Bowler, Sudia, Mergler, Harrison, & Cone, 1992). Since 
neuropsychological deficits in unaffected first-degree relatives of BD patients have 
been shown to be relatively subtle (Arts, et al., 2008), it is important to analyse task 
parameters that vary sufficiently between subjects to be able to detect mild 
cognitive deficits. Therefore, it appears advantageous to assess processing speed 
and cognitive control in high-risk individuals using the SDMT as task performance 
is slightly more challenging.  
Attentional processes and short-term auditory or visuospatial memory can be 
assessed using the Digit Span forwards (Wechsler, 1955), the Spatial Span 
forwards of the Cambridge Neuropsychological Test Automated Battery 
(CANTAB; De Luca et al., 2003) or the Letter-Number Span (Gold, Carpenter, 
Randolph, Goldberg, & Weinberger, 1997). During the Digit Span forwards, 
participants are asked to repeat a string of numbers that is read out to them. During 
the Letter-Number Span, participants are asked to repeat a string of numbers and 
digits that is read out to them. During both tasks, the length of strings presented 
progressively increases (described in detail in paragraph 2.3.3 of Chapter 2). The 
highest amount of digits (or digits and letters for the Letter-Number Span) that a 
participant is able to successfully repeat serves as a measure of attention and 
auditory short-term memory. The Spatial Span forwards can be considered as the 
non-verbal analogue of the Digit Span forwards. During the Spatial Span forwards, 
participants are asked to remember a sequence of squares lighting up on a computer 
screen. Similar to the Digit Span task, the length of sequences of locations 
presented progressively increases. The highest amount of sequences of boxes that a 
participant is able to successfully recall serves as a measure of attention and 
visuospatial short-term memory. Since the highest amount of digits, letters and 
digits or sequences that a participant is able to remember is the only available task 
performance parameter, no alternative performance measure is available that may 
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be superior when examining task performance in unaffected first-degree relatives 
of BD patients. 
To assess attentional processes and short-term verbal (working) memory, the Digit 
Span backwards (Wechsler, 1955) is commonly administered. The task is identical 
to the Digit Span forwards. However, the participant is asked to repeat the strings 
of numbers in reverse order. The task is also fully described in paragraph 2.3.3 of 
Chapter 2. The highest amount of digits that a participant is able to successfully 
repeat in reverse order serves as a measure of attention and auditory short-term 
memory.  
Visual memory can be assessed using subtests of the Wechsler Memory Scale 
(Wechsler, 1987) or the delayed recall of the Rey-Osterrieth Complex Figure Test 
(Rey, 1964b). The Wechsler Memory Scale consists of several subtests to assess 
various components of memory. Tasks assessing visual memory components can 
be grouped together and form the Visual Memory Index, a composite score of 
global visual memory performance. Subtests of the Visual Memory Index of the 
Wechsler Memory Scale include Visual Reproduction I and II. During these two 
tasks, immediate (Visual Reproduction I) and delayed (Visual Reproduction II) 
recall of a visual drawing task is assessed separately. The immediate and 30 
minutes delayed recall of the Rey-Osterrieth Complex Figure Test requires 
participants to reproduce a complex line drawing figure from memory that had 
been previously copied. Since neuropsychological deficits in unaffected first-
degree relatives of BD patients have been shown to be relatively subtle (Arts, et al., 
2008), it is important to analyse task parameters that vary sufficiently between 
subjects to be able to detect mild cognitive deficits. Therefore, it appears 
advantageous to particularly study performance during the delayed stage of the 
task. 
Verbal learning and memory can be assessed using the California Verbal Learning 
Test (CVLT; Delis, Kramer, Kaplan, & Ober, 2000) or the Rey Verbal Learning 
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Task (RVLT; Rey, 1964a). During both tasks, a list of words is read out loud and 
the participant is asked to recall as many words as possible. For the CVLT, the list 
contains 16 words which can be semantically grouped into four categories. For the 
RVLT, the list contains 15 words which are not semantically related to each other. 
The word list of the CVLT or RVLT is then read out four more times to the subject 
and the words recalled are notified each time. Then, an interference list containing 
new words is read out once to the subject and the participant is asked to recall as 
many words as possible from this new list. Subsequently, the short-delay free recall 
of the task is taking place during which subjects are asked to recall again all words 
from the first list. For the CVLT only, this short-delay free recall is followed by the 
short-delay cued recall. During the short-delay cued recall, the subject is presented 
with four categories and asked to recall as many words as possible from the first 
list that belong to a specific category. Then, a 20 minutes delay is taking place 
when administering the CVLT or RVLT, followed by another free recall of the first 
list (long-delay free recall). For the CVLT, this long-delay free recall is followed 
by another cued recall of the first list (long-delay cued recall). Finally, a list of 
words is read out to the participants and they are asked to indicate whether or not 
they think that a given word had been part of the first list or not. For the CVLT and 
RVLT, various performance indices of verbal learning and memory can be 
analysed such as the amount of words correctly recalled during the initial list 
learning stage of the task, the short- and long-delay free recall (and cued recall for 
the CVLT only), the amount of perseveration errors and the amount of intrusions. 
The CVLT is described in more detail in section 2.3.2 of Chapter 2. When studying 
high-risk cohorts, it appears advantageous to administer the RVLT rather than the 
CVLT to assess verbal learning and memory. The RVLT does not rely as 
extensively as the CVLT on executive functions since words cannot be grouped 
into semantic categories and thus provides a purer measure of learning and 
memory. Since words cannot be grouped into categories during the RVLT, this 
verbal learning and memory test is more difficult than the CVLT. Since 
neuropsychological deficits in unaffected first-degree relatives of BD patients have 
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been shown to be relatively subtle (Arts, et al., 2008), it is important to analyse task 
parameters that vary sufficiently between subjects to be able to detect mild 
cognitive deficits. Therefore, it appears advantageous to study verbal learning and 
memory using the RVLT rather than the CVLT.  
Semantic and phonematic verbal fluency can be assessed using the semantic and 
categorical subtests of the Verbal Fluency Test (Benton & Hamsher, 1978). During 
this task, subjects are asked to generate as many words as possible beginning with a 
specific letter (e.g., ‘S’) or belonging to a specific category (e.g., ‘animals’) during 
a period of 60 seconds. The amount of words correctly identified serves as a 
measure of task performance. Additionally, perseverations and errors can be 
assessed. Since neuropsychological deficits in unaffected first-degree relatives of 
BD patients have been shown to be relatively subtle (Arts, et al., 2008), it is 
important to analyse task parameters that vary sufficiently between subjects to be 
able to detect mild cognitive deficits. Therefore, it appears advantageous to study 
the amount of words generated rather than perseverations or errors as these are 
more likely to appear frequently in patients with severe cognitive disabilities.  
To examine executive control and cognitive flexibility, the Trail Making Test part 
B (Reitan, 1958) can be administered. During part B of the Trail Making Test, 
participants are asked to connect numbers and digits in an alternating fashion (e.g., 
1, A, 2, B, 3, C, etc.) as fast and accurate as possible. Task performance relies to a 
large extent on executive function since attention needs to be switched from one 
stimulus dimension to another. Accordingly, the time (measured in seconds) that 
the subject needs to successfully complete the task is a good indicator of cognitive 
control and flexibility. Version B of the Trail Making Test is well-suited to study 
cognitive performance in individuals with mood disorders as well as their 
unaffected relatives since the time needed to complete the task is measured in 
seconds which allows to detect even subtle differences in executive control. By 
contrast, analysing errors made during task performance appears not to be a 
sensible approach when aiming to detect cognitive dysfunction in high-risk 
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individuals since neuropsychological deficits have been shown to be mild in this 
study population (Arts, et al., 2008). 
Apart from the Trail Making Test B, cognitive flexibility can be assessed using 
various card-sorting tests such as the Wisconsin Card Sorting Task (WCST; 
Heaton, 1981), the Modified Card Sorting Task (Nelson, 1976) or the Intra-
/Extradimensional Set Shifting Task (IED) of the CANTAB (Roberts, Robbins, & 
Everitt, 1988). During the WCST, participants are asked to sort cards according to 
a changing rule that is unknown to the subject. The cards can be sorted according 
to shape, colour or number according to visual feedback. When the participant has 
correctly sorted ten cards according to one rule, the rule is changed and the 
participant has to switch to another rule in order to perform the task correctly. In 
total, the rule is changed six times during the task. If a subject fails to learn a rule, 
the task is terminated. By contrast, the Modified Card Sorting Task is a variant of 
the WCST that is less complex and therefore more suitable for cognitively 
impaired individuals. The IED is also a modified version of the WCST that 
assesses different components of cognitive flexibility in a purer form. A detailed 
description of the IED can be found in paragraph 2.3.1 of Chapter 2. Performance 
measures of the WCST include the amount of categories achieved and 
perseveration responses. Categories achieved refers to the number of correct runs 
of ten sorts and can range between zero to six. A score of zero indicates that a 
subject failed to learn the rule so that the task was automatically terminated. A 
score of six indicates that the subject successful learned to sort cards according to 
the changing rules during the task. Since only patients with severe cognitive 
impairments fail to switch responding according to changing rules, this 
performance measure is not suitable when examining high-risk of mood disorders 
cohorts. Perseveration responses occur when a participant continues to sort cards 
according to a previously reinforced rule. Perseveration errors are a good indicator 
of overall task performance and the ability to set shift. Accordingly, it is commonly 
used in high-risk of mood disorders participants.  
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To examine executive control, the Stroop Color-Word Inference Task (Stroop, 
1935) is often administered. During the task, single words are presented in 
coloured ink to the subjects and the subject is asked to name the colour of the ink 
as quickly as possible. The presented words include names of colours that either 
match or conflict with the ink name. Performance indices include the accuracy and 
response time. Since neuropsychological deficits in unaffected first-degree relatives 
of BD patients have been shown to be relatively subtle (Arts, et al., 2008), it is 
important to analyse task parameters that vary sufficiently between subjects to be 
able to detect mild cognitive deficits. Therefore, it appears advantageous to study 
response time rather than the number of errors made. 
To assess immediate and delayed declarative facial memory, the Penn Facial 
Memory Test (Gur et al., 2001) can be administered. During the task, 20 faces are 
presented to the subject. After the initial learning stage of the task, the 20 target 
faces are presented together with 20 new distractor faces. The participant’s score 
reflects the number of correctly recognized target faces and correctly rejected non-
target distractor faces. Moreover, the median response time for correct responses 
serves as a measure of processing speed. After 20 minutes, a long-delay recall is 
taking place. Since neuropsychological deficits in unaffected first-degree relatives 
of BD patients have been shown to be relatively subtle (Arts, et al., 2008), it is 
important to analyse task parameters that vary sufficiently between subjects to be 
able to detect mild cognitive deficits. Therefore, it appears advantageous to 
particularly examine performance during the delayed recall of the task. 
 
1.6.2 Neurocognitive functioning in affected patients 
A broad range of cognitive deficits have been observed in mood disorders patients. 
A recent meta-analysis of neuropsychological performance in first-episode MDD 
patients (Lee, Hermens, Porter, & Redoblado-Hodge, 2012) found cognitive 
impairments in psychomotor speed as measured with the Trail Making Test A 
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(Reitan, 1958), the DSST (Wechsler, 1955) or the SDMT (Smith, 1982). Moreover, 
the authors observed lower attention in the BD patients, assessed with the Digit 
Span forwards (Wechsler, 1955) or the Spatial Span forwards of the CANTAB (De 
Luca, et al., 2003), and visual learning and memory impairments as measured with 
the Visual Reproduction I and II of the Wechsler Memory Scale (Wechsler, 1987), 
the 30 minutes delayed recall of the Rey-Osterrieth Complex Figure Test (Rey, 
1964b) or the Visual Memory Index of the Wechsler Memory Scale (Wechsler, 
1987). Moreover, performance during several domains of executive function was 
significantly worse in first-episode patients than in healthy controls, including 
attentional switching as measured with the Trail Making Test B (Reitan, 1958), 
verbal fluency as assessed with the semantic and categorical subtests of the verbal 
fluency test (Benton & Hamsher, 1978) and cognitive flexibility using the WCST 
(Heaton, 1981), the Modified Card Sorting Task (Nelson, 1976) or the IED of the 
CANTAB (Roberts, et al., 1988). The effect sizes for the identified cognitive 
deficits were small to medium.  
The advantage of studying first-episode MDD subjects is that the 
neuropsychological performance measures are considered to be less confounded by 
duration of illness or medication effects. Research has for example demonstrated 
that neuropsychological impairments are generally greater among MDD patients 
taking psychotropic medication (Snyder, 2013), having more major depressive 
episodes and longer durations of illness (Elgamal, Denburg, Marriott, & 
MacQueen, 2010). 
In a meta-analysis of studies investigating euthymic BD patients, BD was 
associated with worse performance on a number of neuropsychological tests (Arts, 
et al., 2008). The largest effect sizes were observed for working memory as 
measured with the Digit Span backwards (Wechsler, 1955), executive control as 
assessed with the Trailmaking Test B, concept shifting as indicated by 
perseverative errors during the WCST, verbal fluency using words from a defined 
category as measured with the Verbal Fluency Test, delayed and immediate verbal 
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recall during the CVLT (Delis, et al., 2000) and mental speed as measured with the 
DSST. Of note, medium effect sizes were observed for executive control as 
measured with the Stroop Color-Word Inference Task (Stroop, 1935), mental speed 
as assessed with the Trailmaking Test A, delayed visual memory using the Rey-
Osterrieth Complex Figure Test, verbal fluency using words beginning with a 
certain letter as part of the Verbal Fluency Test, sustained attention during the CPT 
(Kurtz, et al., 2001) and concept shifting as indexed by the categories achieved 
during the WCST.  
Similarly, in a large mega-analysis of 1267 euthymic BD patients from 31 
individual studies, Bourne et al. (2013) reported cognitive impairments for all 
studied neuropsychological tests, including various verbal learning and memory 
measures of the CVLT and RVLT (Rey, 1964a), processing speed as assessed with 
the Trail Making Test A and the Digit Span forwards, executive control during 
performance of the Trail Making Test B and cognitive flexibility as assessed with 
the WCST. Since the criteria for an endophenotype include that an endophenotype 
has to be state independent, it is advantageous to study euthymic patients as 
neurocognitive deficits have to be demonstrated in remitted patients to fulfil 
Gottesman and Gould’s (Gottesman & Gould, 2003) criteria.  
 
1.6.3 Neurocognitive functioning in unaffected relatives 
Meta-analyses of neuropsychological performance measures in unaffected first-
degree relatives of BD patients have yielded less widespread neuropsychological 
impairments than observed in mood disorders patients. In particular, executive 
control as measured with the Stroop task and the Trailmaking Task B as well as 
immediate verbal recall during performance of the CVLT have been found to be 
significantly worse in unaffected relatives as compared to control subjects (Arts, et 
al., 2008). By contrast, studying a large sample of multiplex multigenerational 
families, Glahn and colleagues (2010) reported worse performance of first-degree 
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BD relatives on measures of processing speed (Digit-Symbol Coding; Glahn et al., 
2007), working memory as measured with the Object Delayed Reponse task (Glahn 
et al., 2006) and the Letter-Number Span (Gold, et al., 1997) as well as immediate 
and delayed declarative facial memory (Penn Facial Memory Test; Gur, et al., 
2001). BD patients were also impaired on all of these subtests but only three of 
them showed a genetic correlation with affection status and may therefore serve as 
potential neurocognitive endophenotypes: Digit-Symbol Coding, Object Delayed 
Response and immediate facial memory as part of the Penn Facial Memory Test. 
Glahn et al. (2012) also applied a novel approach to facilitate the identification of 
optimal endophenotypes for recurrent MDD. They developed the Endophenotype 
Ranking Value which examines the genetic utility of an endophenotype for a 
disorder by taking in to account the heritability of the disorder, the heritability of 
the candidate endophenotype and their genetic correlation. In a large study 
containing randomly-selected pedigrees, they found several neuropsychological 
measures that may serve as good candidate neurocognitive endophenotypes for 
MDD. These include verbal memory (recognition subtest of the CVLT), working 
memory (Digit Span forwards and Letter-Number Span), facial memory 
(immediate and delayed facial memory subtests of the Penn Facial Memory Test), 
attention (CPT hits and Trail Making Test A) and emotion recognition (Penn Facial 
Memory Test).  
 
1.7 Summary and aims 
The mood disorders BD and MDD are unified by a fundamental disturbance of 
mood. However, they also show a strong heterogeneity with respect to their clinical 
presentation and epidemiological characteristics. For example, MDD has higher 
prevalence estimates, is more common among women than men, is associated with 
an older age at onset and is treated with a different pharmacological approach as 
compared to BD. Despite these differences between the two conditions that suggest 
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a distinct underlying pathology of MDD and BD, research on their genetic 
aetiology also points towards an at least partly shared biological basis.  
Several structural grey matter abnormalities and neurocognitive deficits have been 
detected in mood disorders patients but many findings have been inconsistent 
across studies. Similarly, research on unaffected close relatives has yielded 
inconsistent results. Accordingly, it remains largely unknown which of the 
commonly observed structural brain abnormalities and neuropsychological 
impairments in mood disorders patients are also present in close unaffected 
relatives and may therefore classify as a neuroanatomical or neurocognitive 
endophenotype for the condition. Similarly, it is unclear to what extent structural 
brain abnormalities and cognitive deficits in mood disorders patients and their close 
unaffected relatives change over time. Moreover, there is a lack of prospective 
longitudinal studies examining the nature of neuroanatomical and neurocognitive 
markers in mood disorders patients. For example, it remains controversial if they 
predate the onset of illness, only emerge as a function of illness onset or if they are 
related to medication effects, duration of illness or severity of symptoms. 
Here, I present findings from a prospective longitudinal study of structural MRI 
measures and cognitive functioning in individuals at high familial risk of mood 
disorders who either remained well during a two-year time interval or developed 
MDD. I investigate whether volumes of subcortical brain structures (Chapter 3), 
thickness measures (Chapter 4) or surface area estimates of various cortical ROI 
(Chapter 5) may serve as an endophenotype for mood disorders and if they predate 
the onset of MDD and may therefore distinguish between individuals who develop 
MDD and those who remain well. Moreover, I compare the time-course of the 
structural measures over a two-year time period in high-risk individuals who 
developed MDD, high-risk subjects who remained well and healthy controls. 
Chapter 6 examines whether there are neuropsychological deficits in the high-risk 
group that may form a neurocognitive endophenotype for the condition and if there 
are cognitive deficits that distinguish between individuals who subsequently 
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develop MDD and those who remain well. Moreover, the time-course of cognitive 
deficits over the two-year time interval is investigated. Chapter 7 provides a 
summary of the main findings, lists the methodological limitations of this study and 












2.1 The Bipolar Family Study 
The Scottish Bipolar Family Study is a large prospective longitudinal study of 
individuals at high and low familial risk for mood disorders. It is well designed to 
examine the timing of structural brain abnormalities in mood disorders and their 
relationship to familial risk and onset of illness. The Bipolar Family Study 
examines several neuroscientific dimensions. The initial baseline assessment has 
been conducted between 2007 and 2012 and includes extensive clinical interviews 
and neuropsychological examinations. Moreover, blood samples were taken for 
DNA analysis and structural and functional MRI scans were acquired. The follow-
up assessment has been carried out between 2009 and 2013 and took place 
approximately two years after each participant had completed the initial baseline 
assessment. The second assessment also included a clinical interview and 
neuropsychological testing as well as the acquisition of structural and functional 
MRI scans. The research project is ongoing and currently recruiting individuals for 
their third assessment.  
 
2.1.1 Participants 
Participants of the Bipolar Family Study were either at high familial risk for mood 
disorders or at low familial risk for mood disorders. Individuals are considered at 
high risk of mood disorders because of a close family history of BD. In particular, 
high-risk participants have at least one first-degree or two second-degree relatives 
with a clinical diagnosis of BD-I. As outlined in Chapter 1, mood disorders highly 
co-segregate within families and first-degree relatives of BD patients have a 10-
fold excess risk of BD as compared to the general population, and a 3-fold 
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increased risk of MDD (Smoller & Finn, 2003). Hence, the overall risk of MDD in 
first-degree BD relatives is with 15% about twice as high as the risk of BD since 
MDD is more prevalent in the population than BD (Smoller & Gardner-Schuster, 
2007). Individuals were considered at low familial risk of mood disorders if they 
had no personal or family history of mood disorders. 
Participants at high familial risk of mood disorders were identified via their 
affected relatives as follows: Case loads of psychiatrists across Scotland were 
searched for patients diagnosed with BD-I. The diagnosis of affected subjects was 
confirmed with the Operational Criteria Symptom Checklist (OPCRIT; McGuffin, 
Farmer, & Harvey, 1991) using information from clinical case notes and the 
Structured Clinical Interview for DSM-IV Axis-I Disorders (SCID; First, Spitzer, 
Gibbon, & Williams, 1996). The BD-I patients were asked to identify close family 
members aged 16-25 years. Following informed consent, unaffected individuals 
with at least one first degree, or two second degree relatives with BD-I were invited 
to participate. The high risk of mood disorders participants were currently well and 
did not fulfil any exclusion criteria outlined below. 
Unaffected, unrelated control subjects with no personal or family history of bipolar 
disorder were identified from the social networks of the high risk subjects and 
group-matched for age, sex and premorbid intelligence estimated with the National 
Adult Reading Test (NART; H. Nelson, 1982). Comparison subjects were screened 
for Axis-I disorders using the SCID. 
At baseline assessment, exclusion criteria for all study groups included a personal 
history of major depression, mania or hypomania, psychosis, or any major 
neurological or psychiatric disorder, a history of substance dependence, a history of 
learning disability, any history of head injury that included loss of consciousness 
and any contraindications to MRI.  
Approximately two years after the initial baseline examination, all participants 
were invited for a follow-up assessment. The diagnostic status of consenting 
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subjects who did not return for a second assessment was determined through 
written contact with the National Health Service (NHS). Written informed consent 
was acquired from all subjects and the study was approved by the Multicentre 
Regional Ethics Committee for Scotland. 
 
2.1.2 Clinical assessment 
Clinical assessments were conducted at the time of the first and second MRI scan 
by experienced psychiatrists (Andrew M. McIntosh and Jessica E. Sussmann) using 
the SCID. At both assessments, current manic and depressive symptoms were rated 
using the Young Mania Rating Scale (YMRS; Young, Biggs, Ziegler, & Meyer, 
2000) and Hamilton Depression Rating Scale (HAM-D; M. Hamilton, 1960). 
Whilst there have been a lot of research efforts to determine and quantify 
prodromal symptoms in psychosis (Fusar-Poli et al., 2013), prodromal criteria have 
not yet been applied to the study of mood disorders (Howes et al., 2011). 
Accordingly, no specialised clinical instruments capturing prodromal symptoms for 
mood disorders were available when this study was designed. Moreover, since 
depressed mood, irritability, racing thoughts and physical agitation have been 
associated with a subsequent onset of BD (Howes, et al., 2011), the YMRS, HAM-
D and SCID appear to be well-suited to capture these putative prodromal 
symptoms of BD. Moreover, they are the most commonly applied clinical 
instruments in research on BD and administering them was considered to be 
advantageous given that it maximizes the ability to synthesize findings with other 
studies and increase chances of later replication. 
Based on the follow-up clinical examination or the information provided by the 
case notes, high-risk subjects were grouped into those who remained well (HR-
well), and those who subsequently developed MDD (HR-MDD). In total, 114 high-
risk individuals provided suitable MRI data along with clinical information at 
baseline assessment. Of these, two individuals developed BD-I during the two-year 
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follow-up period and were subsequently excluded from all analyses due to the 
small sample size. Overall, 20 high-risk participants received a diagnosis of MDD 
within the two-year period, but one individual had to be excluded from baseline 
analysis due to unsatisfactory quality of the MRI scan. Accordingly, our analyses 
included 92 HR-well and 19 HR-MDD subjects at baseline. Of the healthy control 
subjects (HC), 96 provided suitable MRI data along with clinical information at 
baseline. Three of them developed MDD in the follow-up period and were 
therefore excluded from all analyses, leading to a sample size of 93 HC subjects. 
At follow-up, 63 HR-well, 20 HR-MDD, and 62 HC subjects provided suitable 
data. Four HR-MDD participants were prescribed antidepressant medication at 
follow-up. Three subjects were taking selective serotonin reuptake inhibitors (1 
fluoxetine, 1 citalopram, 1 sertraline) and one participant was on a tricyclic 
antidepressant (lofepramine). The remaining 16 HR-MDD subjects were 
unmedicated. 
 
2.1.3 Neuropsychological assessment 
Several neuropsychological tasks were administered at baseline and follow-up 
assessment by trained research assistants. These include the IED to assess various 
components of cognitive flexibility, the CVLT to measure verbal learning and 
memory performance and the Digit-Span to assess attentional processes and 
(working) memory functions. A detailed description of these tasks and their 
supposed underlying brain regions are provided in paragraph 2.3 of this chapter.  
 
2.1.4 Magnetic resonance imaging acquisition and pre-processing 
Structural brain imaging at baseline and follow-up assessment was carried out at 
the Brain Imaging Research Centre (BIRC) for Scotland on a GE 1.5 T Signa 
Horizon HDX scanner (GE Medical, Milwaukee, USA). The T1 sequence was a 
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coronal gradient echo sequence with magnetisation preparation (MPRAGE) and 
yielded 180 contiguous 1.2 mm coronal slices (TI = 500 ms; TE = 4 ms; matrix = 
192 x 192; flip angle = 8°).  
The acquired T1 brain images from baseline and follow-up assessments were 
converted to mgz format and processed using the surface-based and volume-based 
streams of the FreeSurfer software package version 5.1.0 
(http://surfer.nmr.mgh.harvard.edu/fswiki/recon-all/). Measures of volume, cortical 
thickness and surface area of several brain ROI were acquired (see paragraph 2.2 
for more details about the processing with FreeSurfer).  
 
2.2 Principles of structural magnetic resonance brain imaging 
Structural MRI is a powerful in-vivo imaging technique that allows to obtain 
noninvasively information regarding the brain’s anatomy. Further processing of the 
acquired MRI data enables the estimation of volume, thickness and surface area of 
several brain structures. 
 
2.2.1 Magnetic resonance imaging 
The development of MRI dates back to the 1940s when scientists at Harvard and 
Stanford University discovered a resonance phenomenon in samples that were 
placed in a magnetic field. Edward Purcell and Felix Bloch were jointly awarded 
the 1952 Nobel Prize for Physics for this ground-breaking discovery (Jezzard & 
Clare, 2008).  
MRI makes use of the magnetic property of the atomic nuclei of hydrogen 
(protons) which are predominantly found in soft tissue of the human body such as 
the brain. A fundamental physical property of protons is that they are positively 
charged and possess an angular momentum which is called ‘spin’. Accordingly, 
protons have a minute magnetic field and tend to align along the direction of an 
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applied magnetic field, similar to a compass needle. If there was no thermal 
agitation of the nuclei, all spins would align parallel to the external magnetic field 
and the nuclear moment would be in the lowest energy state. However, there is 
great amount of thermal agitation of the nuclei at physiological temperature which 
causes the spins to align parallel or anti-parallel (highest energy state) to the 
magnetic field. Only the small imbalance of slightly higher numbers of spins 
pointing parallel than anti-parallel to the field contributes to the net magnetic 
moment of the ensemble (Jezzard & Clare, 2008). 
When a person is placed inside the MRI scanner, a strong magnetic field is 
generated by a large electromagnet which causes the average magnetic moment of 
protons to become aligned along the direction of the magnetic field. Subsequently, 
radiofrequency (RF) energy is briefly applied which induces energy transitions 
between the two energy states and causes the protons aligned with the magnetic 
field to absorb the energy and to flip their spin. The specific frequency of the 
radiofrequency energy is called Lamor or resonance frequency. Depending on the 
selected intensity and duration of the resonance frequeny, the degree to which the 
spin of the proton is affected varies. When the RF magnetic field is switched off, 
the protons release the absorbed energy and their spins return to their initial state of 
equilibrium at a rate determined by the T1 and T2 relaxation times. It is this energy 
which is detected with large coils as a RF signal that forms the final MR signal. 
Depending on the physical and chemical properties of the tissue, the T1 and T2 
relaxation times vary. Spatial localization is obtained by superimposing a spatially 
varying gradient magnetic field on the uniform main magnetic field which causes 
nuclei at different positions to precess at different frequencies. Multiple slices can 
be acquired simultaneously and the distribution of protons can be calculated from 
the signal using inverse Forier transformation (Edelman & Warach, 1993).  
The resulting magnetic resonance images consist of spatially localized signal 
intensities which are represented by greyscale colour codings. Depending on the 
tissue properties, strength of the magnetic field, pulse sequence, and other factors, 
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the signal intensities vary. Images can be T1-weighted which causes fat-containing 
tissues to appear brighter and liquor darker and provides a good contrast of white 
and grey matter. Using T2-weighed images by contrast, liquor appears bright and 
the soft tissue dark. This contrast is for example particularly well suited when 
investigating ischemic lesions (Edelman & Warach, 1993; Jezzard & Clare, 2008). 
 
2.2.2 Processing structural brain images with FreeSurfer 
FreeSurfer is a set of automated tools for subcortical segmentation and 
reconstruction of the brain's surface based on structural MRI data. This freely 
available software package has been developed by the Laboratory for 
Computational Neuroimaging of the Athinoula A. Martinos Center for Biomedical 
Imaging in Boston. It contains a fully automated structural imaging stream for 
processing cross-sectional and longitudinal data. Broadly, there are two different 
processing pipelines. The volume-based stream facilitates the segmentation of 
macroscopically visible subcortical brain structures and calculation of their 
volumes. The surface-based stream facilitates the reconstruction of cortical surfaces 
and provides several measures, including cortical thickness and cortical surface 
area (Fischl, 2012). According to FreeSurfer’s terminology, ‘cortical’ essentially 
refers to brain regions that are considered to be part of the cerebral cortex. By 
contrast, ‘subcortical’ refers to brain structures of the diencephalon (e.g., thalamus) 
or telencephalon (e.g., basal ganglia, amygdala and hippocampus) that are located 
inferior to the cortices of the cerebral cortex. Although the hippocampus is, strictly 
speaking, anatomically part of the cerebral cortex, the term ‘subcortical’ will be 
used throughout the thesis to collectively refer to the diencephalic and 
telencephalic brain structures outlined.  
There are several advantages of using (semi-)automated segmentation tools such as 
FreeSurfer when compared to manual segmentation approaches. First of all, the 
segmentation of regional brain volumes, cortical thickness and surface area using 
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FreeSurfer is less time-consuming and thus less labour-intensive than hand-tracing 
methods. Accordingly, processing large data sets may not be feasible using manual 
segmentation approaches and relies on optimised automated tools (Wenger et al., 
2014). Second, automated morphometry approaches are to a greater extent user 
independent as they do not rely as heavily on expert knowledge in neuroanatomy as 
manual morphometry approaches (Eggert, Sommer, Jansen, Kircher, & Konrad, 
2012). However, it needs to be highlighted that FreeSurfer includes various 
processing steps that have to be checked visually for accuracy and edited where 
required (see paragraphs 2.2.2.1 and 2.2.2.2 for details) so that sufficient 
neuroanatomical expertise is needed, too. Third, when combining data sets from 
different research groups for mega-analysis, segmentation results obtained from 
one specific automated segmentation tool such as FreeSurfer are not prone to 
interindividual differences in employing hand tracing guidelines and may thus 
result in higher interrater reliabilities than manual segmentation methods. However, 
as already pointed out earlier, FreeSurfer also requires visual inspection and 
manual intervention if needed which may also lower interrater reliability. 
Several disadvantages exist when applying automated morphometry approaches. 
First of all, differences in brain structure between individuals may be very subtle 
and automated segmentation tools may not (yet) be able to detect them as 
accurately as neuroanatomical experts do (Eggert, et al., 2012). Second, automated 
tools such as FreeSurfer apply various processing algorithms to the MRI data 
which influence the accuracy of the final neuroanatomical volume, thickness or 
surface area measurements. In particular, it has been shown that the choice of 
algorithms for intensity correction, skull-stripping and tissue class segmentation 
impacts on the quality of the resulting segmentations (Acosta-Cabronero, Williams, 
Pereira, Pengas, & Nestor, 2008; Clark, Woods, Rottenberg, Toga, & Mazziotta, 
2006; Eggert, et al., 2012; Fein et al., 2006). Importantly, research has shown that 
the version of FreeSurfer as well as the type of workstation and operating system 
used interact with these segmentation algorithms and influence the final 
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segmentation results (Gronenschild et al., 2012). Moreover, scanner-specific 
parameters such as type of scanner, field strength and pulse sequence have been 
shown to impact on regional brain volume, cortical thickness and surface area 
estimates (Han et al., 2006; Jovicich et al., 2009; Schnack et al., 2010). 
Accordingly, scientists are advised to segment and parcellate brain regions with 
FreeSurfer for their study cohort in exactly the same manner without changing any 
scanner-specific parameters, updating the FreeSurfer version or changing the type 
of workstation or operating system used for data processing. Although following 
these guidelines will help to achieve high reliability of the resulting brain volumes, 
cortical thickness and surface area estimates, this methodological issue results in 
difficulties when trying to compare and combine data from different study cohorts. 
The FreeSurfer processing pipeline also includes the registration of the MRI scan 
to a brain atlas template which - depending on age, gender, handedness, disease 
status and other features of a study cohort - may not always have a good fit. For the 
volume-based stream of FreeSurfer, registration to the MNI-305 (Evans et al., 
1993) atlas is conducted (see paragraph 2.2.2.1 for details). Given that this atlas 
template is made up of 239 male and 66 female participants (all right-handed) that 
were between 19 and 27 years old, the MNI-305 atlas template appears to fit the 
BFS data satisfactorily given that our sample consists of a similar age range, is 
predominantly right-handed and unaffected by neurological diseases. However, it 
should be considered that the brains of male and right-handed participants may fit 
the brain atlas template better than the brains of female and left-handed subjects. 
For the surface-based stream, the FreeSurfer pipeline aligns the MRI scans to the 
Desikan-Killiany atlas template (Desikan et al., 2006). This gyral-based template 
has been created by averaging MRI scans of 40 subjects who were between 19 and 
86 years old (26 females and 14 males; handedness has not been reported), with 10 
of them suffering from Alzheimer's disease. The rationale for the inclusion of large 
age ranges and Alzheimer's disease patients has been to create an atlas template 
that captures the range of brain atrophy typically found in studies on ageing 
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(Desikan, et al., 2006). Accordingly, it could be assumed that this atlas template 
may not ideally fit the data of the BFS given the young age of the BFS participants. 
However, since the geometry of the grey and white matter boundary drives the 
registration and segmentation process which is completely invariant to grey matter 
atrophy and would require huge amounts of white matter atrophy to result in 
unsatisfactory cortical labelling (personal communication with Dr. Bruce Fischl, 
Professor in radiology and software developer of FreeSurfer), it appears to be 
suitable to use the Desikan-Killiany atlas across all age ranges. Moreover, all 
cortical parcellations were visually inspected for accuracy and edited where 
necessary (see paragraph 2.2.2.2). 
The limitations of FreeSurfer addressed above are particularly important when 
analysing longitudinal data. Research has shown that inter-scan variability due to 
limited accuracy of FreeSurfer may be in the same magnitude as the changes in 
brain morphology over time (Klauschen, Goldman, Barra, Meyer-Lindenberg, & 
Lundervold, 2009). It needs to be highlighted, however, that Klauschen et al. 
(2009) did not manually edit the resulting brain volume segmentations and that 
careful inspection and editing of FreeSurfer's segmentation and parcellation 
boundaries may enhance accuracy and thus allow for detecting subtle changes in 
brain architecture over time. 
Despite these disadvantages of using automated morphometry tools such as 
FreeSurfer that impact on the accuracy and reliability of the resulting brain volume, 
cortical thickness and surface area estimates, both the volume-based and surface-
based approach of FreeSurfer have already been shown to have a good validity 
when compared to manual segmentation (Kuperberg et al., 2003; Morey et al., 
2009; Salat et al., 2004) and to histological analyses (Rosas et al., 2002). Moreover, 
good test-retest reliability has been demonstrated (Clarkson et al., 2011; Han, et al., 
2006; Morey et al., 2010; Wonderlick et al., 2009). To allow for feasibility of this 
research project given its time limitations, it has been decided to process the BFS 
MRI scans with FreeSurfer rather than employing hand-tracing methods. To 
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improve accuracy, all regional brain segmentations and parcellations were visually 
checked and edited where needed as described in paragraphs 2.2.2.1 and 2.2.2.2.  
 
2.2.2.1 The volume-based stream 
The volume-based stream consists of several processing steps that facilitate the 
segmentation and labelling of various brain structures and provides measures of 
their volumes (in mm
3
). The volumes of the following brain structures were 
assessed using the volume-based stream of FreeSurfer for each hemisphere 
separately: caudate, hippocampus, lateral ventricles, pallidum, putamen, thalamus 
and amygdala (see Figure 2.1). The volume-based stream of FreeSurfer has been 
shown to have a good validity when compared to manual segmentation (Dewey et 
al., 2010) and a generally good test-retest reliability except for the amygdala 
(Morey, et al., 2009). 
The volume-based stream consists of several processing stages (Fischl et al., 2002; 
Fischl et al., 2004; 
https://surfer.nmr.mgh.harvard.edu/fswiki/FreeSurferAnalysisPipelineOverview). 
First, the data is converted into mgz format which is readable by the FreeSurfer 
software. Next, non-parametric non-uniform intensity normalization is carried out 
to correct for intensity non-uniformity in the MRI data. Then, an affine registration 
to the MNI-305 atlas is calculated, designed to be insensitive to pathology and to 
maximise the accuracy of the segmentations. The MNI-305 atlas is a template of 
the average of 305 volumetric MRI scans of healthy control subjects which were 
each registered to the Talairach atlas brain (Talairach & Tournoux, 1988). The 
work has been conducted at the Montreal Neurological Institute in Canada, hence 
the name MNI (Evans, et al., 1993). Several of the other processes use Talairach 
coordinates as seed points. Next, an intensity normalisation is carried out to correct 
for fluctuations in intensity due to field inhomogeneity and all voxels are scaled so 
50 
 
that the mean intensity of white matter is 110. Subsequently, non-brain tissue is 
removed using a hybrid watershed deformation procedure (Segonne et al., 2004).  
The resulting skull-stripped brain images were carefully visually inspected and 
edited where necessary according to standard FreeSurfer guidelines 
(http://surfer.nmr.mgh.harvard.edu/fswiki/Edits). An example of the intensity 
normalised brain image before and after the removal of non-brain tissue is shown 








Figure 2.1 Three-dimensional representation of the subcortical ROI extracted with 




Finally, the procedure assigns a neuroanatomical label to each voxel in the 
resulting MRI volume based on a probabilistic atlas and segments the subcortical 
white matter and deep grey matter volumetric brain structures (Fischl, et al., 2002; 
Fischl, et al., 2004). This last step is based on a subject-independent probabilistic 
atlas as well as subject-specific measured values. The atlas is based on a data set of 
manually segmented images that were used to create statistics about the likelihood 
of a particular label being at any given location. The labels are then mapped into 
Talairach space to achieve voxel-wise correspondence for all subjects. Three types 
of probability are calculated at each voxel: (1) the probability that a given voxel 
belongs to each of the label classes (i.e. grey matter, white matter, cerebrospinal 
fluid); (2) the likelihood that a given voxel belongs to a label given the 
classification of its neighbouring voxels; (3) the probability distribution function of 
the measured intensity value. The classification of each voxel to a label is achieved 
by finding the segmentation that maximizes the probability of input given the prior 
probabilities from the probabilistic atlas (Fischl, et al., 2002; Fischl, et al., 2004). 
The final segmentations were carefully visually inspected for accuracy and edited 
Figure 2.2 Visual illustration of a FreeSurfer processed brain scan before (A) and 
after (B) removal of non-brain tissue. 
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according to standard FreeSurfer guidelines (http://surfer.nmr.mgh.harvard.edu/ 
fswiki/Edits) where necessary. A visual representation of the segmentations is 
provided in Figure 2.3. 
 
 
2.2.2.2 The surface-based stream 
The surface-based stream consists of several stages that facilitate the reconstruction 
of cortical surfaces and provides measures of several cortical parameters 
(https://surfer.nmr.mgh.harvard.edu/fswiki/FreeSurferAnalysisPipelineOverview). 
Amongst others, FreeSurfer provides information about volumes (in mm
3
), cortical 
thickness in mm (defined as distance between white and pial surface) and surface 
area (mm²) of many cortical brain regions. The surface-based stream of FreeSurfer 
has been shown to have a good validity when compared to manual measurement 
Figure 2.3 Coronal (A) and horizontal (B) visual illustration of volume-based 
segmented brain regions. Brown: grey matter; white & light green: white matter; 
yellow: hippocampus; dark green: thalamus; pink: putamen; blue: pallidum. 
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(Kuperberg, et al., 2003; Salat, et al., 2004) and to histological analyses (Rosas, et 
al., 2002). Moreover, good test-retest reliability has been demonstrated (Clarkson, 
et al., 2011; Han, et al., 2006). 
There are two types of cortical parcellations available: Cortical measures can either 
be based on the Desikan-Killiany atlas or on the Destrieux atlas. All brain measures 
of this thesis are based on the Desikan-Killiany atlas which subdivides the cerebral 
cortex into several gyral-based neuroanatomical regions (Desikan, et al., 2006). 
The following ROIs were assessed for subsequent analyses for each hemisphere 
(see Figure 2.4): frontal pole, inferior frontal gyrus, middle frontal gyrus, superior 
frontal gyrus, orbitofrontal gyrus (including lateral and medial orbitofrontal gyrus), 
anterior cingulate (including rostral and caudal anterior cingulate), precentral 
gyrus, superior temporal gyrus, parahippocampal gyrus and fusiform gyrus. 
There are several advantages of selecting ROIs for analysis rather than performing 
vertex-wise comparisons. First, the selected ROIs encompass larger brain areas as 
compared to a single vertex and their grey matter estimates are thus supposed to 
vary to a larger extent between individuals and across time. Accordingly, 
comparing cortical surface area and thickness of ROIs cross-sectionally and 
longitudinally appears to be more powerful when aiming at detecting subtle 
differences between groups and over time. Second, findings deriving from the ROI 
approach chosen may provide more meaningful insights into the pathophysiology 
underlying mood disorders than vertex-wise approaches. For example, if cortical 
thickness of a single vertex in the inferior frontal gyrus is found to be reduced in 
high-risk individuals who go on to develop MDD as compared to subjects who 
remain unaffected by the disease, it appears challenging to further investigate and 
interpret the origin of this small-sized brain abnormality. By contrast, if cortical 
thickness of the inferior frontal gyrus as a whole is found to be reduced in high-risk 
individuals who go on to develop MDD as compared to subjects who remain 
unaffected by the disease, this finding can be more easily further investigated using 
fMRI paradigms, postmortem histological analyses or animal models and may lead 
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more easily to new hypotheses regarding the origin and effects of this widespread 
brain abnormality. Third, to avoid false positive findings, analyses are to be 
corrected for multiple testings. Given the relatively small sample size of the HR-
MDD subjects however, it appears vital to select a small number of ROIs to have 
enough statistical power to be actually able to detect significant differences after 
correcting for multiple comparisons.  
Nevertheless, the ROI approach also has several disadvantages. First, small 
circumscribed cortical thickness or surface area abnormalities may not be detected 
because only the mean value of a large brain structure is compared between groups 
and over time. Second, the precise location and extent of cortical thickness or 
surface area abnormalities remains unknown. For example, if cortical thickness in 
the inferior frontal gyrus as a whole is found to be reduced in high-risk individuals 
who go on to develop MDD as compared to subjects who remain unaffected by the 
disease, it remains unknown how the reduced mean cortical thickness emerged. It 
might have been caused by reduced thickness of all vertices of the inferior frontal 
gyrus or it might have been caused by some very extensive thickness reductions in 




The surface-based analysis pipeline consists of several processing steps designed to 
create a three-dimensional model of the cortical surface to extract neuroanatomical 
measures such as cortical thickness and cortical surface area (Dale, Fischl, & 
Sereno, 1999; Fischl, Sereno, & Dale, 1999). First, an affine registration to 
Figure 2.4 Visual representation of the cortical ROIs. 
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Talairach space (Talairach & Tournoux, 1988) is conducted which allows 
FreeSurfer to compute seed points in later processing stages. This is a different 
algorithm than the one used for the volume-based stream. The B1 bias field is 
estimated automatically by measuring variation in white matter intensity. The main 
body of white matter is used to estimate the field across the entire volume. Based 
on their locations in Talairach space, their intensity and the intensity of their local 
neighbouring voxels, likely white matter points are selected. Then, a bias field 
correction is applied by dividing the intensity at each voxel by the estimated bias 
field at that location. Next, non-brain tissue is removed using a hybrid watershed 
deformation procedure  (Segonne, et al., 2004), following segmentation of white 
matter by classifying voxels as either being white matter or non-white matter on the 
basis of intensity, neighbourhood and smoothness constraints (see Figure 2.5). The 
hemispheres are then separated from each other (see Figure 2.5) and the cerebellum 
and the brain stem are removed by cutting planes. The locations of the cutting 
planes are selected on the basis of the expected Talairach locations of the corpus 
callosum and pons as well as several rule-based algorithms that encode the 
expected shape of these structures. The software then generates an initial surface 
for each hemisphere by tiling the outside of the white matter mass for that 
hemisphere, followed by an automated topology correction that removes 
topological defects such as holes in a hemisphere (Fischl, Liu, & Dale, 2001; 
Segonne, Pacheco, & Fischl, 2007). Subsequently, the initial surface is refined 
following intensity gradients to optimally place the grey and white matter borders 
as well as the grey matter and cerebrospinal fluid borders at the location where the 
greatest shift in intensity defines the transition to another tissue class (Dale, et al., 
1999). Accordingly, the surface that follows the intensity gradients between the 
white and grey matter is referred to as white surface and the surface that follows 
the intensity gradients between grey matter and the cerebrospinal fluid is referred 
to as pial surface. The resulting tissue type segmented surfaces were visually 
inspected and edited where necessary according to standard FreeSurfer guidelines 
(http://surfer.nmr.mgh.harvard.edu/fswiki/Edits). An example, illustrating the white 
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As a last processing step, the cortical surfaces are inflated, morphed and registered 
to an average spherical surface representation which utilises individual cortical 
folding patterns to improve the alignment (Fischl, Sereno, & Dale, 1999; Fischl, 
Sereno, Tootell, & Dale, 1999). The cortex is subsequently parcellated into distinct 
brain regions based on the gyral and sulcal structure defined by the Desikan-
Killiany atlas (Desikan, et al., 2006) 
(http://surfer.nmr.mgh.harvard.edu/fswiki/CorticalParcellation). Using this atlas, 
each vertex within each subject's inflated surface is probabilistically annotated with 
a neuroanatomical atlas label. The accuracy of all cortical parcellations was 
inspected visually blind to diagnostic status.  
Figure 2.5 Illustration of the segmentation of white matter (A) and the subsequent 
separation of the two hemispheres (B), represented by distinct intensity values 
which are visualised as different shades of gray. 
58 
 
Measures of cortical thickness and surface area were then extracted for ROIs from 
the data. Cortical thickness is measured as the average shortest distance between 
the white and pial surfaces at each location (Fischl & Dale, 2000). Cortical surface 




2.3 Principles of neuropsychological assessment 
Major attempts have been undertaken to divide neuropsychological functions into 
small distinct cognitive components that are thought to rely at least partially on 
dissociable brain areas. In the BFS, the IED, CVLT and Digit-Span were used to 
cover the main domains of cognitive function. The IED was employed to assess 
Figure 2.6 Visual illustration of the white (shown in yellow) and the pial (shown in 
red) surfaces, overlaid onto the original brain scan. 
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components of executive function (cognitive flexibility and attentional set-
shifting), the CVLT was administered to measure verbal learning and memory 
performance and the Digit-Span was used to assess short term verbal memory and 
attentional processes. Moreover, it was initially decided to include these three 
neuropsychological tasks as studies had previously reported performance 
abnormalities in BD (Arts, et al., 2008). This paragraph introduces the 
neuropsychological concepts of the IED, CVLT and Digit-Span task and highlights 
their proposed underlying neural substrates as these tasks are the focus of Chapter 
6. 
 
2.3.1 The Intra-/Extradimensional Set Shifting Task 
The IED is a computerized adaptation of the WCST and part of the CANTAB. The 
task has been developed to assess different components of cognitive flexibility, 
including attentional set-shifting. It is less complex than the original WCST and 
enables researchers “to study the formation, maintenance and shifting of cognitive 
set in a purer form” (Lawrence, Sahakian, & Robbins, 1998, p. 384). 
The term attentional set-shifting refers to “the ability to switch attention from one 
aspect of a stimulus to another in an ongoing task, in accordance with changing 
reinforcement contingencies” (Chamberlain, Blackwell, Fineberg, Robbins, & 
Sahakian, 2005). This cognitive ability is crucial to flexibly alter behaviour 
according to environmental changes and therefore carries survival value (Kehagia, 
Murray, & Robbins, 2010). Two types of attentional set-shifting have been 
proposed (Downes et al., 1989), intradimensional and extradimensional set-
shifting. An intradimensional shift requires switching attention from exemplars of 
one stimulus dimension (e.g., circles) to newly introduced stimuli of the same 
perceptual dimension or sensory modality (e.g., squares) on the basis of feedback. 
This cognitive ability reflects rule generalisation when novel stimuli are presented. 
In contrast, an extradimensional shift occurs when attention needs to be switched 
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between different perceptual dimensions or sensory modalities (e.g., from lines to 
shapes) on the basis of feedback, and is thought to reflect rule transfer from one 
stimulus dimension to another (Pantelis et al., 1999; Robbins & Arnsten, 2009). 
The IED is made up of nine consecutive stages, with each stage consisting of at 
least six trials. On each trial, two visual stimuli are presented simultaneously on the 
computer screen and subjects are asked to touch (i.e. select) the one that 
subsequently leads to positive visual and auditory feedback. In the beginning of the 
task, the participants can only figure out which of the two stimuli is the relevant 
one by trial and error. However, once they learned which stimulus to select, the 
subjects are instructed to keep on touching the correct stimulus until they realise 
that the rule has changed, in which case they need to start choosing the newly 
relevant stimulus. During the task, the two visual stimuli randomly vary between 
four possible locations on the computer screen. If subjects fail to learn a rule at any 
stage of the task within 50 trials, the whole task terminates.  
During the first stage of the IED, subjects are presented two visual stimuli of the 
same dimension (pink shapes), with one of them being reinforced by positive 
computer feedback. This block requires simple discrimination learning. After 
successfully completing this stage, the same two stimuli are presented during the 
second block of the task. However, the rule is now reversed so that the previously 
irrelevant stimulus becomes relevant. Therefore, stage two is a good indicator of 
reversal learning, “the ability to switch responding to a previously non-reinforced 
stimulus” (Kehagia, et al., 2010). During the third and fourth stage of the task, the 
rule remains unchanged. However, another stimulus dimension is introduced: in 
stage three, white stripes appear adjacent to the pink colour-filled shapes; and in 
stage four, the same white stripes are randomly superimposed on the relevant 
dimension (shapes). After successfully completing these stages, the fifth stage 
begins which contains identical stimuli as the fourth block, however the rule is 
reversed so that the previously irrelevant stimulus becomes relevant. Thus, this 
stage is another indicator of reversal learning. In the sixth stage of the task, novel 
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exemplars of stimuli for both dimensions are introduced and subjects are required 
to shift attention to the novel exemplar of the previously relevant perceptual 
dimension of shapes. This block of the IED is a good measure of intradimensional 
set-shifting, the ability to switch attention from exemplars of one stimulus 
dimension to novel exemplar of the same perceptual dimension. During stage 
seven, the rule is reversed so that the previously not reinforced exemplar of the 
same dimension becomes relevant. Thus, this stage requires reversal learning. The 
eighth stage introduces novel exemplars of stimuli for both dimensions and 
subjects are required to shift attention to the novel exemplar of the previously 
unrewarded perceptual dimension of lines. Thus, this stage assesses 
extradimensional set-shifting, the ability to shift attention between different 
perceptual dimensions. Finally, the rule is reversed in stage nine so that the 
previously irrelevant stimulus of the same perceptual dimension is now reinforced. 
Accordingly, this block is another indicator of reversal learning. 
In summary, performance during stage one is a good indicator of simple 
discrimination learning; stages two, five, seven, and nine are a good measure of 
reversal learning; stage six is an indicator of intradimensional set-shifting; and 
stage eight is a measure of extradimensional set-shifting (see Figure 2.7).  
Early research in marmosets has shown that lesions of the lateral prefrontal cortex 
(BA 9) impair extradimensional, but not intradimensional set-shifting (Dias, 
Robbins, & Roberts, 1996). Of interest, the same study reported that orbitofrontal 
lesions selectively impaired reversal learning, the ability to switch responding to a 
previously non-reinforced stimulus (Kehagia, et al., 2010). Further studies in 
humans have linked extradimensional set-shifting to the function of anterior and/or 
dorsolateral prefrontal regions (Nagahama et al., 2001; Rogers, Andrews, Grasby, 
Brooks, & Robbins, 2000).  
Hampshire and Owen (2006) applied an event related functional MRI (fMRI) 
paradigm which led to the hypothesis that lateral prefrontal, orbital, and parietal 
brain areas may form a supervisory network that controls the focus of attention 
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during task performance but that there is also a potential functional specialisation 
of each brain region. In detail, extradimensional set-shifting has been associated 
with increased activation of the ventrolateral prefrontal cortex, while 
intradimensional set-shifting appears to be particularly influenced by the function 
of the dorsolateral prefrontal and posterior parietal cortex. By contrast, reversal-
learning likely relies especially on the function of the lateral orbitofrontal cortex 
and changes in stimulus-response mapping appear to be mediated by the posterior 
parietal cortex. Finally, the authors showed that the dorsolateral prefrontal cortex 
appears to be generally involved in the search for a solution, but no other specific 








Figure 2.7 The IED task. Blocks 1 and 2 require discrimination and reversal 
learning, respectively. In blocks 3 and 4, a second dimension is introduced. In 
stage 5, the rule is reversed. Novel exemplars of stimuli are introduced in block 6 
and require an intradimensional shift, followed by a reversal of the rule in block 7. 
In block 8, novel exemplars of stimuli are presented and an extradimensional shift 
is required, followed by a reversal of the rule in block 9. Green arrows indicate the 
correct stimulus during each stage of the task. 
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2.3.2 The California Verbal Learning Test 
The CVLT assesses various measures of verbal learning and memory. It should be 
noted that a good performance on the CVLT presupposes organisational strategies 
as learning and memorising the word lists is easier when categorising them into 
different dimensions. Poor task performance therefore does not necessarily reflect 
verbal learning and memory deficits per se but may rather be caused by poor 
strategy formation.  
The CVLT consists of two different lists of words (list A and list B), each 
consisting of 16 words. Every word can be subgrouped into one of four distinct 
categories, with each category being composed of four words. List A is composed 
of four fruits, four herbs and spices, four articles of clothing and four tools. List B 
also contains four names of fruits and four names of herbs and spices (different 
ones than included in List A) but also four types of fish and four types of kitchen 
utensils.  
At first, the examiner reads the words of list A in a pseudo random order to the 
participant with the instruction to recall the words in any given order which enables 
one to assess the subject’s spontaneous use of semantic associations. The list is 
presented for five consecutive times and the words remembered by the subject are 
recorded (free recall of list A). Subsequently, words of the interference list B are 
read to the participant for one single time and the subject again is asked to recall 
the words in any given order (free recall of list B). Next, the subject is asked to 
recall once more the words from list A (short delay recall), immediately followed 
by a cued recall. During the short delay cued recall, the participant is asked to 
recall the items from the different four semantic categories of list A. Subjects who 
have not used semantic clustering during learning trials typically benefit from 
cueing while the performance of participants who have already used this strategy 
usually does not improve. The task is then interrupted for 20 minutes in which the 
participant usually completes other neuropsychological tasks. After the 20 minutes 
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delay, the subject is again asked to recall all words from list A (long delay free 
recall), followed by a cued long delay recall of list A. Finally, the participant is 
presented with words that were either included in list A, items that were not 
included in list A but are from the same categories, items that phonetically 
resemble list A items and every-day items that were not part of list A (recognition).  
Several measures of verbal learning and memory performance can be obtained. The 
number of items from list A that were correctly recalled during all five trials (recall 
of list A) provides a good indicator of verbal learning. The number of items 
remembered during the free recall of list B provides another measure of verbal 
learning performance. It assesses the effects of proactive interference on learning, 
i.e. the effect of prior learning (free recall trials of list A) on the retention of 
subsequently learned items (free recall of list B). The number of recalled words 
during the short delay free and cued recall provide a good estimate of short-term 
verbal memory. The number of recalled words during the long delay free and cued 
recall is a good indicator of long-term verbal memory. The recognition trial enables 
the assessment of discriminality and response biases. Moreover, perseverations 
(repetitions of words that have already been named), false positives (i.e. words 
from list A that were recalled during short or long delay recall trials or words from 
list B that were incorrectly named during other trials) and intrusions (words that 
were recalled during free or cued recall trials that were not part of list A or B) can 
be assessed. Intrusions can be divided into semantic intrusions (words that are 
semantically related to the target word) and non-semantic intrusions (words that are 
not semantically related to any target word).  
fMRI studies indicate that complex functions such as verbal memory are subserved 
by a wide range of brain regions, with each of them being more or less specifically 
engaged during the distinct verbal memory components encoding, consolidation 
and retrieval. Encoding of verbal information has been linked to increased brain 
activation in the left anterior and posterior medial temporal lobe, prefrontal cortex, 
supplementary motor area and the inferior parietal cortex (Jansen et al., 2009). The 
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short-term storage and retrieval of verbal information has been linked to a bilateral 
frontal and parietal network of brain regions, including the posterior inferior 
frontal, anterior middle frontal, anterior cingulate and supramarginal gyrus 
(Henson, Burgess, & Frith, 2000). Long-term memory storage and retrieval of 
verbal information has been linked to a similar network of brain regions as short-
term storage (Andreasen et al., 1995; S. Dupont, Samson, Le Bihan, & Baulac, 
2002). Interestingly, a positive relationship between brain activation in the right 
hippocampus and right frontal lobe and CVLT performance has been established, 
indicating that better verbal memory processing results is higher engagement of 
these brain areas, potentially reflecting particularly efficient encoding and retrieval 
strategies (Johnson, Saykin, Flashman, McAllister, & Sparling, 2001). The 
recognition of learned words has been specifically associated with the function of 
the right dorsolateral prefrontal cortex (Johnson, et al., 2001). 
 
2.3.3 The Digit Span 
The Digit Span is a subtest of the Wechsler Adult Intelligence Scale (Wechsler, 
1997) and assesses attentional processes and short-term verbal (working) memory. 
During the forward condition of the Digit Span, participants are asked to repeat a 
string of numbers. At first, a string of three numbers is read to the subject. During 
the task, the length of strings presented progressively increases. If a participant 
successfully passes the first two trials (e.g., 3 digits), the next two trials are read to 
the subject which contain one more digit than the previous trials (e.g., 4 digits). 
The task is terminated when a participant fails to repeat the string of digits 
correctly for a given length of digits for two consecutive times. The numbers 
should be read by the examiner at a rate one per second in a monotonous way to 
avoid any clustering that aids repetition performance. During the backward 
condition of the Digit Span, exactly the same rules apply. However, the participant 
is asked to repeat the strings of numbers in reverse order. 
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During serial digit learning and recall (forwards), brain activation of the 
hippocampus, superior frontal gyrus and cingulate have been observed for both 
conditions (Karakas & Karakas, 2006). It has been suggested this brain activation 
may reflect various executive function components that are required for a 
successful task performance. Others have reported that a broad bilateral 
frontoparietal network is implicated during task performance, encompassing 
mainly the dorsal prefrontal cortex, premotor cortex, anterior portion of the 
supplementary motor area and inferior parietal lobes (Jantzen, Anderson, 
Steinberg, & Kelso, 2004). Research on the brain regions involved in the backward 
version of the Digit Span which loads more heavily on working memory, has 
shown a positive relationship between task performance and grey matter volumes 
of the right anterior and posterior superior temporal gyrus, left inferior frontal 
gyrus and the left Rolandic operculum (Li, Qin, Zhang, Jiang, & Yu, 2012). Lesion 
and fMRI studies have suggested an involvement of the left inferior parietal cortex, 
left inferior frontal gyrus, dorsolateral prefrontal cortex, anterior cingulate, 
premotor and supplementary motor area in working memory tasks (Li, et al., 2012).  
 
2.4 Statistical analyses 
All statistical analyses were conducted in SPSS version 19 (http://www.spss.com), 
except for False-Discovery Rate (FDR) corrections which were computed in R 
version 2.13.0 (http://www.r-project.org/). Statistical analyses of demographic and 
clinical data were conducted using one way analyses of variance (ANOVA), chi-
squares tests or Kruskal-Wallis tests where appropriate. 
Both cross-sectional and longitudinal analyses in Chapter 3, 4, 5 and 6 were 
conducted to evaluate structural brain differences or neuropsychological 
performance differences between the HC, HR-well and HR-MDD groups at 
baseline and over time. First, a cross-sectional analysis of cortical and subcortical 
brain measures for each ROI and neuropsychological measures that were acquired 
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at baseline assessment was performed. Analyses of covariance (ANCOVA) were 
conducted for each ROI to compare the cortical and subcortical brain measures and 
neuropsychological data between the three groups at baseline, covarying for age 
and sex. For the subcortical volumes, intracranial volume was also included as a 
covariate in the analysis. 
Due to the longitudinal nature and the fact that the data consists of nonuniform 
numbers of repeated measurements, linear mixed-effects models were applied to 
investigate each ROI and neuropsychological performance over time. The linear 
mixed effects model approach has several advantages over the often used repeated-
measures ANOVA design. It takes into account that the baseline and follow-up 
data within each subject are correlated, thereby circumventing the need to make 
adjustments for heteroscedascity and sphericity assumption violations. Moreover, it 
permits the inclusion of multiple measurements per person as well as incomplete 
data sets so that casewise deletion of missing data is not needed, leading to 
increased statistical power (Diggle, Heagerty, Liang, & Zeger, 2013). In the linear 
mixed-effects model used, the intercept term is treated as a random effect that 
varies by individual so that intraindividual correlation among the structural brain 
measures of a particular individual is taken into account. The following 
independent variables were used as predictors of volume for the subcortical and 
cortical ROI and the neuropsychological measures: group, time (baseline versus 
follow-up assessment), group-by-time interaction. Age and sex served as covariates 
in all longitudinal analyses, with intracranial volume being used as an additional 
covariate in the longitudinal analyses of subcortical brain volumes.  
A statistical significance level of p ≤ 0.05 was chosen for both cross-sectional and 
longitudinal analyses, fully corrected for multiple comparisons using the Benjamini 
& Hochberg FDR procedure (Benjamini & Hochberg, 1995). To allow for 
comparison with previous studies, effect sizes for nominal significant group 
differences were additionally calculated using Cohen's d (Cohen, 1988). Wherever 
significant between-group differences were found, pairwise comparisons were 
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performed between the three groups, for which p-values were corrected according 
to Tukey's “Honest significance difference” method (pHSD ≤ 0.05). For significant 
interaction effects in the longitudinal analysis, subsequent pairwise comparisons 
were performed with p-values being adjusted according to Bonferroni procedure 
(pBonf ≤ 0.05). 
To assess the relationship between depression symptoms and each neuroanatomical 
and neurocognitive measures at baseline, Spearman’s rank correlation coefficient 
between the HAM-D sum scores and each subcortical and cortical ROI and 
neuropsychological parameter for each group was calculated. All p-values were 
corrected according to Benjamini & Hochberg FDR procedure and considered 
significant when p ≤ 0.05. To examine whether changes in structural brain 
measures and neuropsychological performance over time are related to changes in 
depression symptom severity, Spearman’s rank correlation coefficients were 
calculated between the change in each neuroanatomical and neurocognitive 
measure and the change of the HAM-D sum score for each group. 
To examine the potentially confounding effects of exposure to medication and 
relatedness of subjects on regional brain volumes, the following additional analyses 
were performed: The analyses were repeated excluding medicated HR-MDD 
subjects (n=4), followed by randomly excluding related subjects (n=2 HC; n=17 













As outlined in chapter 1, mood disorders such as BD and MDD often aggregate 
within families and there is evidence pointing towards an overlap in the 
pathogenesis of the two conditions (Craddock & Forty, 2006). Close relatives of 
BD patients are at enhanced risk for developing mood disorders during the course 
of their lives themselves. First-degree relatives of BD patients have a 10-fold 
excess risk of BD as compared to the general population and a 3-fold increased risk 
of MDD (Smoller & Finn, 2003). Given that MDD is more prevalent in the 
population than BD, the overall risk of MDD in first-degree BD relatives is with 
15% about twice as high as the risk of BD (Smoller & Gardner-Schuster, 2007). 
A large body of structural MRI studies in mood disorders has been published to 
identify structural brain abnormalities that may help to elucidate the 
pathophysiology of the condition. Most consistently, volumetric abnormalities of 
the thalamus, limbic and basal ganglia subcortical regions in affected patients have 
been reported (Arnone, et al., 2009; Beyer & Krishnan, 2002; Bora, et al., 2012; 
Hallahan, et al., 2011; Kempton, et al., 2008; Kempton, et al., 2011; Konarski, et 
al., 2008; Koolschijn, et al., 2009; Savitz & Drevets, 2009).  
In brief, reduced basal ganglia volumes of the caudate, putamen and pallidum have 
been repeatedly documented in MDD (Bora, et al., 2012; Kempton, et al., 2011; 
Koolschijn, et al., 2009), with inconsistent findings being observed for BD (Beyer 
& Krishnan, 2002; Savitz & Drevets, 2009). In MDD but not BD patients, the 
thalamus and hippocampus have been found to be reduced (Arnone, et al., 2009; 
Kempton, et al., 2008; Kempton, et al., 2011; Koolschijn, et al., 2009). Moreover, 
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there is some evidence for volume reductions of the amygdala in both conditions 
(Bora, et al., 2012; Hallahan, et al., 2011). Finally, a significant enlargement of the 
lateral ventricles has been repeatedly documented in both MDD and BD patients 
(Arnone, et al., 2009; Kempton, et al., 2008; Kempton, et al., 2011; McDonald, 
Zanelli, et al., 2004), potentially reflecting medial temporal lobe, lateral prefrontal 
cortex or basal ganglia volume reductions (Savitz & Drevets, 2009). A more 
detailed description of subcortical brain findings in mood disorders is provided in 
Chapter 1. 
Despite strong evidence for subcortical brain abnormalities in mood disorders, their 
aetiology remains largely unknown as most imaging studies have assessed brain 
structure in already affected patients only. These studies cannot discern whether 
structural brain abnormalities represent neuropathological events linked to the 
illness onset, compensatory effects that help to attenuate the severity of the 
condition, nonspecific effects of chronic illness, or effects of medication. They also 
do not provide information to what extent structural brain abnormalities may 
represent neuroanatomical risk markers for mood disorders that are already present 
before illness onset. Only a few studies have examined whether subcortical grey 
matter abnormalities are also evident in unaffected close relatives so that they may 
serve as neuroanatomic endophenotypes for the condition. Imaging studies of 
unaffected relatives of BD patients have yielded inconsistent results, with a recent 
meta-analysis indicating no significant subcortical abnormalities (Fusar-Poli, et al., 
2012). 
The prospective longitudinal Bipolar Family Study is well suited to investigate the 
nature of structural brain changes in mood disorders. The volumes of subcortical 
ROIs were extracted from the baseline and follow-up MRI scans of Bipolar Family 
Study participants and compared cross-sectionally for baseline data and 
longitudinally between the HR-MDD, HR-well and HC groups. The rationale for 
the baseline analysis was to examine whether regional subcortical volume 
abnormalities exist in the HR-MDD group prior to illness onset that may serve as 
72 
 
neuroanatomical markers for a subsequent development of MDD and to assess their 
relationship to familial risk. The longitudinal analysis was intended to explore the 
time course of subcortical brain volumes during a period of two years to detect 
whether abnormal subcortical brain development in the high-risk participants is 
evidence that can be linked to an onset of MDD or familial risk. Similar to a 
repeated measures ANOVA, the longitudinal analysis also allowed for testing with 
an increased power as compared to baseline analysis whether significant 




3.2.1 Participants and clinical assessment 
Participants were recruited as part of the Scottish Bipolar Family Study as outlined 
in more detailed in Chapter 2. At baseline assessment, 93 HC, 92 HR-well and 19 
HR-MDD participants provided suitable data. At follow-up assessment, full data-
sets were available for 62 HC, 63 HR-well and 20 HR-MDD subjects. All groups 
were matched with respect to gender, age and verbal intelligence. The mean age at 
baseline assessment for all groups was 21 years. At follow-up assessment, the 
mean age was 23 years for the HC and HR-MDD groups and 24 years for the HR-
well group. The mean interscan interval (i.e. the time period between the two 
assessments) for all groups was two years (HC: 2.13 years; HR-well: 2.15 years; 
HR-well: 2.10 years). There were no significant differences between the groups at 
baseline or follow-up assessment regarding the YMRS sum score. However, there 
were significant group differences both at baseline and follow-up for depressive 
symptoms assessed with the HAM-D. At baseline, the HR-well and the HR-MDD 
group had significantly higher depression scores (p ≤ 0.047 and p ≤ 0.003, 
respectively) than the HC subjects, with no significant differences between the 
high-risk groups. At follow-up assessment, the HR-MDD had higher depression 
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scores than the HC and the HR-well group (p ≤ 0.013 and p ≤ 0.010, respectively) 
as expected, with no significant differences between the HC and HR-well 
individuals. All demographic and clinical details are provided in Table 3.1.  
 
3.2.2 Magnetic resonance imaging and processing 
Structural MRI scans were acquired on a 1.5 Tesla scanner as outlined in Chapter 
2. The T1 weighted images were processed using the volume-based stream of 
FreeSurfer (fully described in Chapter 2). Based on the literature review provided 
in Chapter 1 and hence the scientific relevance for mood disorders, the volumes of 
the following subcortical brain structures were assessed for each hemisphere 





Table 3.1 Demographic and clinical characteristics 
  Baseline  Follow-up 




















 21.01 (2.45) 21.20 (2.88) 21.10 (2.82) 0.13 0.88  22.82 (2.73) 23.71 (2.84) 23.33 (2.98) 1.77 0.17 




 88:5 81:11 19:0 5.54 0.24  61:1 57:6 20:0 5.43 0.07 
NART IQ 
 
 110.31 (8.00) 108.39 (9.37) 107.26 (6.80) 1.64 0.20  - - - - - 
ISI (years) 
 
 2.13 (0.22) 2.15 (0.22) 2.10 (0.13) 0.20 0.82  - - - - - 
HAM-D* 
 
 0 (1) 0 (2) 1 (5) 9.79 0.01  1 (3) 1 (2) 5 (12) 7.59 0.02 
YMRS*  0 (0) 0 (0) 0 (0) 3.48 0.18  0 (0) 0 (1) 0 (0) 0.79 0.68 
Abbreviations: NART = National Adult Reading Test; ISI = interscan interval; HAM-D = Hamilton Depression Rating Scale; YMRS = Young 
Mania Rating Scale. 
* Kruskal-Wallis test, median and interquartile presented for skewed variables.
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3.2.3 Statistical analysis 
To compare cross-sectionally regional subcortical volume differences between the 
HC, HR-well and HR-MDD groups at baseline, ANCOVA’s were conducted. Age, 
sex and intracranial volume served as covariates in this analysis. Next, linear 
mixed-effects models were applied to investigate subcortical brain volumes for 
each region of interest over time (see Chapter 2 for a more detailed methodological 
description). In the linear mixed-effects model used, the intercept term is treated as 
a random effect that varies by individual so that intraindividual correlation among 
the structural brain measures of a particular individual is taken into account. The 
following independent variables were used as predictors of volume for the 
subcortical regions outlined: group, time (baseline versus follow-up assessment), 
group-by-time interaction. Age, sex and intracranial volume served as covariates in 
the analyses. 
A statistical significance level of p ≤ 0.05 was chosen, fully corrected for multiple 
comparisons using the Benjamini & Hochberg FDR procedure (Benjamini & 
Hochberg, 1995). To allow for comparison with previous studies, effect sizes for 
nominal significant group differences were additionally calculated using Cohen's d 
(Cohen, 1988). Wherever significant between-group differences were found, 
pairwise comparisons were performed between the three groups, for which p-
values were corrected according to Tukey’s HSD procedure (pHSD ≤ 0.05). 
To assess the relationship between depression symptoms and the volumetric 
measures of each ROI, Spearman’s rank correlation coefficients between the 
HAM-D scores and the subcortical regions for each group were calculated. To 
assess the relationship between volumetric changes and changes in depressive 
symptoms over time, Spearman’s rank correlation coefficients were calculated 
between the volumetric differences of the ROIs and the differences of the HAM-D 
scores between the two assessments. For ease of interpretation, data derived from 
the follow-up assessment was subtracted from the data acquired at baseline so that 
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positive values reflect increases in volume or depression symptoms over time, 
while negative values represent decreases of these measures over time. All p-values 
were corrected according to Benjamini & Hochberg FDR procedure and considered 
significant when p ≤ 0.05. 
To examine the potentially confounding effects of exposure to medication and 
relatedness of subjects on regional brain volumes, the following additional analyses 
were performed: The analyses were repeated excluding medicated HR-MDD 




3.3.1 Cross-sectional analysis 
 
3.3.1.1 Group differences at baseline 
At baseline assessment, no significant FDR-corrected differences in regional brain 
volume were found between the groups (see Table 3.2). There was a nominal 
significant group difference for the volume of the right caudate (p ≤ 0.014). Post-
hoc tests indicated that the HR-MDD group had smaller volumes of this brain 
structure than the HC (pHSD ≤ 0.033, d = 0.456) and the HR-well group (pHSD ≤ 
0.011, d = 0.553), with no differences between the HC and HR-well group (pHSD ≤ 
0.999, d = 0.109). 
 
3.3.1.2 Correlation analysis 
There were no significant correlations between the severity of depressive 
symptoms as measured with the HAM-D and subcortical volumes that remained 
significant after FDR correction. However, one nominal significant result was 
detected that just failed the FDR procedure. For the HR-MDD group, the volume of 
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the left lateral ventricle was positively correlated with depressive symptom severity 
(p ≤ 0.005), indicating that higher depression symptoms are associated with larger 
left lateral ventricles. 
 
3.3.1.3 Analysis of potential confounders 
To eliminate the potential confounding effects of familial relatedness of some 
subjects, the analyses were repeated, excluding randomly individuals from the 
same pedigree (Table 3.4). This analysis similarly yielded no significant FDR-
corrected group differences. The nominal significant finding for the right caudate 
in the whole study sample remained nominally significant (p ≤ 0.023). 
 











Volumes are measured in cm
3




 HC  HR-well  HR-MDD    Statistics 
Region Mean (SD)  Mean (SD)  Mean (SD)    F p 
L lat ventricle 6.69 (2.05)  7.17 (2.50)  5.71 (2.45)    1.70 0.19 
R lat ventricle 6.04 (2.44)  6.48 (2.20)  5.40 (2.83)    1.25 0.29 
L caudate 3.68 (0.43)  3.71 (0.44)  3.53 (0.46)    2.41 0.09 
R caudate 3.83 (0.45)  3.88 (0.47)  3.62 (0.47)    4.34 0.01 
L putamen 5.91 (0.78)  6.03 (0.72)  6.09 (0.77)    0.43 0.65 
R putamen 5.71 (0.67)  5.72 (0.61)  5.82 (0.65)    0.11 0.89 
L pallidum 1.94 (0.29)  1.87 (0.29)  1.94 (0.29)    2.26 0.11 
R pallidum 1.86 (0.28)  1.83 (0.29)  1.94 (0.29)    1.19 0.31 
L thalamus 6.58 (0.75)  6.56 (0.73)  6.66 (0.75)    0.58 0.56 
R thalamus 6.62 (0.67)  6.56 (0.73)  6.75 (0.76)    1.43 0.24 
L hippocampus 3.50 (0.45)  3.49 (0.46)  3.61 (0.54)    0.44 0.64 
R hippocampus 3.58 (0.46)  3.56 (0.47)  3.65 (0.59)    0.31 0.74 
L amygdala 1.77 (0.32)  1.79 (0.35)  1.79 (0.34)    0.04 0.96 
R amygdala 1.96 (0.30)  1.92 (0.33)  2.06 (0.33)    2.65 0.07 
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Table 3.3 Correlation between regional subcortical volumes and HAM-D sum 
scores 
 HC  HR-well  HR-MDD 
Region  R p  R p  R p 
L lat ventricle 0.02 0.88  0.11 0.29  0.61 0.01 
R lat ventricle -0.01 0.93  0.09 0.39  0.20 0.42 
L caudate -0.04 0.71  -0.10 0.33  0.14 0.57 
R caudate 0.01 0.96  -0.08 0.48  0.18 0.45 
L putamen 0.11 0.29  -0.02 0.82  0.22 0.37 
R putamen -0.01 0.92  -0.18 0.08  0.16 0.52 
L pallidum -0.01 0.90  0.02 0.86  0.05 0.85 
R pallidum --0.02 0.87  -0.11 0.30  -0.06 0.81 
L thalamus -0.10 0.34  -0.01 0.94  0.16 0.50 
R thalamus -0.03 0.79  -0.13 0.22  0.15 0.55 
L hippocampus 0.03 0.79  -0.07 0.52  0.35 0.14 
R hippocampus -0.05 0.64  0.06 0.58  0.19 0.45 
L amygdala -0.06 0.55  0.05 0.61  -0.37 0.12 
R amygdala 0.12 0.27  -0.06 0.56  0.05 0.85 
Abbreviations: L = left; R = right; lat = lateral. 
 















Volumes are measured in cm
3
. Abbreviations: L = left; R = right; lat = lateral. 
 
 HC  HR-well  HR-MDD S   Statistics 
Region Mean (SD)  Mean (SD)  Mean (SD)    F p 
L lat ventricle 6.68 (2.09)  7.07 (2.78)  5.69 (2.79)    1.40 0.25 
R lat ventricle 6.08 (2.46)  6.52 (2.43)  5.40 (1.89)    1.10 0.34 
L caudate 3.68 (0.43)  3.69 (0.47)  3.54 (0.47)    2.15 0.12 
R caudate 3.83 (0.45)  3.86 (0.49)  3.62 (0.48)    3.84 0.02 
L putamen 5.92 (0.79)  6.04 (0.74)  6.07 (0.79)    0.19 0.83 
R putamen 5.71 (0.67)  5.73 (0.64)  5.80 (0.66)    0.15 0.86 
L pallidum 1.94 (0.29)  1.87 (0.29)  1.95 (0.29)    2.82 0.06 
R pallidum 1.86 (0.28)  1.82 (0.30)  1.95 (0.29)    1.99 0.14 
L thalamus 6.58 (0.76)  6.58 (0.73)  6.69 (0.76)    0.76 0.47 
R thalamus 6.62 (0.68)  6.56 (0.71)  6.77 (0.78)    1.97 0.14 
L hippocampus 3.50 (0.45)  3.48 (0.46)  3.59 (0.55)    0.64 0.53 
R hippocampus 3.59 (0.46)  3.56 (0.48)  3.65 (0.61)    0.65 0.52 
L amygdala 1.76 (0.32)  1.79 (0.34)  1.82 (0.31)    0.09 0.91 
R amygdala 1.96 (0.30)  1.91 (0.33)  2.04 (0.33)    2.65 0.07 
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3.3.2 Longitudinal analysis 
 
3.3.2.1 Group differences over time 
The linear mixed-effects model analyses revealed no significant effects of group, 
time or group-by-time interaction (see Table 3.5). A trend towards a significant 
group effect was observed for the right caudate (p ≤ 0.024), with the HR-MDD 
group having smaller volumes than the HC (pHSD ≤ 0.024, d = 0.639) and the HR-
well (pHSD ≤ 0.016, d = 0.687) group across time. This effect was only significant at 
nominal level and did not survive FDR correction. No nominal significant effect of 
time or group-by-time interaction for the right caudate was detected. There was a 
nominally significant group-by-time interaction for the volume of the left amygdala 
(p ≤ 0.036), with no (nominal) significant effect of group or time. Post-hoc 
analyses revealed that the volume of this structure decreased over time in the HR-
well as compared to the HC group that in turn displayed volumetric increases (pHSD 
≤ 0.024, d = 0.376). No significant interaction effects for the HR-MDD as 
compared to the HC group (pHSD ≤ 0.504, d = 0.291) and the HR-well as compared 
to HR-MDD participants (pHSD ≤ 0.158, d = 0.134) were found.  
 
3.3.2.2 Correlation analysis 
There were no significant FDR-corrected correlations between changes in the 
severity of depressive symptoms as measured with the HAM-D and changes in 
subcortical volumetric measures over time (see Table 3.6). However, several 
correlations that were significant at a nominal significance level were observed for 
the HR-well group. Volumetric changes of the left thalamus were positively 
correlated with changes in depressive symptoms (p ≤ 0.009), indicating that 
volume increases of this subcortical structure over time are associated with 
increases in depressive symptoms. Moreover, changes of the volume of the right 
hippocampus (p ≤ 0.030) and right putamen (p ≤ 0.036) were positively correlated 
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with depressive symptom changes, suggesting that volumetric increases in these 
brain regions over time are associated with increasing depressive symptoms. No 
nominal significant correlations were observed for the HC and HR-MDD group.  
 
3.3.2.3 Analysis of potential confounders 
To eliminate the potential confounding effects of familial relatedness of some 
subjects, the longitudinal analyses were repeated, excluding randomly individuals 
from the same pedigree (Tables 3.7). This analysis similarly yielded no significant 
FDR-corrected effect of group, time or group-by-time interaction. Also, when 
excluding medicated HR-MDD subjects from the analysis, no significant effects 
were observed (Table 3.8). 
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Table 3.5 Longitudinal analysis of regional subcortical volumes 
Volumes are measured in cm
3
. Abbreviations: L = left; R = right; lat = lateral. 
 
 
 HC  HR-well  HR-MDD  Statistics 
 Baseline Follow-up  Baseline Follow-up  Baseline Follow-up    Group effect Time effect GroupXTime 
Region Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)    F p F p F p 
L lat ventricle 6.69 (2.05) 6.98 (2.74)  7.17 (2.50) 7.28 (2.69)  5.71 (2.45) 5.57 (2.65)    1.25 0.29 1.80 0.18 0.62 0.54 
R lat ventricle 6.04 (2.44) 6.27 (2.06)  6.48 (2.20) 6.56 (2.38)  5.40 (2.83) 5.46 (2.01)    0.79 0.46 0.88 0.35 0.13 0.88 
L caudate 3.68 (0.43) 3.70 (0.53)  3.71 (0.44) 3.60 (0.45)  3.53 (0.46) 3.44 (0.51)    1.74 0.18 2.03 0.16 1.27 0.28 
R caudate 3.83 (0.45) 3.89 (0.59)  3.88 (0.47) 3.83 (0.49)  3.62 (0.47) 3.51 (0.50)    3.81 0.02 0.48 0.49 0.92 0.40 
L putamen 5.91 (0.78) 6.02 (0.83)  6.03 (0.72) 6.01 (0.82)  6.09 (0.77) 5.77 (0.83)    0.11 0.90 1.22 0.27 2.42 0.09 
R putamen 5.71 (0.67) 5.81 (0.71)  5.72 (0.61) 5.69 (0.72)  5.82 (0.65) 5.40 (0.79)    0.45 0.64 2.34 0.13 2.52 0.08 
L pallidum 1.94 (0.29) 1.93 (0.29)  1.87 (0.29) 1.88 (0.33)  1.94 (0.29) 1.90 (0.27)    1.27 0.28 0.19 0.66 0.26 0.78 
R pallidum 1.86 (0.28) 1.85 (0.32)  1.83 (0.29) 1.79 (0.33)  1.94 (0.29) 1.83 (0.25)    1.04 0.36 2.93 0.09 0.58 0.56 
L thalamus 6.58 (0.75) 6.60 (0.66)  6.56 (0.73) 6.38 (0.76)  6.66 (0.75) 6.39 (0.74)    0.88 0.42 2.98 0.09 1.42 0.24 
R thalamus 6.62 (0.67) 6.68 (0.70)  6.56 (0.73) 6.48 (0.79)  6.75 (0.76) 6.55 (0.79)    1.10 0.33 0.85 0.36 1.04 0.36 
L hippocampus 3.50 (0.45) 3.47 (0.49)  3.49 (0.46) 3.41 (0.40)  3.61 (0.54) 3.44 (0.53)    0.37 0.69 2.64 0.11 0.28 0.76 
R hippocampus 3.58 (0.46) 3.65 (0.52)  3.56 (0.47) 3.47 (0.38)  3.65 (0.59) 3.38 (0.54)    1.58 0.21 3.33 0.07 2.54 0.08 
L amygdala 1.77 (0.32) 1.83 (0.33)  1.79 (0.35) 1.67 (0.27)  1.79 (0.34) 1.72 (0.23)    1.55 0.22 1.14 0.29 3.40 0.04 
R amygdala 1.96 (0.30) 1.97 (0.30)  1.92 (0.33) 1.92 (0.27)  2.06 (0.33) 1.91 (0.26)    1.31 0.27 1.20 0.28 1.12 0.33 
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Table 3.6 Correlation between changes in regional subcortical volumes and 
changes in HAM-D sum scores 
 HC  HR-well  HR-MDD 
Region  R p  R p  R p 
L lat ventricle -0.06 0.71  0.10 0.51  0.22 0.44 
R lat ventricle -0.19 0.43  0.13 0.37  0.20 0.48 
L caudate -0.11 0.47  0.27 0.06  0.04 0.88 
R caudate -0.13 0.40  0.27 0.06  0.02 0.95 
L putamen -0.16 0.29  0.05 0.74  0.02 0.94 
R putamen -0.15 0.31  0.30 0.04  -0.10 0.72 
L pallidum -0.05 0.75  0.28 0.05  0.19 0.51 
R pallidum -0.20 0.18  0.13 0.36  0.31 0.26 
L thalamus -0.11 0.47  0.37 0.01  0.11 0.69 
R thalamus -0.18 0.23  0.07 0.64  0.22 0.43 
L hippocampus -0.06 0.71  0.19 0.19  0.15 0.59 
R hippocampus -0.17 0.26  0.31 0.03  0.28 0.32 
L amygdala 0.02 0.91  -0.05 0.74  -0.07 0.80 
R amygdala -0.12 0.48  0.03 0.86  0.37 0.17 






Table 3.7 Longitudinal analysis of regional subcortical volumes in unrelated subjects 
 HC  HR-well  HR-MDD  Statistics 
 Baseline Follow-up  Baseline Follow-up  Baseline Follow-up  Group effect Time effect GroupXTime 
Region  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  F p F p F p 
L lat ventricle 6.68 (2.09) 6.99 (2.07)  7.07 (2.78) 7.08 (2.38)  5.69 (2.79) 5.59 (2.33)  0.91 0.40 1.20 0.28 0.73 0.48 
R lat ventricle 6.08 (2.46) 6.27 (2.31)  6.52 (2.43) 6.47 (2.35)  5.40 (1.89) 5.46 (2.19)  0.62 0.54 0.52 0.47 0.28 0.75 
L caudate 3.68 (0.43) 3.70 (0.53)  3.69 (0.47) 3.57 (0.43)  3.54 (0.47) 3.43 (0.52)  1.53 0.22 2.75 0.10 1.65 0.20 
R caudate 3.83 (0.45) 3.89 (0.59)  3.86 (0.49) 3.78 (0.48)  3.62 (0.48) 3.51 (0.51)  2.89 0.06 0.92 0.34 1.25 0.29 
L putamen 5.92 (0.79) 6.02 (0.82)  6.04 (0.74) 5.91 (0.74)  6.07 (0.79) 5.75 (0.84)  0.01 0.99 2.50 0.12 3.22 0.04 
R putamen 5.71 (0.67) 5.81 (0.70)  5.73 (0.64) 5.62 (0.70)  5.80 (0.66) 5.36 (0.79)  0.84 0.45 3.67 0.06 2.89 0.06 
L pallidum 1.94 (0.29) 1.93 (0.29)  1.87 (0.29) 1.84 (0.34)  1.95 (0.29) 1.89 (0.27)  2.08 0.13 0.98 0.33 0.32 0.72 
R pallidum 1.86 (0.28) 1.85 (0.32)  1.82 (0.30) 1.73 (0.30)  1.95 (0.29) 1.83 (0.26)  2.64 0.07 5.01 0.03 1.05 0.35 
L thalamus 6.58 (0.76) 6.60 (0.66)  6.58 (0.73) 6.34 (0.70)  6.69 (0.76) 6.32 (0.69)  1.08 0.34 4.81 0.03 2.16 0.12 
R thalamus 6.62 (0.68) 6.68 (0.70)  6.56 (0.71) 6.38 (0.72)  6.77 (0.78) 6.51 (0.78)  2.13 0.12 2.21 0.14 1.92 0.15 
L hippocampus 3.50 (0.45) 3.46 (0.49)  3.48 (0.46) 3.38 (0.39)  3.59 (0.55) 3.41 (0.53)  0.50 0.61 2.95 0.09 0.34 0.71 
R hippocampus 3.59 (0.46) 3.65 (0.52)  3.56 (0.48) 3.44 (0.37)  3.65 (0.61) 3.33 (0.52)  2.19 0.12 4.52 0.04 2.88 0.06 
L amygdala 1.76 (0.32) 1.83 (0.33)  1.79 (0.34) 1.67 (0.27)  1.82 (0.31) 1.73 (0.23)  1.34 0.26 1.46 0.23 3.40 0.04 
R amygdala 1.96 (0.30) 1.97 (0.30)  1.91 (0.33) 1.90 (0.27)  2.04 (0.33) 1.90 (0.27)  1.55 0.22 1.15 0.26 0.82 0.44 
Volumes are measured in cm
3







Table 3.8 Longitudinal analysis of regional subcortical volumes in unmedicated HR-MDD subjects 
 HC  HR-well  HR-MDD  Statistics 
 Baseline Follow-up  Baseline Follow-up  Baseline Follow-up  Group effect Time effect GroupXTime 
Region (Gyrus) Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  F p F p F p 
L lat ventricle 6.68 (2.09) 6.99 (2.07)  7.07 (2.78) 7.08 (2.38)  5.87 (2.60) 5.83 (2.23)  0.86 0.43 2.01 0.16 0.37 0.69 
R lat ventricle 6.08 (2.46) 6.27 (2.31)  6.52 (2.43) 6.47 (2.35)  5.44 (1.75) 5.63 (2.28)  0.66 0.52 0.91 0.34 0.09 0.91 
L caudate 3.68 (0.43) 3.70 (0.53)  3.69 (0.47) 3.57 (0.43)  3.59 (0.44) 3.45 (0.45)  1.36 0.26 2.21 0.14 1.35 0.26 
R caudate 3.83 (0.45) 3.89 (0.59)  3.86 (0.49) 3.78 (0.48)  3.70 (0.44) 3.50 (0.42)  2.78 0.06 1.01 0.32 1.28 0.28 
L putamen 5.92 (0.79) 6.02 (0.82)  6.04 (0.74) 5.91 (0.74)  6.21 (0.75) 5.73 (0.67)  0.12 0.89 1.92 0.17 2.92 0.06 
R putamen 5.71 (0.67) 5.81 (0.70)  5.73 (0.64) 5.62 (0.70)  5.96 (0.60) 5.57 (0.58)  0.25 0.78 1.81 0.18 2.08 0.13 
L pallidum 1.94 (0.29) 1.93 (0.29)  1.87 (0.29) 1.84 (0.34)  1.96 (0.29) 1.88 (0.28)  1.25 0.29 0.55 0.46 0.54 0.58 
R pallidum 1.86 (0.28) 1.85 (0.32)  1.82 (0.30) 1.73 (0.30)  1.97 (0.30) 1.81 (0.23)  1.10 0.34 4.40 0.04 1.16 0.32 
L thalamus 6.58 (0.76) 6.60 (0.66)  6.58 (0.73) 6.34 (0.70)  6.75 (0.67) 6.38 (0.67)  0.94 0.39 3.97 0.05 1.79 0.17 
R thalamus 6.62 (0.68) 6.68 (0.70)  6.56 (0.71) 6.38 (0.72)  6.87 (0.67) 6.50 (0.63)  1.22 0.30 1.98 0.16 1.72 0.18 
L hippocampus 3.50 (0.45) 3.46 (0.49)  3.48 (0.46) 3.38 (0.39)  3.60 (0.55) 3.45 (0.56)  0.34 0.72 1.81 0.18 0.14 0.87 
R hippocampus 3.59 (0.46) 3.65 (0.52)  3.56 (0.48) 3.44 (0.37)  3.67 (0.60) 3.34 (0.56)  1.65 0.20 4.49 0.04 3.14 0.05 
L amygdala 1.76 (0.32) 1.83 (0.33)  1.79 (0.34) 1.67 (0.27)  1.76 (0.37) 1.72 (0.19)  1.61 0.20 0.72 0.40 3.38 0.04 
R amygdala 1.96 (0.30) 1.97 (0.30)  1.91 (0.33) 1.90 (0.27)  2.02 (0.34) 1.90 (0.25)  1.07 0.35 0.68 0.41 0.67 0.51 
Volumes are measured in cm
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The baseline and longitudinal analyses yielded no significant volumetric 
differences of subcortical brain structures between the groups. However, a nominal 
significant group effect for the right caudate was found both cross-sectionally and 
longitudinally as well as a nominal significant group-by-time interaction for the left 
amygdala. Since this is, to the best of my knowledge, the first prospective 
longitudinal study examining regional subcortical volumes in high-risk of mood 
disorders individuals who were unaffected at initial assessment and subsequently 
either developed MDD or remained well, the discussion focuses on cross-sectional 
analyses.  
The baseline analysis yielded no significant volumetric differences of subcortical 
brain structures between the groups. This finding suggests that young adults at high 
risk of mood disorders because of a close family history of BD do not exhibit 
subcortical volumetric brain abnormalities, regardless of a subsequent onset of 
MDD or not. These results are in line with a recent meta-analysis that did not find 
evidence towards subcortical volumetric brain abnormalities in unaffected relatives 
of BD patients (Fusar-Poli, et al., 2012) and indicate that subcortical brain 
abnormalities do not emerge as a consequence of being at high familial risk for 
mood disorders. Moreover, they appear not to predate an onset of MDD and are 
thus unlikely to be neurodevelopmental in nature.  
The longitudinal analysis also did not reveal any significant effect of group, time or 
group-by-time interaction. These non-significant findings are in contrast to the 
often observed subcortical brain abnormalities in mood disorder patients (Konarski, 
et al., 2008; Koolschijn, et al., 2009). Accordingly, volumetric subcortical brain 
abnormalities in MDD do not appear to emerge prior to illness onset or as a 
consequence of illness-specific mechanisms that are directly linked to the onset of 
the disorder. Rather, it appears likely that volumetric differences only emerge 
during the course of the disorder or in conjunction with psychopharmacological 
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treatment effects. Subcortical brain volumes may also be influenced by the severity 
or length of illness, the age at illness onset or the length and type of 
psychopharmacological treatment. 
Although not significant when FDR-corrected, a nominal significant group effect 
for the volume of the right caudate was found during the baseline and longitudinal 
analyses, indicating smaller volumes in the HR-MDD as compared to the other two 
study groups across both time points. Volume reductions of the caudate in MDD 
patients have been repeatedly documented in volume-based and VBM-based meta-
analyses (Arnone, et al., 2009; Bora, et al., 2012; Kempton, et al., 2011; 
Koolschijn, et al., 2009). Given that our HR-MDD group consisted of 20 
participants only, it may well be that our study sample was underpowered to detect 
this subtle volumetric abnormality. For example, a study by Bremner et al. (2000) 
which consisted of 16 MDD patients did not find volumetric differences of the 
caudate, while Dupont and colleagues (1995) observed a trend towards significant 
volume reductions in a study sample of 30 MDD participants, and in a large study 
sample of 50 MDD patients significant caudate reductions were evident (Krishnan 
et al., 1992). Furthermore, our analysis might have lacked power given that we 
investigated young adults with an early onset MDD as it has been shown that 
volume reductions of the caudate are more pronounced in older individuals with a 
late onset of depression as compared to young MDD patients (Greenwald et al., 
1997). It has also been established that the caudate is particularly decreased in 
severe and treatment-resistant subtypes of depression (Shah, Glabus, Goodwin, & 
Ebmeier, 2002). Given that the majority of the HR-MDD participants of our study 
were not receiving pharmacological treatment for depression and that the average 
HAM-D depression sum score at follow-up assessment was only 5 suggests that the 
symptoms of several individuals were already in remission or mild rather than 
severe. This difference in clinical presentation of the disorder may consequently 
have led to smaller caudate atrophy that is more difficult to detect.  
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Clearly, further longitudinal research with larger sample sizes is needed to clarify if 
the observed nominal significant caudate abnormalities are deemed correct. 
Nevertheless, the findings provide a first hint to suggest that subtle volume 
reductions of the right caudate exist in individuals at familial risk of mood 
disorders who go on to develop MDD and that these remain relatively stable across 
a two-year period of time. Given that there was no evidence towards an effect of 
time or group-by-time interaction, the volumetric decreases cannot be associated 
with the onset of illness but are rather likely to either represent illness-associated 
processes that are already evident two years before the illness onset or are 
neurodevelopmental in nature which may enhance vulnerability to MDD.  
From a functional perspective, the caudate forms together with the putamen the 
striatum which has been traditionally associated with the regulation of motion 
(Savitz & Drevets, 2009). More recently, the striatum has been shown to play an 
important role in mood regulation, cognitive processes and motivation through its 
involvement in several parallel organised cortical-subcortical circuits (Tekin & 
Cummings, 2002). Accordingly, disturbed function of these processes holds the 
potential to mimic the symptoms of depression and mania. In concert with the just 
said, a tryptophan depletion study found depression severity to be linked to reduced 
caudate activity (K. A. Smith, Morris, Friston, Cowen, & Dolan, 1999), while 
manic episodes have been associated with striatal overactivity during reward-
related tasks (Savitz & Drevets, 2009). 
A nominal significant group-by-time interaction was observed for the volume of 
the left amygdala that did not survive FDR correction. The interaction was driven 
by the HR-well group displaying decreasing left amygdala volume over time as 
compared to the HC group which in turn showed a volumetric increase. Although 
not being significant when corrected for FDR, this result may give a first hint of 
evidence to suggest that young unaffected relatives of BD patients display an 
abnormal volumetric decrease of the left amygdala in their early 20s that may 
represent neurodevelopmental processes associated with enhanced vulnerability for 
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mood disorders. Previous cross-sectional studies have not detected volume 
reductions of the amygdala in close relatives of BD patients (Fusar-Poli, et al., 
2012), with studies on BD patients providing inconsistent findings of volumetric 
increases, decreases or no changes (Konarski, et al., 2008). In particular, amygdala 
volume reductions are often found in young BD patients, with enlarged volumes 
being present in older BD patients and it has been shown that the volume is 
inversely influenced by age in BD patients versus control subjects (Konarski, et al., 
2008). Our findings accordingly provide a first line of evidence to suggest that the 
same also holds true for high-risk subjects. 
The amygdala is part of a network of brain areas that are charged with the 
identification of the emotional significance of environmental stimuli, the 
generation of a subsequent affective state, and the production of an autonomic 
response (Phillips, et al., 2003a). Disturbed function of the amygdala therefore 
likely influences a wide range of other brain regions and holds the potential to 
mimic the symptoms of mood disorders (Phillips, et al., 2003b). 
The strengths of this study are its longitudinal nature, the assessment of subjects 
prior to illness onset, the relatively young age of the participants and the 
comparatively large sample size of high-risk subjects and controls. In addition, all 
subjects underwent careful clinical assessment at both time points and the effects of 
medication and relatedness of subjects were ruled out. All brain scans were 
obtained at the same scanner using the identical protocol at both visits and the MRI 
data were processed in an identical way using thoroughly validated methods.  
Several limitations of this study cohort need to be addressed. First, it remains 
unknown whether currently unaffected HR-well subjects may develop MDD in the 
future. Second, previous longitudinal studies have reported that the majority of the 
high-risk subjects who developed BD themselves experienced depressive episodes 
years before conversion (Duffy, 2010; Hillegers et al., 2005) so that it appears 
likely that some of our HR-MDD subjects may develop BD in the future. The 
follow-up assessments of our study cohort will clarify if some of the HR-MDD 
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participants will convert to BD and if some of our HR-well subjects go on to 
develop a mood disorder. Third, our study groups differed with respect to 
depression symptom severity at baseline. However, the median of the HAM-D total 
score was only 1 in the HR-MDD group, suggesting only sub-syndromal 
depressive symptoms. Therefore, it appears unlikely that general mood differences 
at baseline between the groups have influenced our findings.  
In summary, no significant volumetric subcortical brain abnormalities were 
detected in individuals at high familial risk of mood disorders, regardless of an 
onset of MDD or not. Accordingly, it can be concluded that subcortical volumetric 
brain abnormalities that are often observed in mood disorders only emerge during 
the course of illness and are not related to the illness onset or enhanced familial risk 
for the disorder. However, nominal significant findings provide a first line of 
evidence to suggest that the volume of the right caudate is decreased in individuals 
at high familial risk of mood disorders who go on to develop MDD and that this 
volume reduction is not related to the illness onset but rather appears to be 
relatively stable across time. Moreover, individuals at high familial risk of mood 
disorders who did not develop MDD had a nominal significant abnormal decrease 
of the left amygdala over time as compared to control subjects. Future longitudinal 





Cortical thickness in individuals at high familial risk of mood disorders 
 
4.1 Introduction 
As outlined in chapter 1, close relatives of BD patients have an up to 10-fold 
excess risk of BD as compared to the general population, and an up to 3-fold 
increased risk of MDD (Smoller & Finn, 2003). The aggregation of mood disorders 
within families together with moderate to high heritability estimates and the finding 
of a substantially shared genetic architecture in genome-wide association analyses 
provide strong support for overlapping causal pathways in BD and MDD (Barnett 
& Smoller, 2009; Craddock, 2006; Cross-Disorder Group of the Psychiatric 
Genomics Consortium, 2013; McGuffin et al., 2003; Schulze et al., 2012; Sullivan, 
et al., 2000).  
Accumulating evidence from structural MRI studies indicates that neuroanatomical 
changes in the frontal and temporal lobes are associated with mood disorders 
(Arnone, et al., 2009; Beyer & Krishnan, 2002; Bora, et al., 2012; Hallahan, et al., 
2011; Kempton, et al., 2011; Konarski, et al., 2008; Koolschijn, et al., 2009; Savitz 
& Drevets, 2009). Volumetric grey matter reductions of the prefrontal lobe have 
been consistently found in both MDD and BD, predominantly in the orbitofrontal 
gyrus (Kempton, et al., 2011; Konarski, et al., 2008; Koolschijn, et al., 2009; 
Stanfield, et al., 2009; Wilke, et al., 2004) and the anterior cingulate cortex (Bora, 
et al., 2012; Bora, et al., 2010; Caetano et al., 2006; Koolschijn, et al., 2009; 
Lochhead, Parsey, Oquendo, & Mann, 2004; Sassi et al., 2004), but also repeatedly 
in the inferior frontal (Bora, et al., 2012; Bora, et al., 2010; Du, et al., 2012; 
Matsuo, et al., 2012; Selvaraj, et al., 2012), middle frontal (Bora, et al., 2012; Du, 
et al., 2012; Lopez-Larson, et al., 2002; Lyoo, et al., 2004; Peng et al., 2011) and 
superior frontal gyrus (Bora, et al., 2012; Lopez-Larson, et al., 2002). Furthermore, 
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grey matter decreases have been observed in the precentral gyrus (Bora, et al., 
2012; Lyoo, et al., 2004), superior temporal gyrus (Abe et al., 2010; Peng, et al., 
2011; Selvaraj, et al., 2012) and in the medial temporal lobe, particularly in the 
parahippocampal gyrus (Abe, et al., 2010; Bora, et al., 2012; Peng, et al., 2011). A 
detailed review on frontal and temporal cortical findings for MDD and BD is 
provided in Chapter 1. 
The majority of research has examined grey matter volume in mood disorders but 
not cortical thickness. Grey matter volume is a composite of cortical thickness and 
surface area, and research suggests that grey matter volume is more closely linked 
to surface area than to thickness (Winkler, et al., 2009). Accordingly, the 
contribution of cortical thickness towards structural brain abnormalities in mood 
disorders remains largely unknown. A small number of existing studies have 
however reported cortical thickness abnormalities in both MDD and BD patients in 
the frontal lobe (Elvsashagen et al., 2013; Foland-Ross et al., 2011; Grieve, 
Korgaonkar, Koslow, Gordon, & Williams, 2013; Hartberg et al., 2011; Lan et al., 
2014; Lyoo et al., 2006; Qiu et al., 2014; Reynolds et al., 2014; Rimol et al., 2010; 
Truong et al., 2013; Tu et al., 2012; van Eijndhoven et al., 2013; van Tol et al., 
2013) as well as in the superior temporal gyrus (Elvsashagen, et al., 2013; 
Hartberg, et al., 2011; Rimol, et al., 2010; van Tol, et al., 2013). Moreover, 
thickness reductions in the inferior and middle temporal gyrus (Elvsashagen, et al., 
2013), parahippocampal (Rimol, et al., 2010) and fusiform gyri (Hartberg, et al., 
2011; Lyoo, et al., 2006) has been found in BD patients.  
Prefrontal brain regions are closely involved in emotion processing and affect 
regulation – functions that are clearly disturbed in mood disorders (Phillips, et al., 
2003a, 2003b). Distinct frontal lobe structures maintain reciprocal connections to 
temporal brain areas and are intensively interconnected with limbic regions. On the 
basis of these findings, it has been postulated that a medial prefrontal network, 
highly connected to superior and medial temporal lobe, is centrally involved in 
mood disorders (Drevets, Price, & Furey, 2008; Price & Drevets, 2010).  
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All imaging studies of mood disorders so far have assessed cortical thickness in 
already affected individuals only. These studies can’t discern whether structural 
brain abnormalities reflect early neurodevelopmental disruptions predisposing to 
illness, events linked to the illness onset, or whether they are adaptive or secondary 
to the effects of chronic illness or its treatment. Neuroimaging studies of 
individuals at high risk of mood disorders because of a close family history of BD 
hold the potential to identify the structural brain abnormalities related to enhanced 
familial vulnerability, unconfounded by the presence of illness. However, to the 
best of my knowledge, no study has yet examined the effects of familial risk on 
cortical thickness in a prospective study.  
The longitudinal Scottish Bipolar Family Study is well-designed to examine the 
timing of structural brain abnormalities in mood disorders and their relationship to 
familial risk and onset of illness. In the analyses presented here, cortical thickness 
of frontal and temporal ROIs were compared cross-sectionally for data acquired at 
baseline assessment and longitudinally over time between the HR-MDD, HR-well 
and HC groups. The rationale for the baseline analysis was to examine whether 
regional cortical thickness abnormalities exist in the HR-MDD group prior to 
illness onset that may serve as neuroanatomical markers for a subsequent 
development of MDD and to assess their relationship to familial risk. The 
longitudinal analysis was intended to explore the time course of cortical thickness 
during a period of two years to detect whether abnormal brain development in the 
high-risk participants is evident that can be linked to an onset of MDD or familial 
risk. Similar to a repeated measures ANOVA, the longitudinal analysis also 
allowed for testing with an increased power as compared to baseline analysis 
whether significant thickness differences between the study groups exist across 







4.2.1 Participants and clinical assessment 
Participants were recruited as part of the Scottish Bipolar Family Study as outlined 
more detailed in Chapter 2. The HC, HR-well and HR-MDD groups were matched 
for age, gender, handedness and intelligence and detailed demographic and clinical 
descriptions of the study sample are provided in Table 3.1 in Chapter 3.  
 
4.2.2 Magnetic resonance imaging and processing 
Structural MRI scans were acquired on a 1.5 Tesla scanner as outlined in Chapter 
2. The T1 weighted images were processed using the surface-based stream of 
FreeSurfer (fully described in Chapter 2). Based on the literature review provided 
in Chapter 1 and hence the scientific relevance for mood disorders, cortical 
thickness of the following brain structures was assessed for each hemisphere 
separately: frontal pole, inferior frontal gyrus, middle frontal gyrus, superior frontal 
gyrus, orbitofrontal gyrus (including lateral and medial orbitofrontal gyrus), 
anterior cingulate (including rostral and caudal anterior cingulate), precentral 
gyrus, superior temporal gyrus, parahippocampal gyrus and fusiform gyrus. 
 
4.2.3 Statistical analysis 
An ANCOVA was conducted to compare cross-sectionally regional thickness 
differences between the HC, HR-well and HR-MDD groups at baseline. Age and 
sex served as covariates in this analysis. Next, linear mixed-effects models were 
applied to investigate cortical thickness for each ROI over time (see Chapter 2 for a 
more detailed methodological description). In the linear mixed-effects model used, 
the intercept term is treated as a random effect that varies by individual so that 
intraindividual correlation among the structural brain measures of a particular 
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individual is taken into account. The following independent variables were used as 
predictors of cortical thickness for the regions outlined: group, time (baseline 
versus follow-up assessment), group-by-time interaction. Age and sex served as 
covariates in the analyses. 
A statistical significance level of p ≤ 0.05 was chosen, fully corrected for multiple 
comparisons using the Benjamini & Hochberg FDR procedure (Benjamini & 
Hochberg, 1995). To allow for comparison with previous studies, effect sizes for 
nominal significant group differences were additionally calculated using Cohen's d 
(Cohen, 1988). Wherever significant between-group differences were found, 
pairwise comparisons were performed between the three groups, for which p-
values were corrected according to Tukey’s HSD procedure (pHSD ≤ 0.05). 
To assess the relationship between depression symptoms and cortical thickness of 
each ROI, Spearman’s rank correlation coefficients between the HAM-D scores 
and thickness measures for each group were calculated. To assess the relationship 
between changes in thickness and changes in depressive symptoms over time, 
Spearman’s rank correlation coefficients were calculated between the thickness 
differences of the ROIs and the differences of the HAM-D scores between the two 
assessments. For ease of interpretation, data derived from the follow-up assessment 
was subtracted from the data acquired at baseline so that positive values reflect 
increases in thickness or depression symptoms over time, while negative values 
represent decreases of these measures over time. All p-values were corrected 
according to Benjamini & Hochberg FDR procedure and considered significant 
when p ≤ 0.05. 
To examine the potentially confounding effects of exposure to medication and 
relatedness of subjects on regional brain volumes, the following additional analyses 
were performed: The analyses were repeated excluding medicated HR-MDD 






4.3.1 Cross-sectional analysis 
 
4.3.1.1 Group differences at baseline 
At baseline assessment, no significant FDR-corrected differences in regional 
cortical thickness were found between the groups (see Table 4.1). There was a 
nominal significant group difference for right parahippocampal (p ≤ 0.011), right 
fusiform (p ≤ 0.025) and right frontal pole thickness (p ≤ 0.033). Post-hoc tests 
indicated that the HR-MDD group had reduced right parahippocampal thickness as 
compared to HC participants (pHSD ≤ 0.010, d = 0.757), with no thickness 
differences between the HC and HR-well group (pHSD ≤ 0.251, d = 0.232) and the 
two high-risk groups (pHSD ≤ 0.114, d = 0.501). Post-hoc tests for the right fusiform 
gyrus revealed no significant pairwise group differences (pHSD ≤ 0.086, d = 0.299 
for HC versus HR-well; pHSD ≤ 0.062, d = 0.648 for HC versus HR-MDD; pHSD ≤ 
0.559, d = 0.292 for HR-well versus HR-MDD). For the right frontal pole, post-hoc 
analyses showed cortical thickness differences between the two high-risk groups, 
with the HR-well group having decreased thickness as compared to the HR-MDD 
participants (pHSD ≤ 0.027, d = 0.685). No differences between the HC and the HR-
well subjects (pHSD ≤ 0.445, d = 0.156) and the HC as compared to the HR-MDD 
group were observed (pHSD ≤ 0.146, d = 0.478). 
 
4.3.1.2 Correlation analysis 
For the cortical thickness of the ROIs, there were no significant correlations with 
depression symptom severity that remained significant after FDR correction. There 
were however three nominal significant correlations. The left fusiform gyrus 
thickness was negatively correlated with the HAM-D sum score in the HC (p ≤ 
0.036) and HR-well group (p ≤ 0.035), indicating that thinning of this brain region 
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is associated with higher depression symptoms. For the HR-MDD group, there was 
a nominal significant positive correlation between the left anterior cingulate 
thickness and the severity of depression (p ≤ 0.050), indicating that thickening of 
this brain region is associated with higher depression symptoms (see Table 4.2). 
 
4.3.1.3 Analysis of potential confounders 
To eliminate the potential confounding effects of familial relatedness of some 
subjects, the analyses were repeated, excluding randomly individuals from the 
same pedigree (Table 4.3). This analysis similarly yielded no significant FDR-
corrected group differences. The nominal significant finding for the right 
parahippocampal gyrus (p ≤ 0.006) and right fusiform gyrus (p ≤ 0.017) remained 
nominally significant, but not the observed nominal frontal pole thickness 





Table 4.1 Cross-sectional analysis of cortical thickness 
 HC  HR-well  HR-MDD  Statistics 
Region (Gyrus) Mean (SD)  Mean (SD)  Mean (SD)  F p 
L inf frontal G 2.47 (0.22)  2.49 (0.15)  2.52 (0.20)  0.69 0.50 
R inf frontal G 2.46 (0.17)  2.42 (0.15)  2.50 (0.21)  2.48 0.09 
L mid frontal G 2.38 (0.18)  2.42 (0.16)  2.43 (0.19)  1.89 0.15 
R mid frontal G 2.35 (0.16)  2.34 (0.14)  2.39 (0.20)  1.02 0.36 
L sup frontal G 2.70 (0.18)  2.70 (0.18)  2.72 (0.18)  0.18 0.83 
R sup frontal G 2.65 (0.19)  2.64 (0.19)  2.70 (0.19)  0.89 0.41 
L orbitofrontal G 2.44 (0.23)  2.45 (0.20)  2.42 (0.28)  0.23 0.80 
R orbitofrontal G 2.41 (0.23)  2.38 (0.19)  2.40 (0.21)  0.44 0.64 
L frontal pole 2.95 (0.40)  3.03 (0.43)  3.06 (0.38)  1.30 0.28 
R frontal pole 2.90 (0.41)  2.84 (0.36)  3.08 (0.34)  3.48 0.03 
L ant cingulate 2.48 (0.33)  2.47 (0.32)  2.48 (0.33)  0.04 0.96 
R ant cingulate 2.39 (0.31)  2.43 (0.32)  2.43 (0.36)  0.36 0.70 
L precentral G 2.49 (0.14)  2.49 (0.13)  2.48 (0.18)  0.07 0.94 
R precentral G 2.45 (0.12)  2.44 (0.13)  2.44 (0.14)  0.19 0.82 
L fusiform G 2.33 (0.21)  2.32 (0.18)  2.29 (0.21)  0.44 0.65 
R fusiform G 2.37 (0.18)  2.31 (0.22)  2.25 (0.19)  3.77 0.03 
L sup temporal G 2.42 (0.22)  2.45 (0.19)  2.45 (0.18)  0.73 0.49 
R sup temporal G 2.44 (0.19)  2.42 (0.21)  2.40 (0.18)  0.73 0.48 
L parahippoc G 2.24 (0.34)  2.19 (0.34)  2.14 (0.37)  1.19 0.31 
R parahippoc G 2.23 (0.34)  2.15 (0.35)  1.98 (0.32)  4.61 0.01 
Cortical thickness measures are provided in mm. Abbreviations: inf = inferior; mid = 










Table 4.2 Correlation between cortical thickness and HAM-D sum score 
 HC  HR-well  HR-MDD 
Region (Gyrus) R p  R p  R p 
L inf frontal G -0.16 0.14  0.03 0.81  0.01 0.99 
R inf frontal G -0.20 0.06  -0.02 0.86  0.29 0.23 
L mid frontal G -0.09 0.42  -0.08 0.45  0.11 0.67 
R mid frontal G -0.17 0.11  -0.12 0.25  0.18 0.46 
L sup frontal G -0.15 0.16  -0.06 0.54  0.16 0.51 
R sup frontal G -0.18 0.10  -0.10 0.36  0.03 0.91 
L orbitofrontal G -0.07 0.51  -0.05 0.66  0.21 0.39 
R orbitofrontal G -0.01 0.92  -0.07 0.53  0.19 0.44 
L frontal pole -0.13 0.23  -0.03 0.79  0.03 0.91 
R frontal pole -0.11 0.29  -0.02 0.83  0.17 0.49 
L ant cingulate -0.08 0.48  0.04 0.69  0.46 0.05 
R ant cingulate -0.03 0.81  0.05 0.61  0.36 0.13 
L precentral G -0.20 0.06  -0.15 0.15  -0.40 0.09 
R precentral G -0.14 0.19  -0.07 0.50  -0.31 0.20 
L fusiform G -0.22 0.04  -0.22 0.04  0.06 0.79 
R fusiform G -0.04 0.70  -0.11 0.29  0.22 0.37 
L sup temporal G -0.19 0.07  0.04 0.73  0.12 0.63 
R sup temporal G -0.12 0.27  -0.06 0.54  0.24 0.32 
L parahippoc G -0.16 0.14  0.03 0.78  -0.10 0.70 
R parahippoc G -0.02 0.83  0.12 0.28  0.11 0.65 
Abbreviations: inf = inferior; mid = middle; sup = superior; ant = anterior; G = gyrus; 












Table 4.3 Cross-sectional analysis of cortical thickness in unrelated subjects  
 HC  HR-well  HR-MDD  Statistics 
Region (Gyrus) Mean (SD)  Mean (SD)  Mean (SD)  F p 
L inf frontal G 2.47 (0.22)  2.48 (0.16)  2.53 (0.27)  0.70 0.50 
R inf frontal G 2.47 (0.17)  2.42 (0.15)  2.50 (0.21)  2.83 0.06 
L mid frontal G 2.38 (0.18)  2.42 (0.16)  2.43 (0.19)  1.42 0.25 
R mid frontal G 2.35 (0.16)  2.34 (0.14)  2.40 (0.20)  1.36 0.26 
L sup frontal G 2.70 (0.18)  2.70 (0.18)  2.73 (0.23)  0.32 0.73 
R sup frontal G 2.65 (0.19)  2.63 (0.18)  2.71 (0.20)  1.38 0.25 
L orbitofrontal G 2.44 (0.23)  2.44 (0.20)  2.41 (0.29)  0.18 0.83 
R orbitofrontal G 2.42 (0.23)  2.38 (0.19)  2.39 (0.25)  0.58 0.56 
L frontal pole 2.94 (0.40)  3.06 (0.43)  3.06 (0.39)  1.83 0.16 
R frontal pole 2.90 (0.41)  2.84 (0.37)  3.06 (0.33)  2.56 0.08 
L ant cingulate 2.48 (0.33)  2.47 (0.31)  2.49 (0.39)  0.06 0.95 
R ant cingulate 2.39 (0.31)  2.42 (0.32)  2.40 (0.35)  0.18 0.84 
L precentral G 2.49 (0.14)  2.48 (0.14)  2.48 (0.18)  0.04 0.96 
R precentral G 2.45 (0.12)  2.43 (0.14)  2.44 (0.14)  0.45 0.64 
L fusiform G 2.33 (0.21)  2.31 (0.18)  2.29 (0.21)  0.47 0.63 
R fusiform G 2.37 (0.19)  2.29 (0.22)  2.25 (0.20)  4.15 0.02 
L sup temporal G 2.42 (0.22)  2.45 (0.19)  2.44 (0.17)  0.48 0.62 
R sup temporal G 2.45 (0.19)  2.41 (0.21)  2.41 (0.18)  0.83 0.44 
L parahippoc G 2.25 (0.35)  2.20 (0.34)  2.11 (0.36)  1.42 0.25 
R parahippoc G 2.23 (0.35)  2.14 (0.34)  1.95 (0.30)  5.34 ≤0.01 
Cortical thickness measures are provided in mm. Abbreviations: inf = inferior; mid = 
middle; sup = superior; ant = anterior; G = gyrus; parahippoc = parahippocampal. 
 
4.3.2 Longitudinal analysis 
 
4.3.2.1 Group differences over time 
Tables 4.4 and Figure 4.1 depict the results of the linear mixed-effects model 
analyses. A significant group effect was found for the right parahippocampal gyrus 
(p ≤ 0.002) and right fusiform gyrus (p ≤ 0.005) that passed the FDR procedure. 
Post-hoc analyses revealed that the HR-well (pHSD ≤ 0.049, d = 0.309) and the HR-
MDD (pHSD ≤ 0.011, d = 0.851) group have reduced parahippocampal thickness 
across time as compared to HC subjects. This brain region was on average 4.00% 
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thinner in the HR-well group and 10.89% thinner in the HR-MDD group relative to 
controls. Moreover, the HR-MDD group displayed more pronounced thinning in 
this region as compared to the HR-well (pHSD ≤ 0.041, d = 0.506) group. For the 
right fusiform gyrus, the HR-well (pHSD ≤ 0.028, d = 0.379) and the HR-MDD 
(pHSD ≤ 0.014, d = 0.700) subjects have reduced cortical thickness as compared to 
the HC group, with no significant difference between the high-risk groups (pHSD ≤ 
0.307, d = 0.259). The fusiform gyrus was on average 2.11% thinner in the HR-
well and 4.22% thinner in the HR-MDD group as compared to controls. 
A significant group-by-time interaction (p ≤ 0.05) was detected for the left inferior 
frontal gyrus (p ≤ 0.002) and the left precentral gyrus (p ≤ 0.001). For the inferior 
frontal region, HR-well subjects had a greater cortical thickness decline (3.61% 
thickness decline) relative to the HC group (pHSD ≤ 0.002, d = 0.377; 1.22% 
thickness decline) over time and exhibited a distinct pattern of cortical thickness 
development as compared to the HR-MDD group (pHSD ≤ 0.002, d = 0.503) that 
showed an increasing thickening over time (1.19% thickness increase). For the left 
precentral gyrus, the HR-well group exhibited greater cortical thickness decline 
(2.44% thickness decline) relative to the HC group (pHSD ≤ 0.032, d = 0.280; 1.61% 
thickness decline) over time, while the HR-MDD subjects showed cortical 
thickness expansions (2.02% thickness increase) over time which was in contrast to 
the regional thickness decline observed in the HC (pHSD ≤ 0.001, d = 0.616) and the 
HR-well (pHSD ≤ 0.001, d = 0.786) group.  
 
4.3.2.2 Correlation analysis 
There was no FDR-corrected or nominal significant correlation between regional 
cortical thickness changes over time and changes of depressive symptoms severity 




4.3.2.3 Analysis of potential confounders 
All results remained significant after FDR correction when randomly excluding 
related subjects, except for the group effect of right fusiform gyrus thickness (p ≤ 
0.009) which however remained highly significant at a nominal level (Table 4.3). 
For the right parahippocampus, there was a significant group effect (p ≤ 0.002) and 
significant group-by-time interactions were observed for the left inferior frontal 
and precentral gyrus (p ≤ 0.002 and p ≤ 0.001, respectively). 
Similarly, all results remained significant when excluding medicated subjects, 
except for the group effect of right fusiform gyrus thickness (p ≤ 0.009) which was 
only highly significant at a nominal level (see Table 4.4). A significant group effect 
for the right parahippocampus (p ≤ 0.001) and significant group-by-time 
interactions for the left inferior frontal and precentral gyrus were observed (p ≤ 
0.005 and p ≤ 0.001, respectively). 
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Table 4.4 Longitudinal analysis of cortical thickness 
 HC  HR-well  HR-MDD  Statistics 
 Baseline Follow-up  Baseline Follow-up  Baseline Follow-up  Group effect Time effect GroupXTime 
Region (Gyrus) Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  F p F p F p 
L inf frontal G 2.47 (0.22) 2.44 (0.17)  2.49 (0.15) 2.40 (0.17)  2.52 (0.20) 2.55 (0.22)  3.14 0.05 3.22 0.08 5.35 <0.01 
R inf frontal G 2.46 (0.17) 2.44 (0.19)  2.42 (0.15) 2.42 (0.17)  2.50 (0.21) 2.45 (0.18)  1.69 0.19 3.51 0.06 1.30 0.28 
L mid frontal G 2.38 (0.18) 2.39 (0.16)  2.42 (0.16) 2.39 (0.17)  2.43 (0.19) 2.51 (0.16)  3.41 0.04 0.93 0.34 1.80 0.15 
R mid frontal G 2.35 (0.16) 2.33 (0.17)  2.34 (0.14) 2.34 (0.16)  2.39 (0.20) 2.39 (0.16)  1.54 0.22 0.57 0.45 0.47 0.71 
L sup frontal G 2.70 (0.18) 2.69 (0.19)  2.70 (0.18) 2.68 (0.18)  2.72 (0.18) 2.81 (0.20)  2.40 0.10 0.10 0.76 1.04 0.38 
R sup frontal G 2.65 (0.19) 2.61 (0.17)  2.64 (0.19) 2.61 (0.18)  2.70 (0.19) 2.74 (0.17)  3.11 0.05 0.34 0.56 1.65 0.18 
L orbitofrontal G 2.44 (0.23) 2.39 (0.20)  2.45 (0.20) 2.41 (0.17)  2.42 (0.28) 2.48 (0.20)  0.73 0.48 0.39 0.54 2.66 0.05 
R orbitofrontal G 2.41 (0.23) 2.39 (0.20)  2.38 (0.19) 2.38 (0.19)  2.40 (0.21) 2.42 (0.19)  0.24 0.79 0.04 0.85 0.79 0.50 
L frontal pole 2.95 (0.40) 2.95 (0.41)  3.03 (0.43) 3.03 (0.38)  3.06 (0.38) 3.20 (0.43)  3.00 0.05 0.73 0.40 0.44 0.73 
R frontal pole 2.90 (0.41) 2.87 (0.40)  2.84 (0.36) 2.85 (0.31)  3.08 (0.34) 3.06 (0.44)  2.94 0.02 0.20 0.66 0.22 0.88 
L ant cingulate 2.48 (0.33) 2.46 (0.29)  2.47 (0.32) 2.44 (0.28)  2.48 (0.33) 2.54 (0.29)  0.22 0.80 0.00 1.00 1.57 0.20 
R ant cingulate 2.39 (0.31) 2.37 (0.26)  2.43 (0.32) 2.35 (0.29)  2.43 (0.36) 2.42 (0.23)  0.25 0.78 1.88 0.17 1.90 0.13 
L precentral G 2.49 (0.14) 2.45 (0.13)  2.49 (0.13) 2.43 (0.15)  2.48 (0.18) 2.53 (0.12)  2.10 0.34 2.83 0.10 8.67 <0.01 
R precentral G 2.45 (0.12) 2.43 (0.14)  2.44 (0.13) 2.42 (0.15)  2.44 (0.14) 2.46 (0.16)  0.51 0.60 2.02 0.16 2.19 0.09 
L fusiform G 2.33 (0.21) 2.29 (0.18)  2.32 (0.18) 2.27 (0.18)  2.29 (0.21) 2.24 (0.30)  1.04 0.35 3.35 0.07 1.72 0.17 
R fusiform G 2.37 (0.18) 2.38 (0.17)  2.31 (0.22) 2.33 (0.19)  2.25 (0.19) 2.29 (0.23)  5.20 <0.01 0.66 0.42 0.23 0.88 
L sup temporal G 2.42 (0.22) 2.43 (0.21)  2.45 (0.19) 2.41 (0.20)  2.45 (0.18) 2.41 (0.25)  0.04 0.96 0.98 0.32 1.03 0.38 
R sup temporal G 2.44 (0.19) 2.50 (0.18)  2.42 (0.21) 2.43 (0.21)  2.40 (0.18) 2.40 (0.18)  3.60 0.03 0.50 0.48 1.55 0.21 
L parahippoc G 2.24 (0.34) 2.25 (0.32)  2.19 (0.34) 2.12 (0.37)  2.14 (0.37) 2.13 (0.45)  1.76 0.17 1.73 0.19 1.43 0.24 
R parahippoc G 2.23 (0.34) 2.27 (0.29)  2.15 (0.35) 2.17 (0.31)  1.98 (0.32) 2.03 (0.37)  6.27 <0.01 0.44 0.51 0.20 0.90 
Cortical thickness measures are provided in mm. Abbreviations: L = left; R = right; inf = inferior; mid = middle; sup = superior; G = gyrus; 
parahippoc = parahippocampal; bold indicates significant effect after FDR correction.
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Figure 4.1 Significant group-by-time interactions (a, b) and group effects (c, d) of 
longitudinal cortical thickness analyses. 
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Table 4.5 Correlation between changes in cortical thickness and changes in HAM-D sum score 
 HC  HR-well  HR-MDD 
Region (Gyrus) R p  R p  R p 
L inf frontal G 0.01 0.96  0.05 0.76  -0.04 0.89 
R inf frontal G 0.09 0.55  0.08 0.61  0.12 0.67 
L mid frontal G 0.07 0.63  0.09 0.56  -0.06 0.83 
R mid frontal G -0.01 0.97  -0.05 0.72  0.15 0.59 
L sup frontal G 0.04 0.81  0.06 0.68  0.14 0.61 
R sup frontal G -0.01 0.99  0.03 0.86  -0.04 0.90 
L orbitofrontal G -0.03 0.84  0.21 0.15  -0.05 0.85 
R orbitofrontal G 0.11 0.48  0.02 0.89  -0.18 0.53 
L frontal pole -0.08 0.61  0.01 0.99  -0.21 0.46 
R frontal pole -0.10 0.49  0.12 0.42  -0.17 0.55 
L ant cingulate 0.09 0.56  0.14 0.34  0.14 0.61 
R ant cingulate -0.01 0.97  0.09 0.52  0.23 0.42 
L precentral G -0.04 0.80  0.03 0.83  0.02 0.95 
R precentral G -0.04 0.77  0.17 0.23  0.08 0.77 
L fusiform G 0.01 0.94  -0.05 0.75  -0.02 0.95 
R fusiform G 0.06 0.71  0.11 0.46  0.13 0.65 
L sup temporal G -0.04 0.80  0.07 0.63  -0.05 0.85 
R sup temporal G -0.04 0.79  0.05 0.75  0.08 0.77 
L parahippoc G -0.27 0.07  0.13 0.35  -0.22 0.43 
R parahippoc G -0.16 0.29  0.26 0.07  -0.10 0.72 





Table 4.6 Longitudinal analysis of cortical thickness in unrelated subjects 
 HC  HR-well  HR-MDD  Statistics 
 Baseline Follow-up  Baseline Follow-up  Baseline Follow-up  Group effect Time effect GroupXTime 
Region (Gyrus) Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  F p F p F p 
L inf frontal G 2.47 (0.22) 2.44 (0.16)  2.48 (0.16) 2.39 (0.18)  2.53 (0.27) 2.56 (0.23)  3.82 0.02 2.97 0.09 4.51 <0.01 
R inf frontal G 2.48 (0.17) 2.44 (0.19)  2.42 (0.15) 2.40 (0.18)  2.50 (0.21) 2.43 (0.18)  2.25 0.11 4.86 0.03 0.43 0.65 
L mid frontal G 2.38 (0.18) 2.39 (0.16)  2.42 (0.19) 2.38 (0.16)  2.43 (0.19) 2.52 (0.16)  3.58 0.03 0.73 0.39 2.50 0.09 
R mid frontal G 2.35 (0.16) 2.33 (0.17)  2.33 (0.14) 2.32 (0.16)  2.40 (0.20) 2.39 (0.16)  2.13 0.12 1.07 0.30 0.09 0.92 
L sup frontal G 2.70 (0.18) 2.68 (0.19)  2.69 (0.18) 2.67 (0.18)  2.73 (0.18) 2.80 (0.20)  2.46 0.09 0.00 1.16 0.97 0.32 
R sup frontal G 2.65 (0.19) 2.61 (0.17)  2.63 (0.18) 2.59 (0.18)  2.71 (0.20) 2.74 (0.18)  3.70 0.03 0.61 0.44 1.16 0.32 
L orbitofrontal G 2.44 (0.23) 2.39 (0.20)  2.44 (0.20) 2.40 (0.17)  2.44 (0.22) 2.46 (0.19)  0.21 0.81 0.56 0.45 1.79 0.18 
R orbitofrontal G 2.42 (0.23) 2.39 (0.20)  2.38 (0.19) 2.36 (0.17)  2.39 (0.25) 2.41 (0.19)  0.62 0.54 0.18 0.67 0.72 0.49 
L frontal pole 2.94 (0.40) 2.95 (0.41)  3.06 (0.43) 3.06 (0.36)  3.06 (0.39) 3.16 (0.41)  3.17 0.04 0.43 0.52 0.33 0.72 
R frontal pole 2.90 (0.41) 2.87 (0.40)  2.84 (0.37) 2.85 (0.31)  3.06 (0.33) 3.06 (0.45)  2.71 0.07 0.02 0.90 0.36 0.70 
L ant cingulate 2.48 (0.33) 2.46 (0.29)  2.47 (0.31) 2.44 (0.26)  2.49 (0.40) 2.53 (0.30)  0.20 0.82 0.01 0.92 1.45 0.24 
R ant cingulate 2.39 (0.31) 2.37 (0.26)  2.42 (0.32) 2.34 (0.29)  2.40 (0.35) 2.39 (0.21)  0.02 0.98 1.44 0.23 0.54 0.59 
L precentral G 2.49 (0.14) 2.45 (0.13)  2.48 (0.14) 2.42 (0.15)  2.48 (0.18) 2.53 (0.12)  1.78 0.17 2.93 0.09 7.68 <0.01 
R precentral G 2.45 (0.12) 2.43 (0.14)  2.43 (0.14) 2.41 (0.16)  2.45 (0.14) 2.46 (0.16)  0.87 0.42 2.53 0.11 0.37 0.69 
L fusiform G 2.33 (0.21) 2.29 (0.18)  2.31 (0.18) 2.28 (0.18)  2.29 (0.21) 2.26 (0.30)  0.74 0.48 1.90 0.17 0.06 0.94 
R fusiform G 2.37 (0.19) 2.38 (0.17)  2.29 (0.22) 2.33 (0.19)  2.25 (0.20) 2.30 (0.23)  4.87 <0.01 1.22 0.27 0.19 0.82 
L sup temporal G 2.42 (0.22) 2.43 (0.21)  2.45 (0.19) 2.39 (0.21)  2.44 (0.20) 2.42 (0.26)  0.00 1.00 0.61 0.44 0.82 0.44 
R sup temporal G 2.45 (0.19) 2.50 (0.18)  2.41 (0.21) 2.42 (0.21)  2.41 (0.18) 2.40 )0.18)  3.74 0.03 0.38 0.54 1.41 0.25 
L parahippoc G 2.25 (0.35) 2.25 (0.32)  2.20 (0.34) 2.13 (0.36)  2.11 (0.36) 2.13 (0.36)  1.72 0.18 1.20 0.28 0.48 0.62 
R parahippoc G 2.23 (0.35) 2.27 (0.30)  2.14 (0.34) 2.16 (0.32)  1.95 (0.30) 2.03 (0.38)  6.94 <0.01 0.67 0.42 0.23 0.80 
Cortical thickness measures are provided in mm. Abbreviations: L = left; R = right; inf = inferior; mid = middle; sup = superior; G = gyrus; 




Table 4.7 Longitudinal analysis of cortical thickness in unmedicated subjects 
 HC  HR-well  HR-MDD  Statistics 
 Baseline Follow-up  Baseline Follow-up  Baseline Follow-up  Group effect Time effect GroupXTime 
Region (Gyrus) Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  F p F p F p 
L inf frontal G 2.47 (0.22) 2.44 (0.17)  2.49 (0.15) 2.40 (0.17)  2.52 (0.28) 2.58 (0.22)  3.08 0.05 2.07 0.15 5.33 <0.01 
R inf frontal G 2.46 (0.17) 2.44 (0.19)  2.42 (0.15) 2.42 (0.17)  2.50 (0.21) 2.46 (0.15)  1.85 0.16 1.64 0.11 0.41 0.66 
L mid frontal G 2.38 (0.18) 2.39 (0.16)  2.42 (0.16) 2.39 (0.17)  2.42 (0.21) 2.52 (0.15)  2.81 0.06 1.26 0.26 2.91 0.06 
R mid frontal G 2.35 (0.16) 2.33 (0.17)  2.34 (0.14) 2.34 (0.16)  2.40 (0.20) 2.40 (0.14)  1.52 0.22 0.89 0.35 0.27 0.76 
L sup frontal G 2.70 (0.18) 2.69 (0.19)  2.70 (0.18) 2.68 (0.18)  2.72 (0.23) 2.77 (0.17)  0.84 0.43 0.10 0.75 0.40 0.67 
R sup frontal G 2.65 (0.19) 2.61 (0.17)  2.64 (0.19) 2.61 (0.18)  2.69 (0.21) 2.74 (0.16)  2.22 0.11 0.38 0.54 1.06 0.35 
L orbitofrontal G 2.44 (0.23) 2.39 (0.20)  2.45 (0.20) 2.41 (0.17)  2.41 (0.27) 2.50 (0.19)  0.92 0.40 0.07 0.79 2.44 0.09 
R orbitofrontal G 2.41 (0.23) 2.39 (0.20)  2.38 (0.19) 2.38 (0.19)  2.40 (0.22) 2.44 (0.20)  0.35 0.70 0.00 0.95 0.88 0.42 
L frontal pole 2.95 (0.40) 2.95 (0.41)  3.03 (0.43) 3.03 (0.38)  3.08 (0.40) 3.19 (0.47)  2.93 0.06 0.38 0.54 0.34 0.71 
R frontal pole 2.90 (0.41) 2.87 (0.40)  2.84 (0.36) 2.85 (0.31)  3.05 (0.34) 3.04 (0.44)  2.01 0.05 0.24 0.62 0.19 0.83 
L ant cingulate 2.48 (0.33) 2.46 (0.29)  2.47 (0.32) 2.44 (0.28)  2.49 (0.39) 2.58 (0.32)  0.48 0.62 0.00 0.96 1.54 0.22 
R ant cingulate 2.39 (0.31) 2.37 (0.26)  2.43 (0.32) 2.35 (0.29)  2.43 (0.36) 2.45 (0.24)  0.47 0.63 1.54 0.22 0.69 0.50 
L precentral G 2.49 (0.14) 2.45 (0.13)  2.49 (0.13) 2.43 (0.15)  2.47 (0.19) 2.51 (0.11)  0.35 0.71 3.00 0.09 8.35 <0.01 
R precentral G 2.45 (0.12) 2.43 (0.14)  2.44 (0.13) 2.42 (0.15)  2.44 (0.14) 2.33 (0.14)  0.26 0.77 3.17 0.08 0.16 0.85 
L fusiform G 2.33 (0.21) 2.29 (0.18)  2.32 (0.18) 2.27 (0.18)  2.31 (0.22) 2.26 (0.32)  0.47 0.63 2.65 0.11 0.03 0.97 
R fusiform G 2.37 (0.18) 2.38 (0.17)  2.31 (0.22) 2.33 (0.19)  2.27 (0.20) 2.30 (0.21)  4.88 <0.01 0.67 0.42 0.12 0.89 
L sup temporal G 2.42 (0.22) 2.43 (0.21)  2.45 (0.19) 2.41 (0.20)  2.44 (0.20) 2.43 (0.22)  0.05 0.95 0.56 0.46 0.73 0.48 
R sup temporal G 2.44 (0.19) 2.50 (0.18)  2.42 (0.21) 2.43 (0.21)  2.38 (0.19) 2.41 (0.19)  3.79 0.02 0.94 0.33 1.41 0.25 
L parahippoc G 2.24 (0.34) 2.25 (0.32)  2.19 (0.34) 2.12 (0.37)  2.16 (0.37) 2.17 (0.44)  1.45 0.24 0.69 0.41 0.81 0.45 
R parahippoc G 2.23 (0.34) 2.27 (0.29)  2.15 (0.35) 2.17 (0.31)  2.00 (0.29) 2.06 (0.27)  5.42 <0.01 0.54 0.46 0.22 0.81 
Cortical thickness measures are provided in mm. Abbreviations: L = left; R = right; inf = inferior; mid = middle; sup = superior; G = gyrus; 





This is, to the best of my knowledge, the first prospective longitudinal study 
examining cortical thickness in high-risk of mood disorders individuals who were 
unaffected at initial assessment and either developed MDD or remained well during 
the follow-up period. Reduced cortical thickness in the right parahippocampal and 
fusiform gyrus across the two time points were found in both high-risk groups 
relative to controls, with the HR-MDD group displaying a thinner 
parahippocampus gyrus than the HR-well group. Over time, HR-well subjects had 
progressive thickness reductions in the left inferior frontal and precentral gyrus 
relative to controls, while the HR-MDD group showed cortical thickening of these 
areas.  
The finding of a thinner parahippocampal and fusiform gyrus in high-risk 
individuals, irrespective of time or the onset of MDD, suggests that thinning in 
these temporal brain regions constitutes a familial trait marker for vulnerability to 
mood disorders. Whether these structural brain abnormalities are a consequence of 
shared genetic and/or environmental effects cannot be determined from the data. 
Given that they are already present in early adulthood, they are unlikely to be of 
degenerative origin but likely represent disturbances of normal brain development 
predisposing to illness. Since the HR-MDD subjects displayed a thinner 
parahippocampal gyrus than the HR-well group, these reductions may be related to 
risk of developing MDD. Parahippocampal and fusiform gyrus reductions are thus 
a potential neuroanatomic endophenotype for mood disorders, as thinning is 
evident in both unaffected relatives and affected patients and independent of state.  
Previous studies support the possibility that right parahippocampal and fusiform 
thickness reductions are linked to increased vulnerability for mood disorders. Right 
parahippocampal thinning has been associated with higher genetic liability to BD 
(Hulshoff Pol et al., 2012), and research focussing on candidate genes for mood 
disorders has detected associations between risk allele carriers of the DISC1 or 
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BDNF gene and reductions in parahippocampal volume/thickness (Carless et al., 
2011; Montag, Weber, Fliessbach, Elger, & Reuter, 2009; Takahashi et al., 2008) 
and fusiform volume (Montag, et al., 2009). Right parahippocampal thinning has 
been observed in BD-I patients (Rimol, et al., 2010) and right fusiform thinning in 
a BD cohort (Hartberg, et al., 2011; Lyoo, et al., 2006). The few studies 
investigating cortical thickness in MDD have not detected similar findings (Ajilore 
et al., 2011; Grieve, et al., 2013; Jarnum et al., 2011; Koolschijn et al., 2010; Lan, 
et al., 2014; Qiu, et al., 2014; Reynolds, et al., 2014; Truong, et al., 2013; Tu, et al., 
2012; van Tol, et al., 2013), but since they included predominantly medicated 
and/or older adults, it is likely that age, medication or duration of illness effects 
account for this discrepancy. In keeping with this, a recent voxel-based 
morphometry meta-analysis indeed showed that only first-episode, mainly 
medication naïve, MDD patients have decreased grey matter in a cluster 
encompassing the right parahippocampal gyrus (Bora, et al., 2012). Moreover, 
fusiform thinning in high-risk of depression individuals because of a close family 
history of MDD has been found to be associated with higher depression severity 
(Peterson et al., 2009). 
The parahippocampal gyrus is of particular interest for the aetiology of mood 
disorders because of its potential role in emotional regulation. Functional MRI 
studies applying facial affect processing paradigms found that BD and MDD 
patients have increased activation in the right parahippocampus as compared to 
controls (Delvecchio et al., 2012). Our research group has recently shown that 
high-risk of mood disorders individuals who are homozygous for risk haplotype of 
the DGKH gene show relatively greater brain activation of the right 
parahippocampus during a verbal fluency task as compared to low-risk haplotype 
subjects, with the reverse pattern being observed for healthy control subjects 
(Whalley et al., 2012). Furthermore, it has been shown that remitted depressed 
patients maintain an increased connectivity of the posterior cingulate cortex with 
the parahippocampal gyrus and that greater connectivity appears to represent a 
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prognostic factor for future depressive episodes (Zamoscik, Huffziger, Ebner-
Priemer, Kuehner, & Kirsch, 2014). 
Our analysis yielded significant group-by-time interactions for the left inferior 
frontal and precentral gyrus. The finding of abnormal thinning in these brain areas 
in the HR-well group over time relative to controls suggests that thinning in 
regionally specific left frontal lobe areas forms a familial trait marker for 
vulnerability to mood disorders and that abnormal thinning already takes place in 
early adulthood, potentially reflecting early neurodegenerative processes. 
Our results are in line with a twin study that found liability for BD to be associated 
with inferior frontal and precentral grey matter density reductions (van der Schot, 
et al., 2010), with the precentral grey matter reductions being limited to the right 
hemisphere however. Despite potential differences in underlying environmental 
and genetic risk factors, cortical thinning in both of these frontal areas has also 
been observed in cohort of unaffected relatives of MDD patients, with the inferior 
frontal thinning being restricted to the right hemisphere though (Peterson, et al., 
2009). Also, reduced grey matter volumes of the left precentral gyrus have been 
detected in individuals at high risk of MDD because of negative cognitive styles 
(X. Zhang, Yao, Zhu, Wang, & Zhong, 2012). Moreover, our findings are in 
concert with several neuroimaging studies reporting cortical thinning or grey 
matter volume reductions in the circumscribed brain regions in BD (Bora, et al., 
2010; Doris, Belton, Ebmeier, Glabus, & Marshall, 2004; Foland-Ross, et al., 2011; 
Hartberg, et al., 2011; Rimol, et al., 2010) and MDD patients (Tu, et al., 2012; J. 
Zhang, Xiao, Zhu, Wang, & Yao, 2011; X. Zhang, et al., 2012). 
Importantly, we observed a distinct pattern of increasing relative cortical thickness 
over time in the HR-MDD as compared to the HR-well group due to an absence of 
regional thinning of the left inferior frontal and precentral gyrus in the HR-MDD 
cohort. For the precentral gyrus, the cortical thickness development in the HR-
MDD group was also significantly different from the HC subjects. Since our results 
remained significant after excluding medicated individuals, the observed findings 
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in the HR-MDD group cannot be attributed to medication effects but rather appear 
to be linked to the onset of illness and underlying disease-associated processes. 
Given that human brain maturation involves frontal grey matter loss beyond 
adolescence (Gogtay, et al., 2004; Sowell et al., 2003; Westlye et al., 2010), the 
absence of cortical thinning in the HR-MDD group may reflect a lack or delay of 
normal synaptic pruning processes. 
Although these findings are in contrast to the frequently observed thinning or grey 
matter decrease in MDD patients, they are in line with two of the three existing 
longitudinal studies of MDD patients that found cortical thickening of frontal or 
temporal brain structures over time (Ahdidan et al., 2011; Jarnum, et al., 2011) and 
with recent findings of cortical thickening of various brain areas in MDD patients 
(Grieve, et al., 2013; Qiu, et al., 2014; Reynolds, et al., 2014; van Eijndhoven, et 
al., 2013). Interestingly, our findings overlap with a longitudinal study of paediatric 
prodromal BD subjects, displaying grey matter increases in the left ventrolateral 
prefrontal cortex (including the inferior frontal gyrus) over time as they convert to 
BD (Gogtay et al., 2007).  
The strengths of this study are its longitudinal nature, the assessment of subjects 
prior to illness onset, the relatively young age of the participants and the 
comparatively large sample size of high-risk subjects and controls. In addition, all 
subjects underwent careful clinical assessment at both time points and the effects of 
medication and relatedness of subjects were ruled out. All brain scans were 
obtained at the same scanner using the identical protocol at both visits and the MRI 
data were processed in an identical way using thoroughly validated methods.  
Nevertheless, some limitations need to be addressed. First, it remains unknown 
whether currently unaffected HR-well subjects may develop MDD in the future. 
Second, previous longitudinal studies have reported that the majority of the high-
risk subjects who developed BD themselves experienced depressive episodes years 
before conversion (Duffy, 2010; Hillegers, et al., 2005) so that it appears likely that 
some of our HR-MDD subjects may develop BD in the future. The follow-up 
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assessments of our study cohort will clarify if some of the HR-MDD participants 
will convert to BD and if some of our HR-well subjects go on to develop a mood 
disorder. Third, our study groups differed with respect to depression symptom 
severity at baseline. However, the median of the HAM-D total score was only 1 in 
the HR-MDD group, suggesting only sub-syndromal depression symptoms. 
Moreover, our correlation analysis revealed no relationship between depression 
symptom severity and our structural brain measures. Therefore, it appears unlikely 
that general mood differences at baseline between the groups have influenced our 
findings.  
In summary, our findings suggest that thinning in the right parahippocampal and 
right fusiform gyrus across time constitutes a familial trait marker for vulnerability 
to mood disorders. Moreover, enhanced liability to mood disorders is associated 
with abnormal left inferior frontal and precentral gyrus thinning in early adulthood, 
potentially reflecting early neurodegenerative processes. By contrast, the onset of 
MDD is linked to initially thickening of these brain areas, possibly linked to 
disease-associated processes through a lack of synaptic pruning. These findings 
advance our understanding of the neuropathological processes underlying mood 










Close relatives of BD patients are at enhanced risk of developing BD or MDD 
during their lifetime in comparison to the general population as outlined in more 
detail in Chapter 1 (Smoller & Finn, 2003). Several neuroanatomical abnormalities 
in the frontal and temporal lobes have been associated with mood disorders (Beyer 
& Krishnan, 2002; Bora, et al., 2012; Kempton, et al., 2011; Konarski, et al., 2008; 
Savitz & Drevets, 2009). In brief, grey matter volume reductions of the prefrontal 
cortex (Arnone, et al., 2009; Koolschijn, et al., 2009), particularly in the 
orbitofrontal gyrus (Bora, et al., 2012; Kempton, et al., 2011; Koolschijn, et al., 
2009; Stanfield, et al., 2009; Wilke, et al., 2004), inferior, middle and superior 
frontal gyrus (Bora, et al., 2012; Bora, et al., 2010; Du, et al., 2012; Lopez-Larson, 
et al., 2002; Lyoo, et al., 2004; Selvaraj, et al., 2012) have been observed in both 
MDD and BD patients. Moreover, grey matter decreases in the anterior cingulate 
(Bora, et al., 2012; Bora, et al., 2010; Koolschijn, et al., 2009) and precentral gyrus 
(Bora, et al., 2012; Lyoo, et al., 2004) have been detected. For the temporal lobe, 
there is evidence towards volumetric abnormalities of the superior temporal and 
medial temporal lobe (Bora, et al., 2012; Selvaraj, et al., 2012). A detailed review 
of frontal and temporal brain abnormalities in MDD as compared to BD is provided 
in Chapter 1. 
The majority of research has examined grey matter volume but not cortical surface 
area in mood disorders. Since grey matter volume is a product of cortical thickness 
and surface area (Winkler, et al., 2009), it remains therefore largely unknown if the 
frequently observed regional volume reductions in mood disorder patients reflect 
reduced cortical surface, reduced cortical thickness, or both. Only very few studies 
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have examined cortical surface area in mood disorders patients as yet. Pubmed was 
searched on 19
th
 of August 2013 with the terms (“mood disorder” or “bipolar” or 
“major depressive disorder” or “depression” or “depressive”) and (“surface area”) 
to identify previous studies that have examined cortical surface area abnormalities 
in mood disorders patients or their unaffected close relatives. None of the papers 
matching the search criteria were found to have investigated surface area in MDD 
patients or unaffected close relatives of mood disorders patients. Only a few studies 
were found that examined cortical surface area in BD. 
In a large study sample of 139 BD patients and 207 control subjects, Hartberg and 
colleagues (2011) found larger surface areas of the left superior frontal gyrus and 
right temporal pole in a combined cohort of BD-I and BD-II patients as compared 
to controls. However, a recent analysis of this study cohort revealed no significant 
differences for surface area between the groups when comparing healthy controls 
with BD-I patients only (Rimol et al., 2012). Research focussing on the surface 
area of the anterior cingulate gyrus similarly did not find evidence for surface area 
abnormalities in BD-I patients or BD patients who were experiencing a first 
psychotic episode (Fornito et al., 2008; Fornito et al., 2009). 
To examine whether cortical surface area abnormalities exist in individuals at high 
familial risk of mood disorders and to study their timing and relationship to an 
onset of MDD, cortical surface area for frontal and temporal ROIs were extracted 
from baseline and follow-up scans of Scottish Bipolar Family Study participants. In 
the analyses presented here, cortical surface area of frontal and temporal ROIs were 
compared cross-sectionally for data acquired at baseline assessment and 
longitudinally over time between the HR-MDD, HR-well and HC groups. The 
rationale for the baseline analysis was to examine whether regional cortical surface 
area abnormalities exist in the HR-MDD group prior to illness onset that may serve 
as neuroanatomical markers for a subsequent development of MDD and to assess 
their relationship to familial risk. The longitudinal analysis was intended to explore 
the time course of surface area during a period of two years to detect whether 
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abnormal brain development in the high-risk participants is evident that can be 
linked to an onset of MDD or familial risk. Similar to a repeated-measures 
ANOVA, the longitudinal analysis also allowed for testing with an increased power 
as compared to baseline analysis whether significant thickness differences between 




5.2.1 Participants and clinical assessment 
Participants were recruited as part of the Scottish Bipolar Family Study as outlined 
more detailed in Chapter 2. The HC, HR-well and HR-MDD groups were matched 
for age, gender, handedness and intelligence and detailed demographic and clinical 
descriptions of the study sample are provided in Table 3.1 in Chapter 3.  
 
5.2.2 Magnetic resonance imaging and processing 
Structural MRI scans were acquired on a 1.5 Tesla scanner as outlined in Chapter 
2. The T1 weighted images were processed using the surface-based stream of 
FreeSurfer (fully described in Chapter 2). Based on the literature review provided 
in Chapter 1 and hence the scientific relevance for mood disorders, cortical surface 
area of the following brain structures was assessed for each hemisphere separately: 
frontal pole, inferior frontal gyrus, middle frontal gyrus, superior frontal gyrus, 
orbitofrontal gyrus (including lateral and medial orbitofrontal gyrus), anterior 
cingulate (including rostral and caudal anterior cingulate), precentral gyrus, 




5.2.3 Statistical analysis 
An ANCOVA was conducted to compare cross-sectionally regional surface area 
differences between the HC, HR-well and HR-MDD groups at baseline. Age and 
sex served as covariates in this analysis. Next, linear mixed-effects models were 
applied to investigate surface area for each ROI over time (see Chapter 2 for a 
more detailed methodological description). In the linear mixed-effects model used, 
the intercept term is treated as a random effect that varies by individual so that 
intraindividual correlation among the structural brain measures of a particular 
individual is taken into account. The following independent variables were used as 
predictors of surface area for the cortical regions outlined: group, time (baseline 
versus follow-up assessment), group-by-time interaction. Age and sex served as 
covariates in the analyses. 
A statistical significance level of p ≤ 0.05 was chosen, fully corrected for multiple 
comparisons using the Benjamini & Hochberg FDR procedure (Benjamini & 
Hochberg, 1995). To allow for comparison with previous studies, effect sizes for 
nominal significant group differences were additionally calculated using Cohen's d 
(Cohen, 1988). Wherever significant between-group differences were found, 
pairwise comparisons were performed between the three groups, for which p-
values were corrected according to Tukey’s HSD procedure (pHSD ≤ 0.05). 
To assess the relationship between depression symptoms and surface area of each 
ROI, Spearman’s rank correlation coefficients between the HAM-D scores and 
surface area for each group were calculated. To assess the relationship between 
changes in surface area and changes in depressive symptoms over time, 
Spearman’s rank correlation coefficients were calculated between the surface area 
differences of the ROIs and the differences of the HAM-D scores between the two 
assessments. For ease of interpretation, data derived from the follow-up assessment 
was subtracted from the data acquired at baseline so that positive values reflect 
increases in surface area or depression symptoms over time, while negative values 
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represent decreases of these measures over time. All p-values were corrected 
according to Benjamini & Hochberg FDR procedure and considered significant 
when p ≤ 0.05. 
To examine the potentially confounding effects of exposure to medication and 
relatedness of subjects on regional brain volumes, the following additional analyses 
were performed: The analyses were repeated excluding medicated HR-MDD 




5.3.1 Cross-sectional analysis 
 
5.3.1.1 Group differences at baseline 
At baseline assessment, no significant differences in regional cortical surface area 
were found between the groups (see Table 5.1). Also, there were no nominal 
significant findings. 
 
5.3.1.2 Correlation analysis 
For the ROIs, there was a significant positive correlation between the HAM-D sum 
score and the left frontal pole surface area in the HR-MDD group that remained 
significant after FDR correction (p ≤ 0.002), indicating that surface area increases 
in this brain region are associated with higher depression symptoms in this study 
group. There were no other correlations that remained significant after FDR 
procedure. However, there was a nominal significant negative correlation between 
the HAM-D sum score and the right orbitofrontal surface area in the HC group (p ≤ 
0.022), suggesting that reducing surface area is associated with increasing 
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depressive symptom severity. No other nominal significant correlations were 
found. All results are shown in Table 5.2. 
 
5.3.1.3 Analysis of potential confounders 
To eliminate the potential confounding effects of familial relatedness of some 
subjects, the analyses were repeated, excluding randomly individuals from the 
same pedigree (Table 5.3). This analysis similarly yielded no significant group 
differences. 
 
Table 5.1 Cross-sectional analysis of cortical surface area 
 HC  HR-well  HR-MDD  Statistics 
Region (Gyrus) Mean (SD)  Mean (SD)  Mean (SD)  F P 
L inf frontal G 35.24 (4.37)  35.76 (5.27)  35.51 (2.47)  0.28 0.76 
R inf frontal G 35.71 (4.73)  36.32 (5.38)  36.44 (4.45)  0.41 0.67 
L mid frontal G 76.04 (12.12) 77.75 (10.95) 76.38 (9.26)  0.54 0.59 
R mid frontal G 75.54 (11.58) 77.72 (11.59) 75.83 (10.35) 0.87 0.42 
L sup frontal G 69.41 (8.49)  71.12 (8.66)  69.07 (7.07)  1.12 0.33 
R sup frontal G 67.37 (8.40)  68.62 (9.22)  67.17 (8.97)  0.54 0.59 
L orbitofrontal G 41.60 (5.55)  41.74 (6.13)  42.45 (4.72)  0.17 0.84 
R orbitofrontal G 40.86 (6.12)  41.20 (6.00)  42.09 (4.70)  0.35 0.71 
L frontal pole 2.38 (0.40)  2.40 (0.38)  2.45 (0.51)  0.26 0.77 
R frontal pole 3.20 (0.55)  3.29 (0.51)  3.14 (0.43)  1.03 0.36 
L ant cingulate 13.40 (2.76)  14.31 (3.19)  13.79 (2.02)  2.24 0.11 
R ant cingulate 13.54 (2.76)  13.24 (2.64)  12.64 (2.00)  0.99 0.37 
L precentral G 45.87 (4.65)  47.12 (5.82)  46.33 (4.50)  1.34 0.27 
R precentral G 46.73 (5.18)  46.62 (5.94)  46.35 (5.54)  0.04 0.96 
L fusiform G 31.95 (4.71)  32.46 (4.31)  32.22 (3.54)  0.30 0.74 
R fusiform G 30.19 (4.24)  30.94 (4.65)  30.81 (3.77)  0.68 0.51 
L sup temporal G 36.05 (4.59)  36.79 (4.31)  36.00 (4.55)  0.70 0.50 
R sup temporal G 34.11 (3.68)  34.60 (4.12)  33.06 (4.54)  1.26 0.29 
L parahippoc G 6.88 (0.99)  7.00 (0.97)  6.79 (1.00)  0.51 0.60 
R parahippoc G 6.41 (0.81)  6.47 (0.93)  6.58 (0.88)  0.32 0.73 
Cortical surface area measures are provided in cm
2
. Abbreviations: inf = inferior; mid = 




Table 5.2 Correlation of cortical surface area and HAM-D sum score 
 HC  HR-well  HR-MDD 
Region (Gyrus) R p  R p  R p 
L inf frontal G -0.06 0.60  -0.04 0.68  -0.02 0.94 
R inf frontal G -0.19 0.07  -0.05 0.61  0.16 0.52 
L mid frontal G -0.18 0.09  -0.04 0.71  -0.04 0.89 
R mid frontal G -0.17 0.12  0.03 0.78  -0.12 0.64 
L sup frontal G -0.04 0.71  0.00 0.99  0.30 0.23 
R sup frontal G -0.16 0.13  -0.10 0.39  0.14 0.58 
L orbitofrontal G -0.16 0.14  -0.09 0.37  -0.05 0.84 
R orbitofrontal G -0.24 0.02  0.03 0.77  -0.04 0.88 
L frontal pole -0.13 0.24  -0.11 0.31  0.68 <0.01 
R frontal pole -0.01 0.90  -0.05 0.63  -0.05 0.84 
L ant cingulate -0.10 0.34  -0.08 0.46  -0.02 0.95 
R ant cingulate -0.13 0.22  -0.05 0.67  0.19 0.46 
L precentral G 0.06 0.61  0.08 0.45  0.25 0.33 
R precentral G 0.02 0.86  0.00 0.98  0.30 0.23 
L fusiform G -0.02 0.82  0.04 0.74  0.21 0.41 
R fusiform G -0.02 0.88  0.02 0.83  0.14 0.57 
L sup temporal G -0.07 0.50  -0.06 0.56  0.20 0.42 
R sup temporal G -0.06 0.56  0.03 0.76  0.09 0.74 
L parahippoc G 0.10 0.38  0.06 0.55  0.09 0.71 
R parahippoc G -0.11 0.31  0.03 0.81  0.37 0.13 
Abbreviations: L = left; R = right; inf = inferior; mid = middle; sup = superior; G = gyrus; 
















Table 5.3 Cross-sectional analysis of cortical surface area in unrelated subjects 
 HC  HR-well  HR-MDD  Statistics 
Region (Gyrus) Mean (SD)  Mean (SD)  Mean (SD)  F P 
L inf frontal G 35.22 (4.39)  35.94 (5.12)  35.56 (2.53)  0.52 0.60 
R inf frontal G 35.59 (4.68)  36.58 (5.24)  36.62 (4.52)  0.96 0.39 
L mid frontal G 75.89 (12.22) 78.22 (10.93) 76.94 (9.19)  0.86 0.42 
R mid frontal G 75.51 (11.66) 78.04 (11.43) 76.21 (10.52) 1.02 0.36 
L sup frontal G 69.37 (8.56)  71.60 (8.23)  69.49 (7.03)  1.60 0.21 
R sup frontal G 67.24 (8.45)  68.99 (8.91)  67.71 (8.90)  0.85 0.43 
L orbitofrontal G 41.49 (5.55)  41.81 (6.19)  42.65 (4.77)  0.32 0.73 
R orbitofrontal G 40.76 (6.13)  41.35 (6.08)  42.35 (4.69)  0.60 0.55 
L frontal pole 2.38 (0.41)  2.39 (0.40)  2.46 (0.53)  0.28 0.76 
R frontal pole 3.20 (0.54)  3.35 (0.47)  3.13 (0.44)  2.57 0.08 
L ant cingulate 13.31 (2.72)  14.32 (3.14)  13.91 (2.01)  2.63 0.08 
R ant cingulate 13.47 (2.75)  13.17 (2.57)  12.76 (1.98)  0.66 0.52 
L precentral G 45.86 (4.70)  47.51 (5.68)  46.65 (4.41)  2.14 0.12 
R precentral G 46.69 (5.21)  46.91 (5.86)  46.77 (5.37)  0.03 0.97 
L fusiform G 31.87 (4.73)  32.53 (4.33)  32.42 (3.53)  0.47 0.62 
R fusiform G 30.11 (4.22)  31.00 (4.79)  30.88 (3.86)  0.88 0.42 
L sup temporal G 35.99 (4.60)  36.85 (4.42)  35.98 (4.68)  0.82 0.44 
R sup temporal G 34.10 (3.72)  34.47 (4.15)  33.19 (4.63)  0.78 0.46 
L parahippoc G 6.86 (0.99)  7.01 (1.00)  6.76 (1.00)  0.67 0.51 
R parahippoc G 6.40 (0.81)  6.44 (0.92)  6.58 (0.90)  0.33 0.72 
Cortical surface area measures are provided in cm
2
. Abbreviations: inf = inferior; mid = 
middle; sup = superior; ant = anterior; G = gyrus; parahippoc = parahippocampal. 
 
5.3.2 Longitudinal analysis 
 
5.3.2.1 Group differences over time 
Table 5.4 provides the results of the linear mixed-effects model analyses. The 
analysis yielded no significant FDR-adjusted effects of group, time or group-by-
time interactions. There were, however, four nominal significant findings. First, a 
nominal significant group effect (p ≤ 0.039) was found for the right superior 
temporal gyrus and the right anterior cingulate (p ≤ 0.049). Post-hoc analyses 
revealed that the HR-MDD group has smaller right superior temporal surface area 
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across both time points as compared to HC (pHSD ≤ 0.023, d = 0.704) and HR-well 
subjects (pHSD ≤ 0.036, d = 0.578), with no significant differences between the 
other two groups (pHSD ≤ 0.999, d = 0.036). For the right anterior cingulate, post-
hoc analyses revealed no significant pair-wise group differences (pHSD ≤ 0.170 for 
HC versus HR-well, d = 0.278; pHSD ≤ 0.101, d = 0.539 for HC versus HR-MDD; 
pHSD ≤ 0.988, d = 0.243 for HR-well versus HR-MDD). Moreover, nominal 
significant group-by-time interactions for the left fusiform (p ≤ 0.028) and left 
precentral gyrus (p ≤ 0.034) were found. Post-hoc tests showed that the HR-MDD 
group had a pronounced decrease in fusiform surface area over time as opposed to 
the HC group (pHSD ≤ 0.022, d = 0.590), with no other significant interaction 
effects among the groups (pHSD ≤ 0.099, d = 0.244 for HC versus HR-well; pHSD ≤ 
0.128, d = 0.388 for HR-well versus HR-MDD). Similar results were obtained for 
the left precentral gyrus, with the HR-MDD group displaying an abnormal decrease 
in surface area as compared to the HC group (pHSD ≤ 0.016, d = 0.622) and no 
interaction effects between the other groups (pHSD ≤ 0.165, d = 0.210 for HC versus 
HR-well; pHSD ≤ 0.128, d = 0.377 for HR-well versus HR-MDD). 
 
5.3.2.2 Correlation analysis 
There were no significant correlations between changes in surface area of each ROI 
and changes in depressive symptom severity. There was a nominal significant 
positive correlation between changes in right fusiform gyrus surface area and 
changes in the HAM-D sum score in the HR-well group (p ≤ 0.036), indicating that 
increasing surface area of this brain region is associated with increasing depression 




5.3.2.3 Analysis of potential confounders 
To eliminate the potential confounding effects of familial relatedness of some 
subjects, the analyses were repeated, excluding randomly individuals from the 
same pedigree (Table 5.6). This analysis similarly yielded no significant effect of 
group, time or group-by-time interaction. The nominal significant group effects for 
the right superior temporal gyrus (p ≤ 0.046) and the right anterior cingulate 
surface area (p ≤ 0.044) remained nominal significant. Similarly, the nominal 
significant group-by-time interactions for the left precentral gyrus (p ≤ 0.033) and 
left fusiform gyrus (p ≤ 0.037) remained nominal significant.  
When excluding medicated HR-MDD subjects from the analysis, there were no 
FDR-adjusted significant findings. By contrast, three out of the four nominal 
significant results of the original analysis did not reach nominal significance 
anymore. These were the group effects for the right superior temporal gyrus (p ≤ 
0.210) and the right anterior cingulate (p ≤ 0.125) as well as the group-by-time 
interaction effect for the left fusiform gyrus (p ≤ 0.055). Only the group-by-time 
interaction for the surface area of the left precentral gyrus remained significant at a 




Table 5.4 Longitudinal analysis of cortical surface area 
 HC  HR-well  HR-MDD  Statistics 
 Baseline Follow-up  Baseline Follow-up  Baseline Follow-up  Group effect Time effect GroupXTime 
Region (Gyrus) Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  F p F p F p 
L inf frontal G 35.24 (4.37) 35.43 (4.43)  35.76 (5.27) 35.34 (5.02)  35.51 (2.47) 34.97 (3.82)  0.07 0.93 1.18 0.28 0.25 0.78 
R inf frontal G 35.71 (4.73) 36.31 (4.63)  36.32 (5.38) 35.92 (5.17)  36.44 (4.45) 35.16 (4.50)  0.09 0.91 2.48 0.12 1.56 0.21 
L mid frontal G 76.04 (12.12) 77.38 (10.86)  77.75 (10.95) 77.00 (9.55)  76.38 (9.26) 72.70 (9.30)  0.95 0.39 2.80 0.10 1.19 0.31 
R mid frontal G 75.54 (11.58) 76.77 (10.51)  77.72 (11.59) 77.23 (11.29)  75.83 (10.35) 72.27 (9.96)  1.17 0.31 1.30 0.26 1.23 0.30 
L sup frontal G 69.41 (8.49) 70.77 (7.60)  71.12 (8.66) 70.49 (7.06)  69.07 (7.07) 65.62 (7.76)  2.39 0.09 2.70 0.10 2.33 0.10 
R sup frontal G 67.37 (8.40) 68.28 (7.30)  68.62 (9.22) 68.26 (8.41)  67.17 (8.97) 65.01 (9.88)  0.96 0.39 1.53 0.22 1.35 0.26 
L orbitofrontal G 41.60 (5.55) 41.48 (4.78)  41.74 (6.13) 42.06 (5.07)  42.45 (4.72) 40.61 (5.47)  0.13 0.88 1.07 0.30 2.32 0.73 
R orbitofrontal G 40.86 (6.12) 41.10 (5.19)  41.20 (6.00) 41.25 (5.02)  42.09 (4.70) 40.29 (5.11)  0.03 0.97 0.85 0.36 0.73 0.48 
L frontal pole 2.38 (0.40) 2.38 (0.40)  2.40 (0.38) 2.42 (0.41)  2.45 (0.51) 2.22 (0.35)  0.21 0.81 0.89 0.35 2.77 0.07 
R frontal pole 3.20 (0.55) 3.23 (0.52)  3.29 (0.51) 3.24 (0.51)  3.14 (0.43) 3.22 (0.63)  0.52 0.59 0.28 0.60 0.28 0.76 
L ant cingulate 13.40 (2.76) 13.59 (2.74)  14.31 (3.19) 13.88 (2.91)  13.79 (2.02) 13.52 (2.94)  0.93 0.40 0.05 0.83 1.05 0.35 
R ant cingulate 13.54 (2.76) 13.86 (2.46)  13.24 (2.64) 12.86 (2.66)  12.64 (2.00) 12.76 (2.35)  3.06 0.05 0.28 0.60 1.25 0.29 
L precentral G 45.87 (4.65) 46.67 (3.99)  47.12 (5.82) 46.77 (4.09)  46.33 (4.50) 44.54 (5.02)  1.08 0.34 1.31 0.26 3.47 0.03 
R precentral G 46.73 (5.18) 47.53 (4.51)  46.62 (5.94) 46.23 (4.48)  46.35 (5.54) 44.54 (4.86)  1.70 0.19 0.81 0.37 2.24 0.11 
L fusiform G 31.95 (4.71) 32.91 (4.87)  32.46 (4.31) 32.02 (3.68)  32.22 (3.54) 30.10 (5.56)  1.18 0.31 1.45 0.23 3.66 0.03 
R fusiform G 30.19 (4.24) 30.55 (4.44)  30.94 (4.65) 30.72 (4.60)  30.81 (3.77) 29.84 (4.72)  0.42 0.66 0.01 0.94 0.18 0.83 
L sup temporal G 36.05 (4.59) 36.42 (4.30)  36.79 (4.31) 36.70 (3.89)  36.00 (4.55) 35.00 (5.29)  0.89 0.41 1.23 0.27 0.19 0.83 
R sup temporal G 34.11 (3.68) 34.80 (2.89)  34.60 (4.12) 34.19 (3.56)  33.06 (4.54) 32.15 (4.70)  3.30 0.04 0.63 0.43 1.63 0.20 
L parahippoc G 6.88 (0.99) 6.71 (0.80)  7.00 (0.97) 7.04 (1.40)  6.79 (1.00) 6.55 (0.90)  1.72 0.18 1.40 0.24 0.85 0.43 
R parahippoc G 6.41 (0.81) 6.50 (0.79)  6.47 (0.93) 6.33 (0.86)  6.58 (0.88) 6.45 (0.93)  0.23 0.80 0.40 0.53 1.22 0.30 
Cortical surface area measures are provided in cm
2




Table 5.5 Correlation between changes in surface area and changes in HAM-D 
sum score 
 HC  HR-well  HR-MDD 
Region (Gyrus) R p  R p  R p 
L inf frontal G 0.08 0.60  0.21 0.15  0.07 0.80 
R inf frontal G -0.04 0.82  0.19 0.19  0.30 0.27 
L mid frontal G -0.01 0.95  0.13 0.38  0.30 0.28 
R mid frontal G 0.04 0.80  0.17 0.24  0.14 0.61 
L sup frontal G 0.08 0.58  0.23 0.11  0.39 0.15 
R sup frontal G -0.08 0.60  0.19 0.19  0.11 0.70 
L orbitofrontal G 0.05 0.76  0.01 0.94  -0.14 0.62 
R orbitofrontal G 0.05 0.73  0.09 0.55  0.23 0.41 
L frontal pole -0.12 0.44  0.18 0.21  -0.12 0.66 
R frontal pole -0.01 0.93  -0.03 0.84  -0.07 0.80 
L ant cingulate -0.10 0.52  0.20 0.16  0.26 0.34 
R ant cingulate 0.05 0.75  0.07 0.64  -0.02 0.93 
L precentral G 0.04 0.77  0.26 0.07  0.30 0.28 
R precentral G 0.01 0.98  0.19 0.19  0.17 0.54 
L fusiform G 0.05 0.73  0.20 0.16  0.20 0.47 
R fusiform G 0.09 0.54  0.30 0.04  0.05 0.85 
L sup temporal G -0.01 0.97  0.18 0.21  0.25 0.38 
R sup temporal G -0.07 0.65  0.05 0.72  0.21 0.45 
L parahippoc G -0.09 0.55  -0.03 0.82  0.08 0.77 
R parahippoc G 0.05 0.76  0.06 0.70  0.15 0.58 
Abbreviations: inf = inferior; mid = middle; sup = superior; ant = anterior; G = gyrus; 
parahippoc = parahippocampal. 
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Table 5.6 Longitudinal analysis of cortical surface area in unrelated subjects 
 HC  HR-well  HR-MDD  Statistics 
 Baseline Follow-up  Baseline Follow-up  Baseline Follow-up  Group effect Time effect GroupXTime 
Region (Gyrus) Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  F p F p F p 
L inf frontal G 35.22 (4.39) 35.43 (4.43)  35.22 (5.12) 35.54 (4.88)  35.63 (2.59) 35.26 (3.70)  0.15 0.87 1.01 0.32 0.23 0.79 
R inf frontal G 35.59 (4.68) 36.31 (4.63)  36.58 (5.24) 35.99 (4.84)  36.58 (4.65) 35.28 (4.59)  0.15 0.87 2.65 0.11 1.90 0.16 
L mid frontal G 75.89 (12.22) 77.38 (10.86)  78.22 (10.93) 77.11 (9.60)  76.69 (9.41) 73.41 (8.97)  0.54 0.58 2.74 0.10 1.27 0.28 
R mid frontal G 75.51 (11.66) 76.77 (10.51)  78.04 (11.43) 77.51 (11.54)  75.94 (10.77) 73.17 (9.36)  0.74 0.48 1.06 0.31 1.09 0.34 
L sup frontal G 69.37 (8.56) 70.77 (7.60)  71.60 (8.23) 70.86 (6.48)  69.08 (7.03) 66.05 (7.72)  2.22 0.11 2.58 0.11 2.33 0.10 
R sup frontal G 67.24 (8.44) 68.28 (7.30)  68.99 (8.90) 68.83 (8.55)  67.33 (9.01) 65.46 (9.94)  0.78 0.46 1.40 0.24 1.38 0.26 
L orbitofrontal G 41.89 (5.55) 41.48 (4.78)  41.81 (6.19) 42.22 (4.50)  42.44 (4.83) 40.77 (5.57)  0.21 0.81 0.56 0.45 0.37 0.69 
R orbitofrontal G 40.76 (6.13) 41.10 (5.19)  41.35 (6.08) 41.22 (5.16)  42.13 (4.73) 40.50 (5.17)  0.01 0.99 0.76 0.39 0.79 0.46 
L frontal pole 2.38 (0.41) 2.38 (0.40)  2.39 (0.40) 2.43 (0.43)  2.41 (0.50) 2.21 (0.36)  0.43 0.65 0.38 0.54 2.34 0.10 
R frontal pole 3.20 (0.54) 3.23 (0.52)  3.35 (0.47) 3.33 (0.48)  3.11 (0.45) 3.22 (0.64)  2.28 0.11 0.51 0.48 0.29 0.75 
L ant cingulate 13.31 (2.72) 13.59 (2.74)  14.32 (3.14) 13.98 (3.01)  13.90 (2.07) 13.55 (3.02)  1.05 0.35 0.06 0.81 1.09 0.34 
R ant cingulate 13.47 (2.75) 13.86 (2.46)  13.17 (2.57) 12.81 (2.79)  12.72 (2.04) 12.57 (2.26)  3.17 0.04 0.14 0.71 1.49 0.23 
L precentral G 45.86 (4.70) 46.67 (3.99)  47.51 (5.68) 47.04 (3.94)  46.32 (4.31) 44.52 (5.16)  1.55 0.22 1.46 0.23 3.51 0.03 
R precentral G 46.69 (5.21) 47.53 (4.51)  46.91 (5.86) 46.49 (4.32)  46.55 (5.44) 44.67 (4.96)  1.13 0.33 0.81 0.37 2.33 0.10 
L fusiform G 31.87 (4.73) 32.91 (4.87)  32.53 (4.33) 32.28 (3.66)  32.25 (3.56) 30.26 (5.67)  0.87 0.42 1.01 0.32 3.38 0.04 
R fusiform G 30.11 (4.21) 30.55 (4.44)  31.00 (4.79) 31.12 (4.68)  30.76 (3.94) 30.30 (4.38)  0.44 0.64 0.12 0.73 0.09 0.92 
L sup temporal G 35.99 (4.60) 36.42 (4.30)  36.85 (4.42) 36.67 (3.77)  35.84 (4.79) 35.02 (5.43)  0.99 0.37 1.35 0.25 0.21 0.81 
R sup temporal G 34.10 (3.72) 34.80 (2.89)  34.47 (4.15) 34.11 (3.69)  32.91 (4.63) 32.14 (4.83)  3.13 0.05 0.52 0.47 1.52 0.22 
L parahippoc G 6.86 (0.99) 6.71 (0.80)  7.01 (0.99) 6.99 (1.46)  6.68 (0.99) 6.54 (0.92)  1.79 0.17 1.32 0.25 0.42 0.66 
R parahippoc G 6.40 (0.81) 6.50 (0.79)  6.44 (0.92) 6.28 (0.89)  6.58 (0.93) 6.49 (0.94)  0.41 0.67 0.30 0.59 1.27 0.29 
Cortical surface area measures are provided in cm
2
. Abbreviations: inf = inferior; mid = middle; sup = superior; ant = anterior; G = gyrus; 




Table 5.7 Longitudinal analysis of cortical surface area in unmedicated HR-MDD subjects 
 HC  HR-well  HR-MDD  Statistics 
 Baseline Follow-up  Baseline Follow-up  Baseline Follow-up  Group effect Time effect GroupXTime 
Region (Gyrus) Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  F p F p F P 
L inf frontal G 35.24 (4.37) 35.43 (4.43)  35.76 (5.27) 35.34 (5.02)  35.51 (2.47) 35.29 (3.83)  0.21 0.81 1.47 0.23 0.32 0.72 
R inf frontal G 35.71 (4.73) 36.31 (4.63)  36.32 (5.38) 35.92 (5.17)  36.44 (4.45) 35.08 (4.60)  0.02 0.99 3.37 0.07 1.94 0.15 
L mid frontal G 76.04 (12.12) 77.38 (10.86)  77.75 (10.95) 77.00 (9.55)  76.38 (9.26) 73.35 (9.29)  0.52 0.60 2.61 0.11 1.15 0.32 
R mid frontal G 75.54 (11.58) 76.77 (10.51)  77.72 (11.59) 77.23 (11.29)  75.83 (10.35) 72.25 (10.83)  1.00 0.37 1.05 0.31 1.08 0.34 
L sup frontal G 69.41 (8.49) 70.77 (7.60)  71.12 (8.66) 70.49 (7.06)  69.07 (7.07) 66.41 (7.99)  0.90 0.41 3.07 0.08 2.50 0.09 
R sup frontal G 67.37 (8.40) 68.28 (7.30)  68.62 (9.22) 68.26 (8.41)  67.17 (8.97) 65.80 (10.09)  0.34 0.71 1.29 0.26 1.24 0.29 
L orbitofrontal G 41.60 (5.55) 41.48 (4.78)  41.74 (6.13) 42.06 (5.07)  42.45 (4.72) 41.75 (4.53)  0.17 0.84 0.48 0.49 0.14 0.87 
R orbitofrontal G 40.86 (6.12) 41.10 (5.19)  41.20 (6.00) 41.25 (5.02)  42.09 (4.70) 40.88 (5.03)  0.05 0.95 0.75 0.39 0.68 0.51 
L frontal pole 2.38 (0.40) 2.38 (0.40)  2.40 (0.38) 2.42 (0.41)  2.45 (0.51) 2.27 (0.33)  0.09 0.92 0.44 0.51 1.82 0.17 
R frontal pole 3.20 (0.55) 3.23 (0.52)  3.29 (0.51) 3.24 (0.51)  3.14 (0.43) 3.29 (0.68)  0.36 0.70 0.14 0.71 0.15 0.86 
L ant cingulate 13.40 (2.76) 13.59 (2.74)  14.31 (3.19) 13.88 (2.91)  13.79 (2.02) 13.61 (3.09)  0.81 0.45 0.17 0.68 0.99 0.38 
R ant cingulate 13.54 (2.76) 13.86 (2.46)  13.24 (2.64) 12.86 (2.66)  12.64 (2.00) 13.07 (2.30)  2.10 0.13 0.60 0.44 1.38 0.26 
L precentral G 45.87 (4.65) 46.67 (3.99)  47.12 (5.82) 46.77 (4.09)  46.33 (4.50) 44.36 (5.19)  1.22 0.30 1.46 0.23 3.45 0.04 
R precentral G 46.73 (5.18) 47.53 (4.51)  46.62 (5.94) 46.23 (4.48)  46.35 (5.54) 45.04 (5.03)  1.14 0.32 0.53 0.47 1.88 0.16 
L fusiform G 31.95 (4.71) 32.91 (4.87)  32.46 (4.31) 32.02 (3.68)  32.22 (3.54) 30.53 (5.15)  0.66 0.52 0.93 0.34 2.96 0.06 
R fusiform G 30.19 (4.24) 30.55 (4.44)  30.94 (4.65) 30.72 (4.60)  30.81 (3.77) 30.59 (4.85)  0.17 0.84 0.04 0.85 0.11 0.89 
L sup temporal G 36.05 (4.59) 36.42 (4.30)  36.79 (4.31) 36.70 (3.89)  36.00 (4.55) 35.44 (4.53)  0.28 0.76 1.74 0.19 0.40 0.67 
R sup temporal G 34.11 (3.68) 34.80 (2.89)  34.60 (4.12) 34.19 (3.56)  33.06 (4.54) 32.54 (4.71)  1.57 0.21 0.79 0.38 1.73 0.18 
L parahippoc G 6.88 (0.99) 6.71 (0.80)  7.00 (0.97) 7.04 (1.40)  6.79 (1.00) 6.58 (0.97)  1.46 0.23 1.23 0.27 0.83 0.44 
R parahippoc G 6.41 (0.81) 6.50 (0.79)  6.47 (0.93) 6.33 (0.86)  6.58 (0.88) 6.51 (0.98)  0.72 0.49 0.78 0.38 1.35 0.26 
Cortical surface area measures are provided in cm
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The baseline and longitudinal analyses of surface area yielded no significant 
results. Nevertheless, several nominal significant findings were observed that will 
be discussed here. Given that this is, to the best of my knowledge, the first study 
examining cortical surface area in high-risk of mood disorders subjects and MDD 
patients, the discussion hampers comparison with previous research findings. 
The baseline analysis yielded no significant surface area differences in the ROIs 
between the groups. This finding suggests that young adults at high risk of mood 
disorders because of a close family history of BD do not exhibit cortical surface 
area abnormalities, regardless of a subsequent onset of MDD or not. These results 
are in line with several studies which did not find any frontal or temporal grey 
matter abnormalities in unaffected BD relatives (Kempton, et al., 2009; Kieseppa, 
et al., 2003; McIntosh, et al., 2004; McIntosh, et al., 2006; van der Schot, et al., 
2009). They are in contrast, however, to two studies that did detect an association 
between genetic liability to BD and decreased grey matter volume in the 
medial/dorsolateral frontal gyrus and precentral gyrus (van der Schot, et al., 2010) 
and the medial frontal gyrus and anterior cingulate cortex (McDonald, Bullmore, et 
al., 2004). Furthermore, they are opposed to findings in unaffected young relatives 
of BD patients of increased right inferior frontal gyri (Hajek, et al., 2013) and 
increased parahippocampal volumes (Ladouceur, et al., 2008). All in all, our 
findings suggest that vulnerability to BD in young adolescents is not associated 
with surface area abnormalities and that observed grey matter or volumetric 
differences in previous studies may be related to cortical thickness rather than 
cortical surface abnormalities.  
A significant correlation at baseline between the left frontal pole surface area and 
the HAM-D sum score that passed FDR-correction was found in the HR-MDD 
group, indicating that the surface area of this brain region increases with higher 
depression symptom severity in this study group. Given that this relationship was 
not detected in the HR-well group and that the two high-risk groups did not differ 
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with respect to their baseline depression symptoms as measured with the HAM-D, 
it appears unlikely that the left frontal pole increases in response to higher 
depression symptoms or vice versa in individuals at high familial risk per se. 
Similarly, no significant correlation for this structure was observed when 
examining if changes in surface area are linked to changes in depression symptom 
severity over time. Accordingly, the nature of this finding remains debatable. 
The longitudinal analysis also did not reveal any significant effect of group, time or 
group-by-time interaction. These non-significant findings suggest that the often 
observed frontal and temporal grey matter reductions in MDD patients do not 
emerge as a function of abnormal cortical surface area development that is related 
the onset of MDD or familial risk. Rather, it appears likely that the frequently 
observed cortical brain abnormalities in mood disorders patients only emerge as a 
consequence of cortical thickness pathology or that they only develop with 
increasing length of illness, age, severity of symptoms or as a consequence of 
medication effects.  
Several nominal significant results were found for the longitudinal analysis that did 
not survive FDR-correction. These were nominal group effects for the right 
superior temporal gyrus and the right anterior cingulate, with post-hoc tests 
suggesting smaller surface area across time in the superior temporal gyrus in the 
HR-MDD group as compared to the other study groups and no significant pair-wise 
differences in the anterior cingulate. However, these findings did not remain 
nominally significant when excluding medicated HR-MDD subjects from the 
analysis, indicating that psychopharmacological treatment effects may have 
influenced surface area decreases in these brain regions in the HR-MDD group. 
Furthermore, nominal significant group-by-time interactions were observed for the 
left fusiform and left precentral gyrus, indicating abnormal surface area decreases 
over time in the HR-MDD group as compared to HC subjects. However, only the 
group-by-time interaction for the left precentral gyrus remained significant after 
excluding medicated HR-MDD subjects from the analysis, indicating that the 
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abnormal left fusiform surface development over time in the HR-MDD may have 
been related to the effects of psychopharmacological treatment. Future studies are 
required to examine whether surface area in this region is influenced by 
medication. The group-by-time interaction for the left precentral gyrus that 
remained nominally significant after excluding medicated HR-MDD subjects gives 
a first line of evidence to suggest that abnormal surface area decreases in this brain 
region may be linked to an onset of MDD and reflect illness-associated effects. 
Given that there was no significant correlation between changes in cortical surface 
area in this brain region and changes in the HAM-D sum score, it is unlikely that 
left precentral surface area decreases are linked to depression symptom severity. 
More longitudinal studies with larger sample sizes are clearly needed to investigate 
if this nominal significant finding is deemed correct. 
The strengths of this study are its longitudinal nature, the assessment of subjects 
prior to illness onset, the relatively young age of the participants and the 
comparatively large sample size of high-risk subjects and controls. In addition, all 
subjects underwent careful clinical assessment at both time points and the effects of 
medication and relatedness of subjects were ruled out. All brain scans were 
obtained at the same scanner using the identical protocol at both visits and the MRI 
data were processed in an identical way using thoroughly validated methods.  
Nevertheless, some limitations need to be addressed. First, it remains unknown 
whether currently unaffected HR-well subjects may develop MDD in the future. 
Second, previous longitudinal studies have reported that the majority of the high-
risk subjects who developed BD themselves experienced depressive episodes years 
before conversion (Duffy, 2010; Hillegers, et al., 2005) so that it appears likely that 
some of our HR-MDD subjects may develop BD in the future. The follow-up 
assessments of our study cohort will clarify if some of the HR-MDD participants 
will convert to BD and if some of our HR-well subjects go on to develop a mood 
disorder. Third, our study groups differed with respect to depression symptom 
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severity at baseline. However, the median of the HAM-D total score was only 1 in 
the HR-MDD group, suggesting only sub-syndromal depression symptoms.  
In summary, our findings suggest that individuals at high familial risk of mood 
disorders do not exhibit surface area abnormalities, regardless of an onset of MDD 
or not. Moreover, the frequently observed frontal and temporal grey matter 
decreases in MDD patients do not appear to be driven by abnormal cortical surface 
area development in relation to illness onset or familial high risk in young adults. 
However, a nominal significant interaction effect for the left precentral gyrus 
provides partial support for abnormal surface area decreases over time as high-risk 
















Close relatives of BD patients are at enhanced risk of developing BD or MDD 
during their lifetime as outlined in more detail in Chapter 1. There is strong support 
for an overlap in the causal pathways of both disorders coming from familial 
aggregation and genetic association studies (Barnett & Smoller, 2009; Craddock, 
2006; Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013; 
McGuffin, et al., 2003; Schulze, et al., 2012; Sullivan, et al., 2000).  
A broad range of cognitive deficits have been observed in mood disorders patients, 
with neuropsychological performance impairments being less widespread in 
unaffected BD or MDD relatives (see paragraph 1.6). Amongst others, first-episode 
MDD patients have shown performance deficits during tasks involving attentional 
processing speed such as the Digit Span forwards and cognitive flexibility as 
measured with the WCST or IED (Lee, et al., 2012). Similarly, meta-analyses of 
first-episode or euthymic BD patients have found impairments during attentional 
processing speed and cognitive flexibility (Arts, et al., 2008; Bourne, et al., 2013). 
Moreover, various verbal learning and memory performance measures of the 
CVLT have been found to be impaired (Arts, et al., 2008; Bourne, et al., 2013) in 
both of these patient populations, with working memory impairments as measured 
with the Digit Span backwards being only evident in the euthymic BD subgroup 
(Arts, et al., 2008). 
First-degree relatives of BD patients have also been shown to have deficits during 
tasks involving attentional processing (Glahn, et al., 2010), verbal learning and 
memory (Arts, et al., 2008; Balanza-Martinez et al., 2008; Bora, Yucel, & Pantelis, 
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2009), cognitive flexibility (Bora, et al., 2009) and working memory (Balanza-
Martinez, et al., 2008; Glahn, et al., 2010). It should however be noted that the 
magnitude and consistency of these findings is generally reduced in comparison to 
affected individuals. Further evidence for the importance of attention, verbal 
memory and working memory deficits in the aetiology of mood disorders comes 
from a study by Glahn et al. (2012). Using a large sample of randomly-selected 
pedigrees, the authors showed that neuropsychological impairments in these 
domains may potentially serve as candidate neurocognitive endophenotypes for 
MDD.  
To the best of my knowledge, all neuropsychological studies on BD and MDD thus 
far have assessed neurocognition in affected individuals or their unaffected 
relatives only. These studies can’t discern whether cognitive deficits reflect early 
neurodevelopmental disruptions predisposing to illness, events linked to the illness 
onset, or whether they are adaptive or secondary to the effects of chronic illness or 
its treatment. Neuropsychological examinations of individuals at high risk of mood 
disorders because of a close family history of BD hold the potential to identify 
neurocognitive deficits related to enhanced familial vulnerability, unconfounded by 
the presence of illness. However, to the best of my knowledge, no study has yet 
examined the effects of familial risk on neurocognition in a prospective study.  
The longitudinal Scottish Bipolar Family Study is well-designed to examine the 
timing of neuropsychological impairment in mood disorders and their relationship 
to familial risk and onset of illness. In the analyses presented here, 
neuropsychological measures of attentional processing speed, verbal learning and 
memory, cognitive flexibility and working memory were compared cross-
sectionally for data acquired at baseline assessment and longitudinally over time 
between the HR-MDD, HR-well and HC groups. The rationale for the baseline 
analysis was to examine whether specific neuropsychological deficits exists in the 
HR-MDD group prior to illness onset that may serve as neurocognitive marker for 
a subsequent development of MDD and to assess their relationship to familial risk. 
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The longitudinal analysis was intended to explore the time course of 
neuropsychological performance during a period of two years to detect whether a 
decline in neuropsychological function in the high-risk participants is evident that 
can be linked to an onset of MDD or familial risk. Similar to a repeated measures 
ANOVA, the longitudinal analysis also allowed for testing with an increased power 
as compared to baseline analysis whether significant performance differences 




6.2.1 Participants and clinical assessment 
Participants were recruited as part of the Scottish Bipolar Family Study as outlined 
more detailed in Chapter 2. The HC, HR-well and HR-MDD groups were matched 
for age, gender, handedness and intelligence and detailed demographic and clinical 
descriptions of the study sample are provided in Table 3.1 in Chapter 3. 
 
6.2.2 Neuropsychological assessment 
At baseline and follow-up assessment, the Digit Span forwards and backwards, 
CVLT and IED were administered to assess attentional processing speed, working 
memory, verbal learning, verbal memory and cognitive flexibility. Detailed 
information about the neuropsychological tests is provided in Chapter 2.3. The 
following performance measures were extracted for analysis (see Table 6.1): For 
the Digit Span, the number of correctly recalled strings of numbers during the 
forwards condition (Digit Span forwards) and the number of correctly recalled 
strings of numbers in reversed order during the backwards condition (Digit Span 
backwards) were calculated as measures of attentional processing speed and 
working memory, respectively. For the CVLT, the number of words correctly 
recalled during trials 1-5 (CVLT learning) as an indice of verbal learning ability 
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was computed as well as the number of words recalled during the free short delay 
recall (CVLT short delay) and free long delay recall (CVLT long delay) as 
estimates of verbal memory. For the IED, the number of trials needed to complete 
task stage 1 (IED SDL) and the number of trials needed to complete task stages 2, 5 
and 7 (IED RL) were calculated to assess simple discrimination learning and 
reversal learning performance, respectively. Furthermore, the number of trials 
needed to complete task stage 6 (IED IDS) and the number of trials needed to 
complete task stage 8 (IED EDS) were computed to extract intradimensional set-
shifting and extradimensional set-shifting ability, respectively. 
 
Table 6.1 Neuropsychological performance parameters 
Task parameter Measure Neuropsychological domain 
Digit Span forwards Number of correctly recalled 
strings of numbers 
Attentional processing speed 
Digit Span backwards the number of correctly recalled 
strings of numbers in reversed 
order 
Working memory 
CVLT learning number of words correctly 
recalled during trials 1-5 
Verbal learning 
CVLT short delay number of words correctly 
recalled during free short delay 
recall 
Verbal memory 
CVLT long delay number of words correctly 
recalled during free long delay 
recall 
Verbal memory 
IED SDL Number of trials needed to 
complete stage 1 
Simple discrimination learning 
IED RL Number of trials needed to 
complete stages 2, 5, 7 
Reversal learning 
IED IDS Number of trials needed to 
complete stage 6 
Intradimensional set-shifting 
IED EDS Number of trials needed to 
complete stage 8 
Extradimensional set-shifting 
Abbreviations: CVLT = California Verbal Learning Test; IED = Intra-/Extradimensional Set 
Shifting Task; SDL = simple discrimination learning; RL = reversal learning; IDS = 





6.2.3 Statistical analysis 
An ANCOVA was conducted to compare cross-sectionally neuropsychological 
performance measures between the HC, HR-well and HR-MDD groups at baseline. 
Neurocognitive performance measures that did not conform to assumptions of 
normality and/or homogeneity of variance were transformed using the Box-Cox 
procedure (Box & Cox, 1964) which automatically selects transformations that 
maximise the approximation of the transformed data to a normal distribution using 
a likelihood function. Age and sex served as covariates in this analysis. Next, linear 
mixed-effects models were applied to investigate neuropsychological performance 
over time (see Chapter 2 for a more detailed methodological description). In the 
linear mixed-effects model used, the intercept term is treated as a random effect 
that varies by individual so that intraindividual correlation among the 
neurocognitive measures of a particular individual is taken into account. The 
following independent variables were used as predictors of neurocognitive 
parameters outlined: group, time (baseline versus follow-up assessment), group-by-
time interaction. Age and sex served as covariates in the analyses. 
A statistical significance level of p ≤ 0.05 was chosen, fully corrected for multiple 
comparisons using the Benjamini & Hochberg FDR procedure (Benjamini & 
Hochberg, 1995). To allow for comparison with previous studies, effect sizes for 
nominal significant group differences were additionally calculated using Cohen's d 
(Cohen, 1988). Wherever significant between-group differences were found, 
pairwise comparisons were performed between the three groups, for which p-
values were corrected according to Tukey’s HSD procedure (pHSD ≤ 0.05). 
To assess the relationship between depression symptoms and neuropsychological 
performance of each measure, Spearman’s rank correlation coefficients between 
the HAM-D scores and performance measures for each group were calculated. To 
assess the relationship between changes in performance and changes in depressive 
symptoms over time, Spearman’s rank correlation coefficients were calculated 
between the performance differences of the neurocognitive measures and the 
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differences of the HAM-D scores between the two assessments. For ease of 
interpretation, data derived from the follow-up assessment was subtracted from the 
data acquired at baseline so that positive values reflect increases in performance or 
depression symptoms over time, while negative values represent decreases of these 
measures over time. All p-values were corrected according to Benjamini & 
Hochberg FDR procedure and considered significant when p ≤ 0.05. 
To examine the potentially confounding effects of exposure to medication and 
relatedness of subjects on neuropsychological performance, the following 
additional analyses were performed: The analyses were repeated excluding 




6.3.1 Cross-sectional analysis 
 
6.3.1.1 Group differences at baseline 
At baseline assessment, no significant FDR-corrected differences in 
neuropsychological performance were found between the groups (see Table 6.2). 
There was a nominal significant group difference for extradimensional set shifting 
(p ≤ 0.021). Post-hoc tests indicated that the HR-MDD group (pHSD ≤ 0.019, d = 
0.655) and the HR-well group (pHSD ≤ 0.038, d = 0.201) needed more trials to 
successfully complete the extradimensional set shifting stage of the IED as 
compared to HC participants, with no performance differences between the high-
risk groups (pHSD ≤ 0.232, d = 0.459). 
 
6.3.1.2 Correlation analysis 
For the neurocognitive performance measures, there were no significant 
correlations with depression symptom severity that remained significant after FDR 
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correction. There was one nominal significant correlation. The free long delay 
recall of the CVLT was negatively correlated with the HAM-D sum score in the 
HC sample (p ≤ 0.028), indicating that poorer long delay memory performance is 
associated with higher depression symptoms (see Table 6.3). 
 
6.3.1.3 Analysis of potential confounders 
To eliminate the potential confounding effects of familial relatedness of some 
subjects, the analyses were repeated, excluding randomly individuals from the 
same pedigree (Table 6.4). This analysis similarly yielded no significant FDR-
corrected group differences. The nominal significant group effect for 
extradimensional set-shifting (p ≤ 0.028) remained nominally significant. 
 
Table 6.2 Cross-sectional analysis of neurocognitive performance 
 HC  HR-well  HR-MDD    Statistics 
Task parameter Mean (SD)  Mean (SD)  Mean (SD)    F p 
Digit Span forwards 6.77 (1.28)  6.87 (1.21)  6.68 (1.53)    0.31 0.74 
Digit Span backwards 5.18 (1.24)  4.80 (1.14)  5.22 (1.22)    2.47 0.09 
CVLT learning 54.55 (10.87)  54.35 (9.45)  50.47 (17.72)    0.02 0.98 
CVLT short delay 11.94 (2.74)  11.35 (2.78)  10.18 (4.76)    0.97 0.38 
CVLT long delay 12.73 (2.67)  11.90 (2.88)  11.18 (4.75)    1.50 0.23 
IED SDL 6.61 (0.80)  7.00 (1.87)  6.75 (0.86)    1.75 0.18 
IED RL 22.29 (4.47)  21.97 (2.71)  24.63 (8.78)    0.46 0.63 
IED IDS 6.50 (1.33)  6.50 (1.03)  6.50 (0.89)    0.23 0.79 
IED EDS 24.53 (18.03)  28.07 (17.74)  37.50 (17.49)    3.93 0.02 
Abbreviations: CVLT = California Verbal Learning Test; IED = Intra-/Extradimensional Set 
Shifting Task; SDL = simple discrimination learning; RL = reversal learning; IDS = 










Table 6.3 Correlation between neurocognitive performance measures and HAM-D 
sum scores 
 HC  HR-well  HR-MDD 
Task parameter  R p  R p  R p 
Digit Span forwards 0.14 0.23  0.07 0.55  -0.46 0.06 
Digit Span backwards -0.04 0.71  -0.04 0.73  -0.42 0.11 
CVLT learning -0.21 0.06  -0.10 0.39  0.11 0.71 
CVLT short delay -0.16 0.14  -0.06 0.58  0.13 0.67 
CVLT long delay -0.24 0.03  -0.10 0.39  0.10 0.74 
IED SDL -0.13 0.27  0.10 0.37  0.13 0.65 
IED RL -0.01 0.95  -0.15 0.18  -0.19 0.52 
IED IDS -0.01 0.99  -0.11 0.34  -0.39 0.16 
IED EDS 0.10 0.39  -0.01 0.93  0.03 0.93 
Abbreviations: CVLT = California Verbal Learning Test; IED = Intra-/Extradimensional Set 
Shifting Task; SDL = simple discrimination learning; RL = reversal learning; IDS = 
intradimensional set-shifting; EDS = extradimensional set-shifting. 
 
Table 6.4 Cross-sectional analysis of neurocognitive performance in unrelated  
 subjects 
 HC  HR-well  HR-MDD S   Statistics 
Task parameter Mean (SD)  Mean (SD)  Mean (SD)    F p 
Digit Span forwards 6.75 (1.27)  6.81 (1.17)  6.95 (1.55)    0.01 0.99 
Digit Span backwards 5.16 (1.24)  4.83 (1.16)  5.33 (1.19)    1.98 0.14 
CVLT learning 54.44 (10.89)  54.14 (9.93)  48.65 (17.62)    0.08 0.93 
CVLT short delay  11.97 (2.77)  11.34 (2.79)  9.82 (4.52)    1.44 0.24 
CVLT long delay  12.73 (2.70)  11.81 (2.90)  10.76 (4.56)    1.84 0.16 
IED SDL 6.60 (0.81)  7.06 (2.01)  6.63 (0.89)    1.88 0.16 
IED RL 22.27 (4.51)  22.06 (2.86)  24.63 (8.78)    0.54 0.59 
IED IDS 6.51 (1.35)  6.48 (1.05)  6.63 (0.96)    0.10 0.91 
IED EDS 24.37 (17.97)  27.98 (17.90)  36.38 (18.68)    3.45 0.03 
Abbreviations: CVLT = California Verbal Learning Test; IED = Intra-/Extradimensional Set 
Shifting Task; SDL = simple discrimination learning; RL = reversal learning; IDS = 







6.3.2 Longitudinal analysis 
 
6.3.2.1 Group differences over time 
Table 6.5 provides the results of the linear mixed-effects model analyses. A 
significant group effect was found for the long delay free recall (p ≤ 0.003) and 
extradimensional set-shifting (p ≤ 0.004) that passed the FDR procedure (see 
Figure 6.1). Post-hoc analyses revealed that HC subjects recall significantly more 
words over both assessment time points during the long delay free recall than HR-
well participants (pHSD ≤ 0.002, d = 0.482), with no significant differences between 
the HC and HR-MDD group (pHSD ≤ 0.136, d = 0.461) or the HR-well and HR-
MDD group (pHSD ≤ 0.485, d = 0.041). For the extradimensional set-shifting 
performance, post-hoc analyses showed that HC subjects have a significantly 
superior task performance across both time points as compared to HR-well  (pHSD ≤ 
0.031, d = 0.231) and HR-MDD subjects (pHSD ≤ 0.004, d = 0.849), with no 
significant difference between the two high-risk groups (pHSD ≤ 0.077, d = 0.571). 
Moreover, a significant effect of time was observed for the Digit Span forwards (p 
≤ 0.009), verbal learning (p ≤ 0.003), free short delay recall (p ≤ 0.006), simple 
discrimination learning (p ≤ 0.003) and extradimensional set-shifting (p ≤ 0.001). 
For all neurocognitive measures except for simple discrimination learning, the 
effect was driven by all participant groups displaying enhanced performance during 
the follow-up assessment as compared to the baseline assessment. By contrast, the 
time effect for simple discrimination learning ability was in the opposite direction, 
with all participant groups showing worse performance at follow-up appointment 
as compared to baseline appointment. 
The analyses revealed no significant group-by-time interactions. There was one 
nominally significant group effect for the free short delay recall (p ≤ 0.018) that did 
not pass FDR correction. Post-hoc analyses showed that the HC group performed 
better during this task as compared to the HR-well group (pHSD ≤ 0.010, d = 0.412), 
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with no differences between HC and HR-MDD subjects (pHSD ≤ 0.195, d = 0.364) 
or between the two high-risk groups (pHSD ≤ 0.622, d = 0.062).  
 
6.3.2.2 Correlation analysis 
There were no significant correlations between changes in neurocognitive 
performance measures and changes in depressive symptom severity (see Table 
6.6). There was a nominal significant negative correlation between changes in the 
Digit Span forwards performance and changes in the HAM-D sum score in the HC 
group (p ≤ 0.045), indicating that decreasing task performance in HC subjects is 
associated with increasing depression symptom severity. By contrast, there was a 
nominal significant positive correlation between changes in the Digit Span 
forwards performance and changes in the HAM-D sum score in the HR-well group 
(p ≤ 0.031), indicating that increasing task performance is associated with 
increasing depression symptom severity. As highlighted before, these results were 
only nominally significant and did not hold when applying FDR corrections. 
 
6.3.2.3 Analysis of potential confounders 
All results remained significant after FDR correction when randomly excluding 
related subjects. A significant group effect was found for the long delay free recall 
(p ≤ 0.003) and extradimensional set-shifting (p ≤ 0.003) that passed the FDR 
procedure. Of note, the nominally significant group effect for the free short delay 
recall that did not pass FDR correction in the original analysis reached FDR-
corrected significance when analysing unrelated subjects only (p ≤ 0.015). 
Moreover, a significant effect of time was observed as in the original analysis for 
the Digit Span forwards (p ≤ 0.012), verbal learning (p ≤ 0.005), free short delay 
recall (p ≤ 0.012), simple discrimination learning (p ≤ 0.004) and extradimensional 
set-shifting (p ≤ 0.001).  
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When excluding medicated HR-MDD subjects from the analysis, the significant 
group effect for the long delay free recall (p ≤ 0.003) remained significant after 
FDR correction. The group effect for extradimensional set-shifting (p ≤ 0.035) 
remained significant at nominal level only. The significant effects of time for 
simple discrimination learning (p ≤ 0.003) and extradimensional set-shifting (p ≤ 
0.001) remained significant after the FDR procedure. The observed time effects for 
the Digit Span forwards (p ≤ 0.019), verbal learning (p ≤ 0.029) and free short 
delay recall (p ≤ 0.045) remained significant at a nominal level only. 
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Table 6.5 Longitudinal analysis of neurocognitive performance 
 HC  HR-well  HR-MDD  Statistics 
 Baseline Follow-up  Baseline Follow-up  Baseline Follow-up  Group effect Time effect GroupXTime 
Region Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  F p F p F p 
Digit Span forwards 6.77 (1.28) 7.50 (1.48)  6.87 (1.21) 6.98 (1.34)  6.68 (1.53) 7.10 (1.41)  0.36 0.70 7.02 0.01 1.35 0.26 
Digit Span backwards 5.18 (1.24) 5.46 (1.36)  4.80 (1.14) 5.00 (1.11)  5.22 (1.22) 5.29 (1.71)  2.57 0.08 0.78 0.38 0.20 0.82 
CVLT learning 54.55 (10.87) 60.48 (9.47)  54.35 (9.45) 56.57 (10.34)  50.47 (17.72) 56.23 (10.79)  1.63 0.20 9.32 <0.01 2.05 0.13 
CVLT short delay 11.94 (2.74) 13.18 (2.70)  11.35 (2.78) 11.75 (3.00)  10.18 (4.76) 12.00 (3.18)  4.09 0.02 7.77 0.01 1.38 0.25 
CVLT long delay 12.73 (2.67) 13.73 (2.59)  11.90 (2.88) 12.05 (2.77)  11.18 (4.75) 12.27 (3.04)  6.11 <0.01 1.74 0.19 1.47 0.23 
IED SDL 6.61 (0.80) 6.98 (1.60)  7.00 (1.87) 7.31 (2.37)  6.75 (0.86) 7.30 (1.53)  0.54 0.58 8.89 <0.01 1.28 0.28 
IED RL 22.29 (4.47) 22.30 (2.15)  21.97 (2.71) 24.36 (11.95)  24.63 (8.78) 22.70 (2.58)  0.61 0.54 3.59 0.06 0.21 0.81 
IED IDS 6.50 (1.33) 6.83 (1.67)  6.50 (1.03) 7.10 (2.79)  6.50 (0.89) 6.25 (0.55)  0.76 0.47 0.80 0.37 1.64 0.20 
IED EDS 24.53 (18.03) 17.25 (15.42)  28.07 (17.74) 22.07 (17.47)  37.50 (17.49) 29.20 (19.88)  5.80 <0.01 19.23 <0.01 0.22 0.80 
Abbreviations: CVLT = California Verbal Learning Test; IED = Intra-/Extradimensional Set Shifting Task; SDL = simple discrimination 
learning; RL = reversal learning; IDS = intradimensional set-shifting; EDS = extradimensional set-shifting; bold indicates significant effect 












Table 6.6 Correlation between changes in neurocognitive performance and 
changes in HAM-D sum scores 
 HC  HR-well  HR-MDD 
Region  R p  R p  R p 
Digit Span forwards -0.32 0.05  0.34 0.03  0.03 0.94 
Digit Span backwards -0.01 0.98  -0.23 0.16  -0.03 0.94 
CVLT learning -0.09 0.54  -0.21 0.16  0.35 0.32 
CVLT short delay -0.15 0.31  -0.05 0.76  0.15 0.67 
CVLT long delay  -0.06 0.70  0.03 0.84  0.02 0.96 
IED SDL 0.29 0.08  -0.23 0.14  0.11 0.77 
IED RL 0.04 0.83  0.01 0.95  -0.39 0.27 
IED IDS 0.22 0.19  -0.12 0.45  -0.22 0.55 
IED EDS 0.06 0.72  -0.29 0.07  0.49 0.15 
Abbreviations: CVLT = California Verbal Learning Test; IED = Intra-/Extradimensional Set 
Shifting Task; SDL = simple discrimination learning; RL = reversal learning; IDS = 












Table 6.7 Longitudinal analysis of neurocognitive performance in unrelated subjects 
Abbreviations: CVLT = California Verbal Learning Test; IED = Intra-/Extradimensional Set Shifting Task; SDL = simple discrimination 
learning; RL = reversal learning; IDS = intradimensional set-shifting; EDS = extradimensional set-shifting; bold indicates significant effect 








 HC  HR-well  HR-MDD  Statistics 
 Baseline Follow-up  Baseline Follow-up  Baseline Follow-up  Group effect Time effect GroupXTime 
Region Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  F p F p F p 
Digit Span forwards 6.75 (1.27) 7.51 (1.46)  6.81 (1.17) 6.87 (1.36)  6.95 (1.55) 7.15 (1.42)  0.54 0.58 6.52 0.01 1.41 0.25 
Digit Span backwards 5.16 (1.24) 5.49 (1.36)  4.83 (1.16) 4.98 (1.13)  5.33 (1.19) 5.30 (1.75)  1.94 0.15 0.55 0.46 0.16 0.85 
CVLT learning 54.44 (10.89) 60.35 (9.44)  54.14 (9.93) 56.31 (10.79)  48.65 (17.62) 55.62 (10.67)  1.71 0.18 8.09 <0.01 1.95 0.15 
CVLT short delay 11.97 (2.77) 13.14 (2.70)  11.34 (2.79) 11.73 (3.06)  9.82 (4.52) 11.81 (3.12)  4.31 0.02 6.54 0.01 1.25 0.29 
CVLT long delay 12.73 (2.70) 13.66 (2.62)  11.81 (2.90) 12.04 (2.89)  10.76 (4.56) 12.10 (3.00)  5.99 <0.01 1.87 0.17 0.99 0.37 
IED SDL 6.60 (0.81) 6.96 (1.59)  7.06 (2.01) 7.40 (2.57)  6.63 (0.89) 7.32 (1.57)  0.59 0.55 8.39 <0.01 1.13 0.33 
IED RL 22.27 (4.51) 22.28 (2.14)  22.06 (2.86) 24.77 (13.07)  24.63 (8.78) 22.32 (1.97)  0.41 0.66 2.36 0.13 0.34 0.71 
IED IDS 6.51 (1.35) 6.82 (1.66)  6.48 (1.05) 6.75 (1.54)  6.63 (0.96) 6.21 (0.54)  0.81 0.45 0.30 0.58 2.08 0.13 
IED EDS 24.37 (17.97) 17.85 (15.91)  27.98 (17.90) 21.06 (16.90)  36.38 (18.68) 30.21 (19.89)  6.05 <0.01 16.47 <0.01 0.08 0.92 
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Table 6.8 Longitudinal analysis of neurocognitive performance in unmedicated HR-MDD subjects 
Abbreviations: CVLT = California Verbal Learning Test; IED = Intra-/Extradimensional Set Shifting Task; SDL = simple discrimination 
learning; RL = reversal learning; IDS = intradimensional set-shifting; EDS = extradimensional set-shifting; bold indicates significant effect 
after FDR correction. 
 HC  HR-well  HR-MDD  Statistics 
 Baseline Follow-up  Baseline Follow-up  Baseline Follow-up  Group effect Time effect GroupXTime 
Region Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  F p F p F p 
Digit Span forwards 6.77 (1.28) 7.50 (1.48)  6.87 (1.21) 6.98 (1.34)  6.68 (1.53) 7.12 (1.29)  0.38 0.69 5.64 0.02 1.45 0.24 
Digit Span backwards 5.18 (1.24) 5.46 (1.36)  4.80 (1.14) 5.00 (1.11)  5.22 (1.22) 5.47 (1.66)  3.03 0.05 1.49 0.23 0.05 0.95 
CVLT learning 54.55 (10.87) 60.48 (9.47)  54.35 (9.45) 56.57 (10.34)  50.47 (17.72) 55.11 (11.03)  1.55 0.21 4.88 0.03 2.85 0.06 
CVLT short delay 11.94 (2.74) 13.18 (2.70)  11.35 (2.78) 11.75 (3.00)  10.18 (4.76) 11.67 (3.25)  4.01 0.02 4.10 0.05 1.33 0.27 
CVLT long delay 12.73 (2.67) 13.73 (2.59)  11.90 (2.88) 12.05 (2.77)  11.18 (4.75) 12.11 (3.27)  5.96 <0.01 0.50 0.48 1.79 0.17 
IED SDL 6.61 (0.80) 6.98 (1.60)  7.00 (1.87) 7.31 (2.37)  6.75 (0.86) 7.44 (1.67)  0.68 0.51 9.28 <0.01 1.43 0.24 
IED RL 22.29 (4.47) 22.30 (2.15)  21.97 (2.71) 24.36 (11.95)  24.63 (8.78) 22.69 (2.70)  0.59 0.56 2.59 0.11 0.34 0.72 
IED IDS 6.50 (1.33) 6.83 (1.67)  6.50 (1.03) 7.10 (2.79)  6.50 (0.89) 6.25 (0.58)  0.35 0.70 0.20 0.65 2.36 0.10 




This is, to the best of my knowledge, the first prospective longitudinal study 
examining neurocognitive performance in high-risk of mood disorders individuals 
who were unaffected at initial assessment and either developed MDD or remained 
well during the follow-up period.  
Reduced long delay verbal memory and extradimensional set-shifting performance 
across the two time points were found in the HR-well group relative to controls, 
with the HR-MDD group displaying decreased extradimensional set-shifting 
abilities as compared to the HC group only. Moreover, significant effects of time 
were observed for attentional processing speed, verbal learning, short delay verbal 
memory and extradimensional set-shifting, indicating superior performance during 
these tasks at follow-up assessment as compared to baseline assessment across all 
participant groups. There was also a significant effect of time for simple 
discrimination learning due to decreased task performance at follow-up as 
compared to baseline across all groups. 
The finding of reduced long delay verbal memory and extradimensional set-
shifting performance in the HR-well group across time suggests that 
neurocognitive deficits in these domains constitute a familial trait marker for 
vulnerability to mood disorders. It cannot be determined from the data if the 
decreased task performance is a consequence of shared genetic and/or 
environmental effects. Given that they are already present in early adulthood, they 
are unlikely to be of degenerative origin but likely represent disturbances of normal 
brain development predisposing to illness. Since no significant differences between 
the two high-risk groups and no group-by-time interaction emerged, the results do 
not speak towards reduced verbal memory and extradimensional set-shifting 
abilities to be directly linked to an onset of MDD. It should be highlighted, 
however, that visual inspection of extradimensional set-shifting performance 
(Figure 6.1) shows that the HR-MDD group performed worse than the HR-well 
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group across time. Accordingly, it cannot be ruled out that the small sample size of 
the HR-MDD group did not allow for detection of significant effects due to a lack 
of power. Indeed, a meta-analyses by Bora and colleagues (2009) showed that 
effect sizes for cognitive flexibility in healthy relatives of BD patients were small. 
It appears therefore important to investigate neurocognition further in a larger 
sample size of high-risk subjects who go on to develop MDD. 
The results of decreased verbal memory and extradimensional set-shifting in 
relatives of BD patients are in line with findings from recent meta-analyses (Arts, 
et al., 2008; Balanza-Martinez, et al., 2008; Bora, et al., 2009). However, it should 
be noted that the analyses presented here do not confirm previous reports of 
attentional processing, verbal learning and working memory to be reduced in high-
risk BD subjects (Arts, et al., 2008; Balanza-Martinez, et al., 2008; Bora, et al., 
2009; Glahn, et al., 2010). As outlined earlier, one potential reason for the absence 
of significant findings may well derive from the fact that neurocognitive deficits in 
relatives of BD patients are better detectable in particularly large sample sizes as 
effect sizes generally tend to be small (Arts, et al., 2008). 
From a neuroanatomical point of view, both short-term and long-term storage and 
retrieval of verbal information have been linked to a bilateral frontal and parietal 
network of brain regions including the posterior inferior frontal, anterior middle 
frontal, anterior cingulate and supramarginal gyrus (Andreasen, et al., 1995; S. 
Dupont, et al., 2002; Henson, et al., 2000). Moreover, it has been shown that 
enhanced performance during the CVLT is associated with higher engagement of 
the right hippocampus and right frontal lobe (Johnson, et al., 2001). Dysfunction of 
this network of brain regions may well be in line with studies suggesting that there 
may be diminished prefrontal modulation of various brain regions including the 
anterior cingulate that results in dysregulation of mood as evident in BD 
(Strakowski, Delbello, & Adler, 2005). 
While complex tasks involving extradimensional set-shifting undoubtedly rely on 
the interplay of various brain regions including lateral prefrontal, orbital, and 
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parietal brain areas that may serve as a supervisory attentional network, the 
ventrolateral prefrontal cortex in particular has been hypothesized to be 
functionally specialised for extradimensional set-shifting (Hampshire & Owen, 
2006). Reduced extradimensional set-shifting performance may thus be in line with 
hypothesis of malfunction of the ventral brain system to be underlying the 
pathogenesis of BD which is thought to be essential for affective processing and 
modulation, with the ventrolateral prefrontal cortex playing a central role (Phillips, 
et al., 2003a, 2003b).  
The finding of significant time effects for attentional processing speed, verbal 
learning, short delay verbal memory and extradimensional set-shifting in the 
direction of superior performance during follow-up as compared to baseline 
assessment across groups most likely reflects the effects of repeated task 
presentation. These practice effects during neuropsychological examination have 
been well documented in the literature (Bartels, Wegrzyn, Wiedl, Ackermann, & 
Ehrenreich, 2010). There was also a significant effect of time for simple 
discrimination learning due to decreased task performance at follow-up as 
compared to baseline assessment across all groups. One plausible explanation for 
this conflicting result may be that participants remembered the task from the 
baseline assessment and already shifted their attention to the currently irrelevant 
stimulus as they were expecting the reversal of the rule to occur at follow-up 
examination. 
The strengths of this study are its longitudinal nature, the assessment of subjects 
prior to illness onset, the relatively young age of the participants and the 
comparatively large sample size of high-risk subjects and controls. In addition, all 
subjects underwent careful clinical assessment at both time points and the effects of 
medication and relatedness of subjects were ruled out.  
Nevertheless, some limitations need to be addressed. First, it remains unknown 
whether currently unaffected HR-well subjects may develop MDD in the future. 
Second, previous longitudinal studies have reported that the majority of the high-
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risk subjects who developed BD themselves experienced depressive episodes years 
before conversion (Duffy, 2010; Hillegers, et al., 2005) so that it appears likely that 
some of our HR-MDD subjects may develop BD in the future. The follow-up 
assessments of our study cohort will clarify if some of the HR-MDD participants 
will convert to BD and if some of our HR-well subjects go on to develop a mood 
disorder. Third, our study groups differed with respect to depression symptom 
severity at baseline. However, the median of the HAM-D total score was only 1 in 
the HR-MDD group, suggesting only sub-syndromal depression symptoms. 
Moreover, our correlation analysis revealed no relationship between depression 
symptom severity and our neurocognitive performance measures. Therefore, it 
appears unlikely that general mood differences at baseline between the groups have 
influenced our findings. Last but not least and as already highlighted previously, 
the relatively small HR-MDD sample size might have resulted in a lack of power to 
detect significant effects. 
In summary, our findings suggest that reduced long delay verbal memory and 
extradimensional set-shifting performance across time constitute a familial trait 
marker for vulnerability to mood disorders. Both neurocognitive performance 
deficits appear to be relatively stable over a two-year time period and do not appear 
to be linked to the onset of MDD. These findings advance our understanding of the 
neuropathological processes underlying mood disorders and future longitudinal 




General conclusions and implications for the future 
 
In this thesis, I examined regional subcortical brain volumes, cortical thickness and 
cortical surface area of various brain regions and neuropsychological function in 
111 initially unaffected relatives of BD patients of whom 20 developed MDD 
within a period of two years and matched healthy control subjects. Cross-sectional 
analyses at baseline were conducted to assess whether regional structural brain 
abnormalities and specific neuropsychological dysfunctions exist in the HR-MDD 
group prior to illness onset that may serve as neuroanatomic or neurocognitive 
markers for a subsequent onset of MDD and to assess their relationship to familial 
risk. The longitudinal analysis was intended to explore the time course of regional 
structural brain parameters and neuropsychological function during a period of two 
years to detect whether abnormal brain development or neurocognitive 
deterioration in the high-risk participants is evident that can be linked to an onset of 
MDD or familial risk. In this last chapter, I will summarise the key findings along 
its limitations and suggest implications for future research. 
 
7.1 Summary of main findings 
The cross-sectional and longitudinal analyses of the volumes of subcortical brain 
regions yielded no significant results. This indicates that subcortical brain 
abnormalities that have been reported in mood disorder patients do not appear to 
emerge as a consequence of being at high familial risk for mood disorders and are 
therefore unlikely to form a neuroanatomic endophenotype for the disorder. They 
also do not appear to predate an onset of MDD and are thus unlikely to be 
neurodevelopment in nature. Moreover, they do not appear to emerge as a 
consequence of illness-specific mechanisms that are directly linked to the onset of 
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the disorder. Rather, it appears likely that volumetric differences only emerge 
during the course of the disorder or in conjunction with psychopharmacological 
treatment effects.  
For regional cortical thickness, the cross-sectional analyses at baseline yielded no 
significant results. The longitudinal analyses however revealed several significant 
findings. First, reduced cortical thickness in the right parahippocampal and 
fusiform gyrus across the two time points were found in both high-risk groups 
relative to controls, with the HR-MDD group displaying a thinner 
parahippocampus gyrus than the HR-well group. The fact that thinner 
parahippocampal and fusiform gyrus are evident in high-risk individuals, 
irrespective of time or the onset of MDD, suggests that thinning in these temporal 
brain regions constitutes a familial trait marker for vulnerability to mood disorders. 
Given that they are already present in early adulthood, they are unlikely to be of 
degenerative origin but likely represent disturbances of normal brain development 
predisposing to illness. Since the HR-MDD subjects displayed a thinner 
parahippocampal gyrus than the HR-well group, particular strong thickness 
reductions of this brain area may be related to risk of developing MDD. 
Parahippocampal and fusiform gyrus reductions are thus potential neuroanatomic 
endophenotypes for mood disorders, as thinning is evident in both unaffected 
relatives and affected patients and independent of state.  
Second, the longitudinal analyses of cortical thickness revealed that HR-well 
subjects had progressive thickness reductions in the left inferior frontal and 
precentral gyrus relative to controls, while the HR-MDD group showed cortical 
thickening of these areas over time. The abnormal thinning of these brain areas in 
the HR-well group over time relative to controls suggests that thinning in 
regionally specific left frontal lobe areas forms a familial trait marker for 
vulnerability to mood disorders and that abnormal thinning already takes place in 
early adulthood, potentially reflecting early neurodegenerative processes. 
Importantly, a distinct pattern of increasing relative cortical thickness of the left 
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inferior frontal and precentral gyrus over time in the HR-MDD as compared to the 
HR-well group due to an absence of regional thinning of these brain areas in the 
HR-MDD cohort was found. For the precentral gyrus, the cortical thickness 
development in the HR-MDD group was also significantly different from the HC 
subjects. Absence of cortical thinning of these brain regions thus appears to be 
linked to the onset of illness and underlying disease-associated processes. Given 
that human brain maturation involves frontal grey matter loss beyond adolescence 
(Gogtay, et al., 2004; Sowell, et al., 2003; Westlye, et al., 2010), the absence of 
cortical thinning in the HR-MDD group may reflect a lack or delay of normal 
synaptic pruning processes. 
For cortical surface area, the cross-sectional and longitudinal analyses yielded no 
significant results. This indicates that young unaffected adults at enhanced risk of 
mood disorders because of a close family history of BD do not exhibit cortical 
surface area abnormalities so that it appears unlikely that these may form a 
neuroanatomic endophenotype for the disorder. They also do not appear to predate 
an onset of MDD or to emerge as a consequence of illness-specific mechanisms 
that are directly linked to the onset of the disorder. Nevertheless, it cannot be ruled 
out that regional cortical surface area abnormalities may emerge during the course 
of the disorder or in conjunction with psychopharmacological treatment effects.  
For neuropsychological performance measures, the cross-sectional analyses at 
baseline yielded no significant results. The longitudinal analyses however revealed 
several significant findings. First, reduced long delay verbal memory and 
extradimensional set-shifting performance across the two time points were found in 
the HR-well group relative to controls, with the HR-MDD group displaying 
decreased extradimensional set-shifting abilities as compared to the HC group only. 
The finding of reduced long delay verbal memory and extradimensional set-
shifting performance in the HR-well group across time suggests that 
neurocognitive deficits in these domains constitute a familial trait marker for 
vulnerability to mood disorders. Given that they are already present in early 
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adulthood, they are unlikely to be of degenerative origin but likely represent 
disturbances of normal brain development predisposing to illness. Since no 
significant differences between the two high-risk groups and no group-by-time 
interaction emerged, the results do not speak towards reduced verbal memory and 
extradimensional set-shifting abilities to be directly linked to an onset of MDD.  
Second, significant effects of time were observed for attentional processing speed, 
verbal learning, short delay verbal memory and extradimensional set-shifting, 
indicating superior performance during these tasks at follow-up assessment as 
compared to baseline assessment across all participant groups. These most likely 
reflect practice effects during neuropsychological examination which are well 
documented in the literature (Bartels, et al., 2010). There was also a significant 
effect of time for simple discrimination learning due to decreased task performance 
at follow-up as compared to baseline across all groups. One plausible explanation 
for this conflicting result may be that participants remembered the task from the 
baseline assessment and already shifted their attention to the currently irrelevant 
stimulus as they were expecting the reversal of the rule to occur at follow-up 
examination. 
Taken together, these results suggest that the pathophysiology underlying mood 
disorders in early adulthood is driven by (at least) two factors. First of all, early 
structural brain and neurocognitive abnormalities that are potentially 
neurodevelopmental in nature and enhance disease vulnerability are evident. In 
detail, structural brain abnormalities in the right parahippocampus and fusiform 
gyrus as well as verbal memory and extra-dimensional set-shifting performance 
deficits that are relatively stable over time appear to enhance disease vulnerability. 
This suggests that early abnormal brain developmental processes appear to be 
taking place in mood disorders, leading to decreased cortical thickness in the 
temporal lobe and decreased verbal memory and set-shifting ability. Of note, 
particularly strong thickness reductions of the parahippocampal gyrus appear be 
related to the onset of MDD within a time period of two years. Second, 
154 
 
pathophysiological disease-associated processes are taking place. In detail, the 
onset of MDD is associated with increases in cortical thickness in the left inferior 
frontal and precentral gyrus, suggesting that disease-associated processes are taking 
place in these regions. Future studies should investigate the nature of these 
structural brain and neurocognitive abnormalities associated with enhanced disease 
vulnerability and illness onset.  
Our finding of reduced cortical thickness in the right parahippocampal and 
fusiform gyrus associated with enhanced disease vulnerability is partly in line with 
previous findings of reduced white matter integrity in HR subjects of this study 
cohort (Sprooten, et al., 2011). Using diffusion tensor imaging, Sprooten et al. 
(2011) found reduced fractional anisotropy in the HR as compared to the HC group 
in a large cluster encompassing white matter tracts connecting temporal lobe 
regions with each other or other brain regions. Given that brain maturation in late 
adolescence and early adulthood involves increases in white matter volume and 
fractional anisotropy (Faria et al., 2010; Giorgio et al., 2010), these results similarly 
to the grey matter findings point towards disturbed brain maturation processes in 
the temporal lobe to be associated with an increased risk for mood disorder. A 
similar finding of reduced fractional anisotropy in numerous white matter tracks 
has also been observed in adolescents at high risk of BD because of subthreshold 
bipolar symptoms (Paillere Martinot, et al., 2014). In line with our findings, 
research on white matter integrity in first-episode MDD young treatment naïve 
adults reported decreased fractional anisotropy in the right parahippocampal gyrus 
of the MDD cohort (Zhu et al., 2011). Using diffusion tensor imaging in 
combination with fMRI, de Kwaasteniet et al. (2013) recently showed that white 
matter integrity of the uncinate fasciculus which connects medial temporal lobe 
structures with the anterior cingulate cortex is reduced in MDD and that there is a 
negative correlation between uncinate fasciculus integrity and functional 
connectivity between these brain regions. Taken together, these findings highlight 
the importance of studying structural (grey and white matter) abnormalities in 
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temporal lobe structures of mood disorders as well as their underlying 
pathophysiological mechanisms and their relationship to brain activation.  
Our finding of decreases in cortical thickness in the left inferior frontal and 
precentral gyrus over time in the HR-well subjects may be well in line with 
previous findings of reduced white matter integrity in HR subjects of this study 
cohort, encompassing frontal brain areas (Sprooten, et al., 2011). However, no 
longitudinal analysis of fractional anisotropy of this study cohort has been 
conducted as yet. Similarly, decreased fractional anisotropy in BD and MDD has 
been commonly observed along frontal-subcortical tracts (Adler, et al., 2006; 
Mahon, et al., 2010; Tham, et al., 2011), but there is a lack of longitudinal studies. 
Moreover, there is evidence towards volumetric frontal white matter abnormalities 
in BD patients (Bruno, et al., 2004; McIntosh, et al., 2005; Stanfield, et al., 2009) 
which may be related to our findings. Future longitudinal studies of high-risk 
samples investigating white matter development over time will help to clarify if our 
results are in line with other neuroimaging findings. 
 
7.2 Methodological remarks and limitations 
The methodological strengths of this study are its longitudinal nature, the 
assessment of subjects prior to illness onset, the relatively young age of the 
participants and the comparatively large sample size of high-risk subjects and 
controls. In addition, all subjects underwent careful clinical assessment at both time 
points and the effects of medication and relatedness of subjects were ruled out. All 
brain scans were obtained at the same scanner using the identical protocol at both 
visits and the MRI data were processed in an identical way using thoroughly 
validated methods.  
Several limitations of this study cohort need to be addressed. First, the sample size 
of the HR-MDD subjects was relatively small so that it cannot be ruled out that 
some analyses were under-powered to detect significant differences between the 
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HR-MDD and the other two study groups. Second, it remains unknown whether 
currently unaffected HR-well subjects may develop MDD in the future. Third, 
previous longitudinal studies have reported that the majority of the high-risk 
subjects who developed BD themselves experienced depressive episodes years 
before conversion (Duffy, 2010; Hillegers, et al., 2005) so that it appears likely that 
some of our HR-MDD subjects may develop BD in the future. The follow-up 
assessments of our study cohort will clarify if some of the HR-MDD participants 
will convert to BD and if some of our HR-well subjects go on to develop a mood 
disorder.  
Fourth, the DSM-IV criteria employed to diagnose MDD (and BD) are a subject of 
debate. For example, the DSM-IV criteria for MDD have raised concerns about 
increasing numbers of false positive diagnoses since the criteria for MDD appear to 
be fulfilled by a large percentage of the population at one point in their lives and 
may be considered a normal response to stress (Wakefield, Schmitz, & Baer, 
2010). Moreover, there is large heterogeneity in symptoms that ultimately lead to a 
diagnosis of MDD so that the concept of MDD as being a homogeneous disorder 
has been challenged (Goldberg, 2011). It would have thus been better to account 
for this issue by conducting analyses with respect to separate symptom dimensions 
of MDD. However, given the small sample size of the HR-MDD group, this 
approach was not feasible. 
Fifth, our study groups differed with respect to depression symptom severity at 
baseline. However, the median of the HAM-D total score was only 1 in the HR-
MDD group, suggesting only sub-syndromal depressive symptoms. Therefore, it 
appears unlikely that general mood differences at baseline between the groups have 
influenced our findings. Nevertheless, it needs to be highlighted that the clinical 
instruments employed at baseline and follow-up assessments might have not been 
ideal to detect sub-syndromal depressive and manic symptoms. However, no 
prodromal criteria for BD or MDD had been developed when this study was 
originally designed and putative prodromal symptoms such as depressed mood, 
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irritability, racing thoughts and physical agitation (Howes, et al., 2011) are covered 
by the YMRS, HAM-D and SCID. It would have still been desirable to include 
specialised clinical interviews capturing a broader range of putative prodromal 
symptoms and their varying degrees of severity. 
Sixth, the (semi-)automated brain imaging software FreeSurfer was employed to 
obtain subcortical volumes, cortical thickness and cortical surface area estimates. 
As described in detail in paragraph 2.2.2, this approach has been shown to have 
various disadvantages in comparison to manual hand-tracing methods with respect 
to accuracy and reliability of findings. To minimize this limitation, the performance 
of FreeSurfer was visually checked at various processing stages and regional brain 
segmentations and parcellations were edited where necessary. Nevertheless, it 
cannot be ruled out that these methodological factors might have influenced our 
findings. 
Seventh, given the relatively young age of our study cohort, it appears likely that 
brain development processes known to occur during adolescence and early 
adulthood (see also paragraph 1.5.3) might have influenced the results. It has been 
shown that during this time period, cortical grey matter volume decreases in a non-
linear fashion across different brain regions; reductions first appear in sensorimotor 
areas, followed by decreases in the frontal cortex, parietal cortex and finally in the 
temporal cortex (Gogtay, et al., 2004). These grey matter reductions have been 
linked to increased synaptic and/or neuronal pruning processes taking place at late 
adolescence and early adulthood (Gogtay, et al., 2004). Our findings of abnormal 
cortical thickness reductions in the inferior frontal and precentral gyrus over the 
two-year time period in the HR-well subjects may thus be in line with the fact that 
grey matter reduces in the frontal cortex first. By contrast, reductions in temporal 
brain structures take place at later stages so that they might have been too subtle to 
detect them over the two-year time period studied and may only be evident at older 
age. It would be advantageous to study cortical and subcortical brain development 
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in mood disorders and high-risk populations during a larger time frame. The 
follow-up examinations of the BFS will help to clarify this aspect. 
Eighth, it has been shown that the brain development trajectories differ 
substantially between the sexes. For nearly all cortical and subcortical brain areas, 
grey matter volume increases peak about 1-2 years earlier in women than men 
(Lenroot et al., 2007). For example, the volume of the whole cerebral cortex peaks 
at around the age of 10.5 years in females and around the age of 14.5 years in men 
(Lenroot, et al., 2007). These initial increases in grey and white matter are followed 
by decreases taking place until early adulthood. Accordingly, differences between 
the sexes in brain development trajectories might have influenced the results. It 
would have been advantageous to conduct separate statistical analyses for male and 
female participants. Given the small sample size of the HR-MDD subjects, this 
approach would have lowered the statistical power to be able to detect significant 
differences between the groups or over time so that this analysis was unfortunately 
not feasible. To minimize this limitation, we covaried for this factor in the analyses 
and checked that there were no significant differences in gender distribution 
between the study groups. 
Ninth, the neuropsychological tasks employed appear not to be ideal for detecting 
longitudinal changes in cognitive performance since they have been shown to be 
prone to practice effects (Bartels, et al., 2010). It would have been advantageous to 
assess cognitive function at the second assessment point with parallel versions of 
the CVLT, IED and Digit Span. However, to the best of my knowledge, no parallel 
version for the IED does exist as yet. Moreover, task performance of the CVLT, 
IED and Digit Span relies at least to some extend on executive functions such as 
planning abilities and executive control mechanisms which might have influenced 
task performance. In particular, it can be expected that having performed the CVLT 
previously leads to enhanced performance at the second assessment as the subject 
is already familiar with grouping words according to semantic categories. 
Accordingly, it would have been advantageous to select a verbal learning and 
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memory task that does not include grouping words into semantic categories. 
Similarly, if subjects completed the IED previously, it appears likely that they 
remembered the rules at the second visit and accordingly performed better on intra- 
and extradimensional set-shifting than would have been expected if they were 
asked to complete an unknown task. Last but not least, general differences in IQ 
might have influenced the neuropsychological performance results. 
 
7.3 Implications for the future 
While structural brain abnormalities and neuropsychological performance deficits 
have been repeatedly demonstrated in patients with mood disorders and their 
unaffected close relatives, findings have been largely inconsistent. The observed 
discrepancies likely stem from the effects of age, gender, differences in symptom 
presentation, symptom severity, duration of illness, number of depressive and/or 
manic episodes, age of onset, comorbidity, medication as well as the effects of 
genetic and environmental susceptibility factors and their complex interplay which 
act upon human brain development and functioning. Further, sample sizes may 
often be not large enough to detect significant small structural brain and 
neuropsychological performance abnormalities. Moreover, the use of different 
methodological designs may add to the heterogeneity in findings. 
Future studies should therefore address the complex interactions of various socio-
demographic, clinical and susceptibility factors and take sample size and 
methodological issues into account to investigate the aetiology of neuroanatomic 
and neurocognitive abnormalities in more detail. Several approaches should be 
considered. On the one hand, very large study samples of young individuals at 
familial risk for BD or MDD who are followed longitudinally for years or even 
decades are required to disentangle the time course of structural brain and 
neuropsychological abnormalities in mood disorders. Such large-scale projects may 
however only be feasible if many research centres around the world are 
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collaboratively working together and share their data for mega-analysis. Given the 
large sample size, it should be feasible to analyse particular subgroups of the study 
cohort without losing power to detect significant differences. In detail, subgroups 
covering the particular symptom presentation of affected subjects, age of onset or 
medication status would add important information to the aetiology of structural 
brain and cognitive abnormalities. Moreover, analyses should disentangle the 
effects of age, gender and various other important factors on brain structure and 
function.  
On the other hand, the effects of genetic and environmental susceptibility factors 
and their complex interplay on brain structure and function need to be addressed in 
large sample sizes of healthy control subjects and mood disorder patients. One 
example of such an approach is for example the ENIGMA consortium (Thompson 
et al., 2014), a large network of researchers working together on a range of large-
scale studies that integrate data from 70 institutions worldwide. The consortium has 
been able to detect common variants in the genome that affect subcortical brain 
structure that no individual site could detect on its own.  
Furthermore, new research projects should benefit from improvements made in 
technology and methodology of brain imaging. For example, using 7 tesla MRI 
scanners would provide a higher resolution of the brain and may thus help to detect 
even subtle changes in brain structure. As it has been recently possible to assess 
cortical thickness and surface area separately from each other, future research 
should make use of this advancement in brain imaging software and avoid standard 
VBM analyses which represent the combined effects of thickness and surface area 
only. 
Finally, future studies should try to develop tools to predict the risk of an onset of 
mood disorders as accurately as possible. As this study suggests, these algorithms 
should include cortical thickness measures for the right parahippocampal and 
fusiform gyrus as well as the left inferior frontal and precentral gyrus. Moreover, 
verbal memory and extra-dimensional set-shifting performance indices may help to 
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calculate the relative risks of developing a mood disorder. It needs to be noted, 
however, that the results of this study were obtained in individuals with a family 
history of BD so that future studies need to address if the findings of this study also 
hold in subjects who have no family history of mood disorders. The development 
of such tools should also include measures of clinical (prodromal) symptoms and 
potentially (resting state) fMRI findings, white matter integrity indices and genetic 
measures.  
 
7.4 General conclusion 
Reduced cortical thickness in the right parahippocampal and fusiform gyrus 
constitute a familial trait marker for vulnerability to mood disorders and may thus 
form potential neuroanatomic endophenotypes. Particularly strong thickness 
reductions of the parahippocampal gyrus appear be related to the risk of MDD. 
Moreover, progressive thickness reductions in the left inferior frontal and 
precentral gyrus in early adulthood form a familial trait marker for vulnerability to 
mood disorders, potentially reflecting early neurodegenerative processes. By 
contrast, an absence of cortical thinning of these brain regions in early adulthood 
appears to be linked to the onset of MDD and underlying disease-associated 
processes, potentially reflecting a lack or delay of normal synaptic pruning 
processes. From a neuropsychological perspective, reduced long delay verbal 
memory and extradimensional set-shifting performance across time constitute a 
familial trait marker for vulnerability to mood disorders, likely representing 
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